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ABSTRACT 
 
Myocardial infarction (MI) is the most common cause of heart failure.  Despite 
advancements in cardiovascular treatments and interventions, current therapies can only slow 
down the progression of heart failure, but not tackle the progressive loss of cardiomyocytes after 
MI. One aim of cardiac tissue engineering is to develop implantable constructs (e.g. cardiac 
patches) that provide physical and biochemical cues for myocardium regeneration. To this end, 
vascularization in these constructs is of great importance and one key issue involved is the 
spatiotemporal control of growth-factor (GF)-release profiles. The other key issue is to non-
invasively quantitatively monitor the success of these constructs in-situ, which will be essential 
for longitudinal assessments as studies are advanced from ex-vivo to animal models and human 
patients. To address these issues, the present research aims to develop nanoparticles to modulate 
the temporal control of GF release in cardiac patches, and to develop synchrotron X-ray phase 
contrast tomography for visualization and quantitative assessment of 3D-printed cardiac patch 
implanted in a rat MI model, with four specific objectives presented below.  
The first research objective is to optimize nanoparticle-fabrication process in terms of 
particle size, polydispersity, loading capacity, zeta potential and morphology. To achieve this 
objective, a comprehensive experimental study was performed to examine various process 
parameters used in the fabrication of poly(lactide-co-glycolide) (PLGA) nanoparticles, along 
with the development of a novel computational approach for the nanoparticle-fabrication 
optimization. Results show that among various process parameters examined, the polymer and 
the external aqueous phase concentrations are the most significant ones to affect the nanoparticle 
physical and release characteristics. Also, the limitations of PLGA nanoparticles such as initial 
burst effect and the lack of time-delayed release p
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The second research objective is to develop bi-layer nanoparticles to achieve the controllable 
release of GFs, meanwhile overcoming the above identified limitations of PLGA nanoparticles. 
The bi-layer nanoparticle is composed of protein-encapsulating PLGA core and poly(L-lactide) 
(PLLA)-rate regulating shell, thus allowing for low burst effect, protein structural integrity and 
time-delayed release patterns. The bi-layer nanoparticles, along with PLGA ones, were 
successfully fabricated and then used to regulate simultaneous and/or sequential release of 
multiple angiogenic factors with the results demonstrating that they are effective to promote 
angiogenesis in fibrin matrix.  
The third objective is to develop novel mathematical models to represent the controlled-
release of bioactive agents from nanoparticles. For this, two models, namely the mechanistic 
model and geno-mechanistic model, were developed based on the local and global volume 
averaging approaches, respectively, and then validated with experiments on both single- and bi-
layer nanoparticles, by which the ovalbumin was used as a protein model for the release 
examination. The results illustrates the developed models are able to provide insight on the 
release mechanism and to predict nanoparticle transport and degradation properties of 
nanoparticles, thus providing a means to regulate and control the release of bioactive agents from 
the nanoparticles for tissue engineering applications.  
The fourth objective of this research is to develop a synchrotron-based phase contrast non-
invasive imaging technique for visualization and quantitative assessment of cardiac patch 
implanted in a rat MI model. To this end, the patches were created from alginate strands using 
the three-dimensional (3D) printing technique and then surgically implanted on rat hearts for the 
assessment based on phase contrast tomography. The imaging of samples was performed at 
various sample-to-detector distances, CT-scan time, and areas of the region of interest (ROI) to 
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examine their effects on imaging quality. Phase-retrieved images depict visible and quantifiable 
structural details of the patch at low radiation dose, which, however, are not seen from the 
images by means of dual absorption-phase and a 3T clinical magnetic resonance imaging. 
Taken together, this research represents a significant advance in cardiac tissue engineering by 
developing novel nano-guided approaches for vascularization in myocardium regeneration as 
well as non-invasive and quantitative monitoring techniques for longitudinal studies on the 
cardiac patch implanted in animal model and eventually in human patients. 
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CHAPTER 1 
BACKGROUND 
Notes: Sections 1.1 – 1.6 of this chapter are adopted from the publication of “M. Izadifar, M. 
Kelly and X. B. Chen, 2014, Engineering Angiogenesis for Myocardial Infarction Repair: Recent 
Developments, Challenges, and Future Directions, Cardiovascular Engineering and Technology, 
5(4), 281-307” According to the Copyright Agreement, "the authors retain the right to include 
the journal article, in full or in part, in a thesis or dissertation". 
1.1. Introduction 
Cardiovascular diseases including myocardial infarction are leading causes of death that account 
for nearly 40% of all fatalities, more than all cancers combined [1]. Each year, an estimated 
~620,000 Americans are hospitalized or die due to coronary heart diseases, and ~295,000 have a 
recurrent coronary attack [2]. Heart defects are also the leading cause of death in the first year of 
life [3]. Recognized as a critical public health issue worldwide, heart failure is caused by various 
cardiovascular diseases including acute myocardial infarction, ischemic cardiomyopathy, and 
idiopathic cardiomyopathy [4]. Despite recent achievements in drug-eluting stents [5], off-pump 
cardiac surgery includuing coronary artery bypass grafting [6], mitral valve repair and left 
ventricular reconstruction surgery [7], and permanent pacemakers with left ventricle 
resynchronization devices [8], millions of people continue to suffer from heart failure [9-12].  
The heart is a terminally differentiated organ that fails to repair itself because of the intrinsic 
inability of damaged heart tissue to regenerate [13-15], so the large number of patients 
worldwide who survive myocardial infarction and develop advanced heart failure face largely 
unresolvable issues [16]. At present, heart transplantation is the best solution for patients with 
end-stage heart failure. However, donor supply is declining and creating an increasing gap 
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between supply and demand for heart replacement therapies. Left ventricular assist devices may 
provide a temporary therapeutic option for patients with pump failure but do not provide a 
definitive therapy [17]. Thus, there has been great interest in alternative therapeutic strategies to 
reverse this common and deadly disease. 
Regenerative medicine and tissue engineering are rapidly growing areas that aim to maintain, 
replace, restore, or enhance the functionality of damaged, lost, or degenerated tissues/ organs 
using combinations of cells, biomaterials, and/ or biologically active molecules [18]. Cardiac 
regeneration therapy is a promising approach to revolutionize current therapies for myocardial 
infarction and heart failure towards any successes that can significantly improve the quality of 
life for millions of patients. Although cardiac tissue engineering could be the most valuable 
approach for the regeneration of failing hearts, there are significant challenges associated with 
the complexity of the damaged cardiac tissue. Among the different challenges faced by cardiac 
tissue engineering, angiogenesis and timely connection to the host blood supply are the most 
substantial.  
This chapter presents an overview for cardiac tissue engineering strategies and associated 
challenges, with emphasis on angiogenesis as the major challenge in cardiac tissue engineering. 
Strategies for myocardial infarction repair are examined and recent advances and developments 
in engineering vascularization and inosculation approaches towards the rapid integration of 
cardiac scaffolds, once implanted, with the host tissue are presented.    
1.2. Atherosclerosis  
Atherosclerosis is the major cause of cardiovascular diseases [19]. Arterial wall, which consists 
of intima (endothelium), media (smooth muscle cells (SMCs)) and adventitia, is a dynamic and 
regulated system, but several risk factors can disturb its normal homeostasis and cause 
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atherogenesis. Smoking, aging, hypercholesterolemia, hypertension, hyperglycemia, genetics 
(family history) [20], high levels of reactive oxygen species (ROS) and low density lipid (LDL) 
[21, 22], dyslipidemia [23] and diabetes [20] are among various traditional and novel risk factors 
that can cause endothelial dysfunction. Such endothelial dysfunction allows the permeation of 
LDL into the subendothelial space where LDL accumulates by binding to proteoglycans in the 
extra cellular matrix (ECM). In addition, hypertension may contribute to the LDL retention in 
intima by promoting the production of LDL-binding proteoglycans by SMCs. The trapped LDL 
in the subendothelial space is oxidized by the ROS and continues to promote inflammation by 
triggering the expression of proinflamatory cytokines (chemoattractant signals). The cytokines at 
the endothelial luminal surface direct mainly monocytes to the forming lesion. The monocytes 
role and adhere to the luminal surface and penetrate in the intima, and then differentiate into 
macrophages under the influence of macrophage colony stimulating factor. Mature macrophages 
then engulf oxidized LDL and form foam cells. Immobile foam cells stuck at the focus of the 
lesion form the early atherosclerotic streak. The local accumulation of foam cells fuels foam cell 
apoptosis in the lipid-rich center of the plaque (necrotic core) and augments the release of 
proinflammatory cytokines that promote atherosclerotic plaque progression and SMC migration 
into the intima. During decades of development, the plaque accumulates a distinct thrombogenic 
lipid core surrounded by a protective fibrous cap. In the early stage of the plaque growth, a 
compensatory outward remodeling of the arterial wall preserves the lumen diameter. This early 
stage of plaque growth produces no ischemic symptoms and can evade the detection by 
angiography. In later stages, plaque growth narrows the vessel diameter and impedes the blood 
flow, leading to tissue ischemia and tissue injury. Meanwhile, the extracellular matrix plays a 
pivotal role in fortifying the fibrous cap that isolates the plaque thrombogenic core from the 
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blood circulation. If the fibrous cap of the plaque ruptures due to an unstable ECM and the 
release of matrix metaloproteinases, the exposure of the procoagulants within the plaque to the 
circulating blood causes platelet aggregation and which leads to thrombus formation which can 
occlude the vessel and results in infarction of the involved myocardium [24]. 
1.3. Myocardial infarction  
The progression of vascular disease, which can cause myocardial infarction, is intimately related 
to the dysfunction of the endothelial cells (ECs) of blood vessels. Blood vessels are basically 
composed of three layers: the intima (endothelium), an intermediate layer of media (muscle 
cells), and an outer layer of adventitia (connective tissue). The inner layer, consisting of a thin 
layer of ECs, provides a smooth and protective surface preventing toxic and blood-borne 
substances from penetrating into the media. However, factors including high levels of low-
density lipoprotein (LDL) cholesterol, high levels of triglycerides, hypertension, a high omega-
6:omega-3 ratio, excess insulin, insufficient vitamin D and K, and nitric oxide deficit in the 
blood can cause endothelial dysfunction, ultimately resulting in lipids and toxics permeating to 
the intermediate layer (media) [25-29]. The accumulation of lipids and toxics in the media along 
with oxidative and inflammatory cascades leads to the development of plaque deposits that 
slowly grow and locally narrow the blood vessel. This slow process is known as atherosclerosis. 
Over time, the plaques calcify and become susceptible to rupture. If a plaque in the artery breaks, 
a blood clot forms around the plaque and can eventually block the blood flow. If this process 
happens in a coronary artery of the heart, the blood flow that supplies oxygen to the heart muscle 
is severely reduced or cut off such that the heart muscle is starved for oxygen and nutrients. This 
occurrence is called ischemia. Because the heart wall is composed of tightly packed myocytes 
and fibroblasts with high metabolic demand, the myocardium requires large amounts of oxygen 
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and cannot tolerate ischemia. Thus, ischemia can lead to the serious damage or death of part of 
the heart muscle in a process known as heart attack or myocardial infarction. 
When myocardial infarction occurs, the myocardium reacts to the ischemia with a series of 
changes in cellular and extracellular matrix (ECM) components that lead to left ventricular 
remodelling [30]. The lack of oxygen in the myocardium causes cardiomyocyte necrosis and a 
subsequent inflammatory response. The inflammatory response consists of upregulation of a 
series of cytokines, chemokines, and cell adhesion molecules that triggers the recruitment of 
neutrophils and monocytes to the infarct region [31]. Monocyte adherence to ECM initiates 
conversion to macrophages, in part by inducing the expression of cytokines including 
macrophage colony stimulating factor (M-CSF) that is necessary for macrophage survival [32]. 
The primary role of the macrophage in the post-myocardial infarction is to facilitate wound 
healing through phagocytosis of necrotic cells and secretion of angiogenic factors for 
angiogenesis, fibroblast activation and proliferation, and collagen metabolism [33, 34]. Activated 
macrophages in the myocardial infarction zone are key angiogenic effector cells and influence 
each phase of the angiogenic process, including local ECM destabilization; induction of ECs to 
differentiate, migrate, and proliferate; and maturation of new microvessels [35]. Induction of EC 
sprouting requires the dissolution of the local extracellular matrix. Macrophages secrete matrix 
metalloproteinases (MMPs) that degrade the ECM and liberate extracellular matrix-bound 
growth factors to facilitate new blood capillary formation [36]. Macrophages are also a major 
source of initiating factors that activate fibroblasts that secrete collagen to form scar tissue in the 
myocardial infarction zone [37]. During the healing process, post-myocardial infarction, central 
necrosis, infiltration of inflammatory cells, and secretion of MMPs by macrophages weaken the 
infarcted myocardium for several weeks until the end of scar formation [38]. Over subsequent 
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weeks to months, a granulation tissue is created and ultimately becomes a thick and stiff 
collagenous scar [39]. The fibrotic scar tissue formed is unable to actively contract thus imposing 
an extra burden on the remaining healthy myocardium, reducing the contractile function of the 
heart, and leading to ventricle wall thinning [40]. When the infarct is large, infarct expansion is 
promoted such that the progressive increase in left ventricle volume can lead to chronic heart 
failure [38]. Although the inflammatory response modulated by macrophages is a necessary 
component of the post-myocardial infarction healing process [41], post-infarction inflammation 
can be a double-edged sword as excessive inflammation can play an important role in infarct 
expansion [38]. The role of macrophages following myocardial infarction has been well 
reviewed by Lambert et al. (2008) [42]. Cardiac ECM also plays a very important role during 
infarct healing. Beyond the mechanical support, ECM proteins perform as regulators by 
modulating cellular interactions that are involved in the inflammatory response including 
angiogenesis. An excellent review on the role of ECM as a modulator of the inflammatory 
response post-myocardial infarction was published by Dobaczewski et al. (2010) [43]. 
1.4. Strategies for myocardial infarction repair 
Regeneration of heart tissue through direct cell transplantation, scaffold-based tissue 
engineering, and mobilization of heart progenitor cells with active biomolecules holds 
tremendous potential for the treatment of myocardial infarction and other forms of heart injury 
although this has remained an elusive goal for over a decade. Classical treatments for heart 
diseases continue to evolve; cell therapy combined with tissue engineering techniques now offer 
novel therapeutic concepts for myocardial repair [44]. Cardiac regeneration therapy strategies 
can be classified into two general categories: cardiac graft engineering and in situ cell-based 
cardiac regeneration therapy. 
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1.4.1. Graft-based cardiac tissue engineering  
The goal of graft-based cardiac tissue engineering is to repair the myocardial infarction area 
using a supporting scaffold/ sheet/ gel containing functional cells and signaling molecules. The 
strategy is based on growing selected cells (e.g., progenitor cardiac cells) on a three-dimensional 
(3-D) scaffold or patch in bioreactors followed by implanting the graft to direct new cardiac cell 
formation and maturation in the damaged area. The critical elements of a successful cardiac 
tissue engineered construct include the graft biomaterial that serves as a mechanical and 
biological support for cells, progenitor cells that must be differentiated into cardiac cells, and 
inductive growth factors that instruct cellular activities. 
A successful cardiac tissue construct must demonstrate functional and morphological properties 
of native heart muscle, mechanically/ electrically integrate into the heart muscle after 
implantation, and improve systolic and diastolic function of the damaged myocardium over time 
[45]. Therefore, a cardiac tissue engineered graft should be contractile, mechanically robust but 
flexible, electrophysiologically stable, non-immunogenic, and quickly vascularized after 
implantation in order to mimic the functionality and properties of native heart muscle. Different 
3-D myocardial tissue constructs have been developed by a number of research groups [46-49]. 
Despite numerous efforts devoted to scaffold-based cardiac tissue engineering, a tissue 
engineered substitute suitable for replacing non-functioning myocardium is not on the horizon; 
however, adding cardiac-engineered patches to the damaged heart muscle rather than replacing 
part of the heart muscle seems more pragmatic. Table 1.1 provides a summary of the 
biodegradable and biocompatible materials used for graft-based cardiac tissue engineering. High 
mechanical stability, which is required for any cardiac scaffold to withstand systolic pressure, is 
one of the significant characteristics that biomaterials fail to offer. 
 8 
Table 1.1. Biodegradable and biocompatible materials used in graft-based cardiac tissue 
engineering. 
Material Research objective Ref. 
Collagen Development of contractile bioartificial 
myocardial tissue 
[50] 
Collagen-
glycosaminoglycan 
(GAG) 
Evaluation of the tissue response to collagen-
GAG scaffolds 
[51] 
Alginate Stimulation of neovascularization and attenuate 
left ventricle dilation 
[52] 
PGAa copolymerized with 
PLAb 
Development of contractile bioartificial 
myocardial tissue 
[53] 
PLLAb Formation of synchronously contracting 
engineered human cardiac tissue 
[54] 
PCLc copolymerized with 
PLA 
Development of contractile cardiac grafts in vitro [55] 
Polyurethane coated with 
gelatine/ laminin/ collagen 
Development of contracting films  [56] 
Collagen/ Matrigel Engineering cardiac muscle constructs with 
functional and morphological properties similar to 
native cardiac muscle 
[57] 
apoly(glycolic acid), bpoly(lactic acid), cpoly(L-lactic acid), dpoly(ε-caprolacton) 
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1.4.2. In situ cardiac regeneration therapy 
A second approach to cardiac tissue engineering is based on in vivo myocardium regeneration 
with the aim to repair myocardial infarction by regenerating the heart muscle in situ. In situ 
cardiac regeneration therapy can be further categorized into: i) cell suspension direct injection, ii) 
biomolecule/ biomaterial-enhanced myocardium self-repair, and iii) cell-containing hydrogel 
injection. Although scaffold-based cardiac tissue engineering allows for good control over the 
cardiac tissue engineered construct size, shape, development, and in vitro function, it has been 
unable to create a robust and stable heart muscle-like tissue construct; thus, the risk of tissue 
necrosis after implantation remains.  
1.4.2.1. Cell suspension direct injection 
This approach aims to repopulate cardiac cells in the damaged myocardium by injecting cell 
suspensions with a syringe or the minimally invasive approach of cardiac catheterization. Fetal 
cardiomyocytes, skeletal myoblasts, and bone marrow stem cells have been employed in this 
method; however, restoring damaged heart muscle has met with limited success. Due to 
inflammation, fibrosis, and the lack of blood supply, a major challenge in cell therapy 
approaches is maintaining the survival of newly implanted cells [58]. Cell survival rates range 
from 1 to 32% within one week post-injection into injured hearts [59], with three major causes of 
cell death being the loss of ECM support, ischemia, and inflammation. Preparation of cell 
suspensions to be injected into the site of therapy inevitably leads to decreased ECM adhesion-
related survival signals that are important for cell survival; specifically, the loss of cell contacts 
with the extracellular environment eliminates protective signalling pathways [60]. A recent study 
suggests that inhibition of Rho-associated kinase can improve the viability of human embryonic 
stem cells possibly due to the prevention of anoikis [61]. Ischemia that increases the production 
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of reactive oxygen species and mitochondrial dysfunction is followed by inflammation that 
causes a harsh environment leading to cell death. Improved cell survival rates can be achieved by 
stimulating cell protective mechanisms against oxidative stress and inflammation with insulin-
like growth factor-1 (IGF-1) [62-64].  
In addition to the challenges associated with cell death following cell injection, EC-
cardiomyocyte crosstalk plays a very important role in the context of ischemia/ infarction 
injuries and reperfusion. Crosstalk modulates vascular tone and stimulates proliferation of 
neighbouring cells during cell stresses due to ischemia, where ECs might promote the survival of 
cardiomyocytes [65]. Paracrine function of ECs enhances signaling in cardiomyocytes that 
secrete factors affecting EC functionality [66]. The secretion of paracrine and autocrine factors 
may contribute to endogenous and pharmacological cardioprotective pathways during ischemia-
induced cell stresses [67]. In a recent study by Thorsten et al. (2011), observations support the 
hypothesis that ECs contribute to isoflurane-enhanced protection of cardiomyocytes against 
hypoxia, with such protection dependent on a hypoxia-inducible factor and nitric oxide 
[66].  Recent insights in the paracrine modulation of cardiomyocyte contractility by cardiac ECs 
are well reviewed by Noireaud et al. (2014) [68]. 
1.4.2.2. Biomolecule/ biomaterial-induced myocardium self-repair  
In this second approach, bioactive materials and growth factors are injected into the damaged 
myocardium to stimulate heart muscle self-regeneration. Biomaterials such as hyaluronan [69], 
fibronectin, vitronectin, laminin, and collagen [70] enable cell matrix crosstalk that enhances cell 
proliferation in the damaged tissue. In addition, biomaterials can be administered with several 
bioactive molecules (e.g., growth factors, cytokines) that stimulate cells to produce additional 
growth factors that regulate cell proliferation and differentiation in order to potentially stimulate 
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myocardial self-repair [71, 72]. The heart contains progenitor cells that can differentiate to 
cardiomyocytes [73, 75]. In the presence of biomaterials and bioactive molecules that can 
stimulate and instruct the progenitor cells, these cardiac progenitors can potentially differentiate 
into cardiomyocytes for myocardial infarction repair. This strategy of growth factor-mediated 
cardiac regeneration therapy is evolving dramatically by means of catheter-based injection, as 
this therapeutic approach can avoid the need for surgery. Table 1.2 summarizes important 
cytokines and their roles in stimulating myocardial repair.  
Table 1.2. Potential bioactive molecules for stimulating myocardial infarction repair.  
Biomolecule Activity Ref. 
Granulocyte colony-
stimulating factor (G-
CSF) 
- Critical role in regulation of proliferation, differentiation, 
and survival of myeloid progenitor cells 
- Hematopoietic stem cell mobilization 
- Improving cardiac function after myocardial infarction 
- Reducing mortality after acute myocardial infarction 
[76-
79] 
Stromal derived growth 
factor (SDG) 
- Important role in trafficking and survival of hematopoietic, 
endothelial progenitor, and mesenchymal stem cells 
- Augmenting endothelial progenitor cells 
[80-
82] 
Insulin-like growth 
factor (IGF) 
- Enhancing nuclear phospho-Akt and telomerase and 
delaying cardiomyocyte aging and death 
- Improving stem cell homing, healing, and regeneration of 
the injured muscle 
[83-
85] 
Erythropoietin (EPO) - Important for erythrocyte survival and differentiation 
- Maintaining vascular auto-regulation and attenuating 
primary (apoptotic) and secondary (inflammatory) causes of 
[86, 
87] 
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cell death 
- Recruitment of stem cells into the region of damage 
Leukemia inhibitory 
factor (LIF) 
- Increasing cardiac L-type Ca2+channel current 
- Inducing endothelial differentiation in cardiac stem cells 
[88-
90] 
Bone morphogenic 
protein (BMP) 
- Regulation of cardiomyocyte differentiation from 
mesoderm in the heart-forming region 
- Formation of the ventricular chambers and 
septovalvulogenesis in the atrioventricular canal and outflow 
tract 
[91] 
 
1.4.2.3. Cell-containing hydrogel injection for cardiac regeneration therapy 
Hydrogels offer great advantages including shielding cells from the harsh environment of 
ischemic areas, having the ability to be polymerized in situ after injection, mediating growth 
factor delivery to enhance the vasculogenic and myogenic capacity of encapsulated cells, and 
improving cell retention in the heart [92]. Three therapeutic approaches involving injectable 
hydrogels are epicardial, endocardial, and intracoronary injection (Fig. 1.1). Epicardial hydrogel 
injection can be performed through direct injection or can use a catheter to puncture and inject 
the hydrogel into the damaged heart wall. Direct epicardial injection is the most controllable 
injection technique, with the surgeon able to precisely control the location of injection as well as 
the amount of the hydrogel injected via syringe into the ischemic/ infarcted area; however, this  
approach requires an invasive surgical procedure. Because patients with recent myocardial 
infarction are typically at higher risk for conventional surgical approaches, efforts have been 
devoted to employ minimally invasive catheter-based injection approaches to deliver the 
hydrogel into the ischemic/ infarcted myocardium. One such approach is catheter-based 
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Figure 1.1. Schematic diagram of intravenous, intracoronary, and intramyocardial delivery 
of angiogenic factors. 
 
epicardial injection, in which the coronary system is used as a roadmap to the heart and a 
composite catheter system allows for stable access to the remote myocardium with intravascular 
ultrasound and fluoroscopic guidance. Catheter-based transendocardial injection is another 
alternative for minimally invasive hydrogel injection, guided by endoscopic surgical techniques 
to deliver hydrogel into the myocardial infarction region in the left ventricle. Catheter-based 
transendocardial injection may be unstable in the mobile ventricular wall. Contrary to epicardial 
and transendocardial injection approaches that puncture the heart wall, intracoronary injection 
utilizes a percutaneous transluminal coronary angioplasty balloon to deliver the liquid form of 
the hydrogel into the cardiac tissue from the blood stream [93]. This delivery method is unique 
as it uses leaky vessels of the myocardial infarction region rather than puncture injection. In 
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terms of therapeutic yield, intracoronary and catheter-based injection approaches are generally 
less specific than the direct injection method and may potentially decrease the therapeutic yield. 
Considering that catheter technology and endoscopic techniques have been extensively used, 
minimally invasive surgery procedures have been well established, and the safe use of these 
approaches has been demonstrated, many cell and growth factor delivery strategies to maintain 
and repair the infarcted myocardium are moving towards transendocardial injection. This 
delivery method avoids the risk of open chest surgery, reduces the time of treatment post-
myocardial infarction, provides quicker patient recovery, and facilitates clinical translations of 
achievements in cardiac regeneration therapy. Table 1.3 summarizes the advantages and 
disadvantages associated with each of the three clinical hydrogel delivery approaches for 
myocardial infarction repair. The hydrogels used to date for injectable hydrogel-based 
myocardial infarction repair include fibrin, chitosan, alginate, collagen, hyaluronic acid, 
Matrigel, polyethylene glycol, and poly(N-iso-propylacrylamide) [94]. Efforts need to be 
devoted to developing/ improving new biomaterials with unique properties suitable for 
transendocardial injection that have been found promising for in vivo cardiac regeneration. 
1.5. Challenges in myocardial infarction repair 
Despite advances in graft-based and in situ cardiac tissue engineering, cardiac regeneration 
therapy still faces significant challenges associated with cells, biomaterials, and angiogenesis. 
Increasing evidence shows promising results in the area of in vivo regeneration of functional 
myocardium, but issues in this area need to be identified and addressed in future studies. Below, 
the major challenges in the area of cardiac regeneration therapy are outlined. 
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Table 1.3. Pros and cons of epicardial, endocardial, and intracoronary injection approaches. 
Injection 
approach 
Pros Cons 
Intracoronary - Uses standard, routine, and well-
established interventional cardiology 
techniques  
- No direct puncturing of the heart wall 
required 
 
- Material must be non-thrombogenic 
- Gel must set only once delivered to the 
tissue (not in bloodstream) 
- No precise control over the delivered 
volume of the material  
- Limited material delivery to the entire 
infarct due to inadequate vasculature 
- Spatially less specific compared to direct 
epicardial injection 
Direct 
epicardial  
- Precise control over the volume of 
material delivery into the myocardial 
infarction region 
- Clear visual delivery and good control 
over the location of injection 
- Double-barrel syringes can be used to mix 
polymerizable hydrogel materials right 
before injection 
- Surgical procedure required 
- Relatively long patient recovery time 
needed 
 
Catheter-based 
epicardial 
- Short and flexible time for injection post-
myocardial infarction  
- Minimally invasive 
- Stable access to the remote myocardium 
- Precise control over the volume of the 
- Spatially less specific compared to direct 
epicardial injection 
- Needs to be combined with an imaging 
modality 
- Accuracy of localization of ischemic/ 
infarcted area and injection location relies 
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delivered hydrogel 
- No general anesthesia 
on the imaging technique 
- Special training for catheter injection use 
and imaging required  
- Hydrogel biomaterial must remain in 
liquid form during the injection  
- Gel must not set in the catheter 
Catheter-based 
transendocardial  
- Minimally invasive 
- Short and flexible time for injection post-
myocardial infarction  
- Short patient recovery time 
-Well established endoscopic surgery 
procedures and catheter-based techniques 
used 
- Precise control over the volume of the 
delivered hydrogel 
- No general anesthesia 
- Needs to be combined with an imaging 
modality 
- Localization of injections relies on the 
imaging technique 
- Very hard to control the injection into the 
constantly moving ventricle wall 
- Special training for catheter injection use 
and imaging required  
- Biomaterial must be in a liquid form 
during the injection 
- Gel must not set in the catheter 
 
1.5.1. Cell source 
Regardless of cardiac tissue engineering strategy used for myocardial infarction repair, cardiac 
muscle regeneration relies on the source of cells used. Ideally, the cells employed should be able 
to easily expand, proliferate, and differentiate into mature and functional cardiomyocytes. Many 
studies have been performed to evaluate a wide variety of cells for this purpose, including stem 
cells and cardiac progenitor cells, to find an optimal cell source for myocardium regeneration 
[95-98]. Potential cell sources for cardiac tissue engineering are crude bone marrow [99], 
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endothelial progenitor cells [100], umbilical cord cells [101], skeletal myoblasts [102], human 
embryonic stem cells [103], smooth muscle cells [104], fibroblasts [105], fetal cardiomyocytes 
[106], adipose-derived adult stem cells [107], and resident cardiac stem cells [108, 109]. Of 
these, resident cardiac stem cells are known to be endogenous myogenic progenitors; however, 
their numbers are too limited to be reliable in cell-based cardiac regeneration therapy. Induced 
pluripotent stem cells, which are genetically modified adult cells, also have demonstrated 
potential to differentiate into the cardiovascular lineage [110]. Studies show that human 
embryonic-stem-cell-derived cardiomyocytes (hESC-CMs) can result in favourable effects of 
cardiac regeneration therapy in animal models [111, 112]. Recently, Chong et al. showed that 
cryopreservation and intra-myocardial delivery of one billion hESC-CMs can generate extensive 
remuscularization of infarcted monkey heart with a progressive but incomplete maturation within 
3 months [113]. Cardiomyocytes derived from pluripotent stem cells are currently the most 
attractive exogenous myogenic cell source for cardiac tissue engineering although the use of 
undifferentiated cells carries the risk of uncontrolled differentiation [114]. Non-myogenic cell 
sources are also used for vascularization although they do not increase new cardiomyocytes 
[115]. 
A variety of ECs including human dermal microvascular ECs, human umbilical vein ECs 
(HUVECs), bovine aortic ECs (BAECs), and bovine capillary ECs (BCEs) [116] have been used 
as sources of endothelial cells; however, low proliferation rates, limited availability, and 
heterogeneity in EC genotype and phenotype are disadvantages [117]. In addition, HUVECs are 
of macrovascular origin whereas the cells most involved in inflammation, wound healing, and 
vascularization in vivo are microvascular ECs [118]. Human blood outgrowth ECs demonstrate 
stronger contractive function on malleable substrates compared to HUVECs [119]. Furthermore, 
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although HUVECs have been widely used in numerous experimental models for human 
macrovascular ECs, they are incapable of fully representing the metabolic properties and 
interactions of the ECs distributed in the entire organism [120]. These disadvantages have led to 
the use of other sources of cells. Human pluripotent stem cells including embryonic stem cells 
(hESCs) and induced pluripotent stem cells (hiPSCs) are promising sources for the generation of 
healthy ECs [121, 122]. Although hiPSCs and hESCs can unlimitedly self-renew and 
differentiate into various lineages, hiPSCs can be used to derive autologous ECs for regenerative 
medicine applications [123]. Several studies that investigated the therapeutic efficacy of 
pluripotent stem cell-derived ECs in pre-clinical models of ischemic cardiovascular disease have 
shown that these cells can enhance angiogenesis, tissue perfusion, and organ function [124-127]. 
iPSC-derived ECs exhibit the rich functional phenotypic plasticity of mature primary vascular 
endothelium, can be directed to an atheroprotective phenotype via pharmacological stimulus, 
undergo endothelial activation, and maintain dynamic permeability [128]. Furthermore, ECM 
can differentially promote iPSC differentiation into ECs, possibly through binding to various 
types of integrins [129]. Endothelial progenitor cells (EPCs) from peripheral blood or cord blood 
can be also a potential cell source to enhance neovascularization of tissue engineered constructs 
or ischemic tissues. EPCs have been studied for their role in endogenous maintenance and for 
their therapeutic potential in vascular regenerative medicine; despite their obvious potential in 
clinical practice, however, many questions still remain regarding how EPCs actually enhance 
endothelial repair and neovascularization [130]. Furthermore, the number of EPCs in bone 
marrow or peripheral blood is limited and, unlike hESCs which possess the capacity for 
unlimited self-renewal, EPCs usually have limited expansion ability [131].  
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1.5.2. Biomaterials 
Biomaterials are one of the major components of tissue engineering. In addition to 
biocompatibility and biodegradability, they should support cell attachment, differentiation, and 
proliferation; provide mechanical support to cells during ECM synthesis; have an interconnected 
porous structure to allow for tissue ingrowth and vascularization; and possess the desired 
dispensability (e.g., for 3D-printed scaffolds), fluidity (e.g., for injectable hydrogels), and 
thermal sensitivity (e.g., for in situ polymerizing hydrogels). The selection and design of 
biomaterials for myocardial infarction repair strongly depends on the cardiac tissue engineering 
approach adopted. 
In classical scaffold-based cardiac tissue engineering, which aims to reconstruct heart muscle 
tissue using a cell-incorporated construct, the biomaterials must be able to imitate the ECM of 
the myocardium to support the cells, provide mechanical support to the cells, and develop 
contractile functionality while withstanding expansion loads associated with diastolic events. 
Yet, no example of an engineered myocardium made of scaffolds has been reported. In fact, no 
biomaterial is able to beat without cardiomyocytes. Assuming the scaffold contains a sufficient 
population of cardiomyocytes, the transfer of a beating signal from cells to the scaffold strongly 
relies on the softness of the scaffold. If the scaffold is stiff enough to withstand the required 
mechanical loads and stresses, beating signals from cells cannot be adequately transferred. On 
the other hand, if the scaffold is soft enough to beat, it may fail to withstand systolic/ diastolic 
loads. Thus, efforts to build a functional myocardium construct have so far been disappointing 
[132].     
One graft-based cardiac tissue engineering approach applies heart patches made of cell/ bioactive 
molecule-incorporated biomaterials to the infarct region to deliver healthy and functional 
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cardiomyocytes to the damaged area while the patch degrades with time. When using stiffer 
biomaterials, the patches can also serve as a mechanical support to the damaged muscle of the 
left ventricle. Despite successes and promising results with this approach, the most significant 
challenge is associated with designing biomaterials with nonlinear elasticity similar to that of 
heart muscle so the patch and heart can beat together. Some studies indicate promising paths 
towards achieving nonlinear elastic biomaterials for patch-based cardiac tissue engineering [133-
135]. In addition to nonlinear elasticity, another challenge is that the biomaterial stiffness must 
be close to ~50 kPa in normal hearts or 200-300 kPa in congestive heart failure cases at the end 
of diastole. 
Minimally invasive transendocardial injection of hydrogels that contain cells and growth factors 
is potentially the most promising strategy to be translated into clinical practice. As mentioned 
earlier (see §3.2.3), hydrogels injected to the infarct region via image-guided catheter technology 
must be fluidic enough to be easily injected and have a gelling behavior that avoids clogging the 
catheter during multiple injections but results in in situ polymerization once injected. In situ 
copolymerization of two polymeric biomaterials is not an alternative because no double-barreled 
catheter system can facilitate multiple injections without clogging [92]. Thermo-responsive 
polymers and self-assembly polymers with optimized properties can be good candidates for in 
situ polymerization post-injection. Fibrin properties can be adjusted to provide different gelation 
rates [136]; however, due to the multiple injections that last up to an hour, more studies need to 
be done to optimize fibrin properties. Only alginate has reached Phase II clinical trials for 
minimally invasive endocardial hydrogel injection-based cardiac regeneration therapy [137]. 
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1.5.3. Vascularization  
Despite great advances in tissue engineering, much still needs be learned about translating in 
vitro achievements into clinically relevant successes. One major hurdle challenging clinical 
implementation of tissue engineering is vascularization.  
In vitro perfusion bioreactors are often used to supply nutrients and oxygen to cells seeded onto 
tissue engineered constructs; however, creation of an oxygen and nutrient supply from the host 
tissue to the implanted tissue construct or injected hydrogel remains the most challenging issue 
in tissue engineering. Following the injection or implantation of a scaffold, blood circulation is 
the only source of oxygen and nutrients for the cells. 
The issue of vascularization is very critical in cardiac tissue engineering because the ischemic 
and infarct area have already undergone a blood vessel shortage, thus reducing the blood supply 
for the survival of cardiomyocytes and the rate of potential angiogenesis during cardiac 
regeneration therapy. Thus, the success of any cardiac tissue engineering scenario including 
graft- or in situ injectable hydrogel-based approaches requires a timely and effective connection 
to the blood network of the healthy myocardium surrounding the infarcted region. In particular, 
the cardiomyocytes in the center of the hydrogel injected into the infarcted region will require a 
vascular supply of their own because the hydrogel can only supply nutrients for a short period of 
time. Angiogenesis is currently considered the most pressing obstacle for the implementation of 
cardiac tissue engineering and myocardial infarction repair. Due to the high metabolic rate of 
cardiomyocytes within the injected hydrogel at the infarcted region, timely vascularization with 
an intercapillary distance of 19 to 20 μm [138, 139] within the injected scaffold or implanted 
cardiac engineered graft is crucial for cardiomyocyte survival. In the past two decades, many 
studies have been conducted on angiogenesis to promote reperfusion to improve the function of 
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ischemic/ infarcted heart tissue; however, vascularization in a damaged heart muscle or in 
engineered cardiac patches/ injected hydrogels is still a central and unresolved problem for 
myocardial infarction repair [140].  
Stimulating angiogenesis and inosculation [141-146] are principal strategies of vascularization 
within cardiac tissue engineered constructs or hydrogels that are implanted or injected at the 
infarcted region. The first strategy is based on stimulating and guiding the ingrowth of newly 
formed blood vessels into the injected/ implanted scaffold from the surrounding vascular 
network of the host tissue (Fig. 1.2a); the second approach focuses on prevascularization of the 
engineered cardiac graft or injectable hydrogels and interconnection with the host 
microvasculature within a short period of time (Fig. 1.2b). When angiogenesis is the only 
mechanism of vascularization within the injected hydrogel, the physiologically slow blood vessel  
ingrowth (Fig. 1.2a) prevents the timely supply of oxygen and nutrients to myocytes in the 
center. In contrast, inosculation can lead to the rapid establishment of an adequate blood supply 
to the center of the injected hydrogel (Fig. 1.2b). 
1.6. Strategies for engineering microvascular networks 
As previously discussed, new blood vessels are formed by either angiogenesis, which is the 
sprouting of new vessels from pre-existing ones, or vasculogenesis, which is the assembly of 
undifferentiated EPCs. In vitro tube formation by capillary ECs was first reported in 1980 by 
Folkman and Haudenschild, who developed a microvascular network on a gelatin substrate 
within several weeks of culture [147]. Since then, critical factors that affect vascularization have 
been better identified and methods for blood vessel formation have been significantly refined as 
the understanding of vascularization mechanisms has evolved.  
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Figure 1.2. Schematic of principal vascularization strategies: (a) angiogenesis only and (b) 
inosculation within the hydrogel injected into the myocardial infarcted region. 
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It is now well known that insoluble components of ECM including fibrin, fibronectin, 
hyaluronan, and laminin have very critical roles in many events during blood vessel formation 
[148]. The regulation of EC growth, differentiation, migration, pericyte recruitment, and vessel 
formation are largely influenced by cell-cell interactions and growth factors. ECs from human 
tissues behave differently than those from rat or bovine aorta; contrary to ECs from animals that 
spontaneously differentiate into capillary structures, ECs from human tissue require growth 
factor-based regulation and may degenerate in some basic culture conditions [149]. Although 
microvascular cells are mostly involved in inflammation, wound healing, and vascularization, the 
commonly used ECs for vascularization studies are HUVECs isolated from macrovascular 
origins [150]. Endothelial progenitor cells have been also used for capillary formation in 
neovascularization studies [151, 152]. The physicochemical and biological properties of cardiac 
engineered patches or injectable hydrogels have a significant role in regulating vascularization. 
Porosity, morphology, interconnectivity, and size of pores; ability to facilitate localized and 
sustained delivery of growth factors; inclusion of ECM components; cell attachment properties; 
and biodegradability significantly influence vascularized tissue ingrowth. 
In cardiac tissue engineering, speedy establishment of vascularization that provides a high 
microvascular network density is crucial for long-term cardiomyocyte survival; however, it still 
remains a major challenge. Engineering of microvascular networks ranges from controlling 
vascular signalling pathways and cellular interactions to direct assembly of engineered blood 
vessels using microfabrication techniques. Numerous strategies have been proposed in recent 
years to stimulate vascularization within implanted cardiac scaffolds based on the two principal 
mechanisms of endogenous stimulation (angiogenesis only and inosculation, Fig. 1.2), and here 
we highlight those involving different levels of engineering guidance. 
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1.6.1. Stimulating angiogenesis at the implantation site 
Several approaches have been under investigation for improving vascularization of infarcted 
myocardium based on stimulating angiogenesis at the implantation site. These strategies include: 
i) direct angiogenic factor delivery, ii) stem cell-based vascularization at the implantation site, 
iii) scaffold and biomaterial-guided vascular ingrowth, iv) functionalized cardiac scaffolds and 
injectable hydrogels, and v) micro-patterning of bioactive ligands. Direct angiogenic factor 
delivery approaches including intravenous, intracoronary, or intramyocardial delivery of 
angiogenic factors to induce vascularization in ischemic areas have been investigated in recent 
decades; however, many challenges must be overcome before this strategy advances to a clinical 
angiogenesis therapy for humans. Table 1.4 presents important angiogenic factors, their roles, 
associated critical issues, and desired release criteria for angiogenesis stimulation. Recent 
progress in delivery strategies of angiogenic factors and targeting neovascular maturation as well 
as critical challenges in this area have been recently reviewed by Chu and Wang (2012) as well 
as Said et al. (2013) [162, 163]. Stem cell-based approaches for vascular regeneration have 
demonstrated the capacity to replicate, differentiate, and form new blood vessels in a directed 
fashion; however, clinical translations of this strategy have been very limited. Recent advances 
in stem cell-based strategies for vascular regeneration have been reviewed and presented in 
recent articles by Hutton and Grayson (2014), Silvestre (2012), and Leeper et al. (2010) [164-
166].   
1.6.1.1. Scaffold architecture and biomaterial support guidance   
Conceptually, the easiest way to stimulate angiogenesis is to use scaffolds with appropriate 
structures to allow for blood vessel penetration into the scaffold, such as porous collagen 
scaffolds and decellularized porcine myocardial matrix [167, 168]. Recent studies indicate that 
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Table 1.4. Summary of important angiogenic factors, roles critical issues and release 
characteristics. 
Growth 
factor 
Roles Issues Release criteria Ref. 
VEGFa • Motivates proliferation, 
migration, 
differentiation, and 
survival of ECs  
• Promotes vascular 
permeability 
• Short half-life 
• Excessive dose 
causes tumor, leaky 
and congested 
vessels  
• Tightly controlled dose 
• Slow and sustained release  
[153-
157]  
bFGFb • Stimulates proliferation, 
migration, and survival 
of ECs 
• Motivates collagenase 
and plasminogen 
activator 
• Rapid diffusion 
• Mitogen for variety 
of cells 
• Simultaneous release with 
VEGF desired 
[155, 
158] 
HGFc • Promotes motility, 
survival, and invasion of 
ECs  
• Rapid diffusion 
• Short half-life 
• High level of dose and 
sustained release 
[159] 
PDGFd • Promotes vascular 
maturation by regulating 
recruitment and 
proliferation of pericytes 
and SMCse  
• Regulates the integrity 
and survival of ECs  
High dose causes 
vessel destabilization 
• Controlled dose  
• Temporally and 
sequentially controlled 
release  
[160, 
161] 
avascular endothelial growth factor, bbasic fibroblast growth factor, chepatocyte growth factor, dplatelet-
derived growth factor, esmooth muscle cells 
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scaffolds with pore sizes smaller than 200 µm facilitate shallow ingrowth of small-diameter 
blood vessels, whereas those with pore diameters larger than 200 µm allow for deeper ingrowth 
of larger blood vessels [169-171]. Pore interconnectivity is a critically important factor for the 
formation of a hierarchical blood vessel structure. A technique involving salt fusion, porogen, 
and foaming poly(lactic-co-glycolic acid) (PLGA) has been used for increasing the 
interconnectivity of cardiac scaffolds; however, nondirectional high humidity of the fusion 
causes an unpredictable geometry of connecting pores [172]. Modification of these physical 
characteristics of cardiac scaffolds can now be made using micro-biofabrication techniques that 
enable full control over the 3D configuration [173]. Recently, microstructured ice templates have 
been used to fabricate silk fibroin-chitosan (SF-CS) scaffolds with predefined microfluidic 
channels, open-pore surface, and oriented porous structures to enhance cell growth and nutrient 
delivery [174]. A sprayed phase separation technique has been also used for patterning 
polyurethane sheets laminated together to form micro-channeled scaffolds [175]. Fabrication of 
3-D branching and interconnected flow-channel networks comprising multiple tetrahedral units 
using a micro-fabrication technique has provided control over pore size and interconnectivity as 
well as architectural and geometrical characteristics of scaffolds [176]. Another study fabricated 
micropores at different length scales in cell-laden hydrogels by micromolding fluidic channels 
and leaching sucrose crystals [177]. In addition to structural characteristics that can promote 
blood vessel ingrowth into scaffolds, different biomaterial chemical compositions can result in 
different angiogenic responses after scaffold implantation. Recent studies reveal that PLGA 
hydrogel can markedly promote vascular ingrowth, guaranteeing more adequate engraftment 
with the host tissue than collagen, chitosan, and hydroxyapatite hydrogels [178, 179]. Scaffolds 
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made of isogeneic acellular dentin also promote angiogenesis and neovascularization to rapidly 
incorporate the scaffold into the host tissue [180].  
1.6.1.2. Functionalized cardiac scaffolds and injectable hydrogels   
Endogenous blood vessel formation can be stimulated by chemoattractants, such as stromal cell-
derived factor-1, granulocyte monocyte colony-stimulating factor, granulocyte colony-
stimulating factor, vascular endothelial growth factor (VEGF), placental growth factor, 
erythropoietin, and angiopoietin-1 to mobilize EPCs in vivo [181]. Preclinical and clinical 
investigations indicate that therapeutic administration of angiogenic factors, such as VEGF and 
basic fibroblast growth factor (bFGF), to sites of ischemia in the heart can improve regional 
blood flow [182, 183]. Thus, functionalization of injectable and implantable cardiac scaffolds 
with biologically active motifs offers many possibilities for stimulating vascularization in vivo. 
Biologically functionalized scaffolds can be achieved by direct incorporation of growth factors 
into the scaffold, immobilization of GFs onto biomaterials, or encapsulation of GFs within nano/ 
micro-particulate delivery systems that are subsequently incorporated with scaffolds. As direct 
incorporation can reduce the half-life of GFs due to oxidation and proteolysis within the scaffold 
microenvironment, particularly for prolonged release, this approach may be less desirable. Some 
studies have used angiogenic factors covalently immobilized onto biomaterials to promote EC 
proliferation and tube formation of primary rat aortic ECs in vitro [184-186]. Immobilized GF-
based bioactive scaffolds for engineered vascularized cardiac tissues are reviewed by Chiu et al. 
(2010) [187]. Although covalently immobilized angiogenic factors promote localized EC 
proliferation for vasculogenesis, the lack of mobility of the immobilized angiogenic factors 
prevents VEGF diffusion and induction of the VEGF concentration gradient that is considered 
crucial for navigating tip cells in angiogenesis in vivo [188]. Critical regulatory factors of a 
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functionalized cardiac scaffold include the dose, timing, sequence, and sustainability of release 
of angiogenic factors. These factors can be well controlled by hybrid delivery systems consisting 
of particulate delivery vehicles incorporated into injectable or implantable scaffolds, thus 
providing high flexibility in modulating release profiles of multiple angiogenic factors [189]. In 
this context, micro- and nano-particulate delivery systems have pivotal roles in regulating the 
timing, dose, and sequence of release of angiogenic factors for spatiotemporal control of 
angiogenesis stimulation. Table 1.5 summarizes recent studies on micro/ nano-particulate 
delivery systems used for controlled release of different angiogenic factors to stimulate 
angiogenesis or vasculogenesis in vivo or in vitro in cardiac tissue engineering.  
Sequential release of VEGF and platelet derived growth factor (PDGF) through an alginate 
hydrogel in the myocardial infarction region results in blood vessel maturation and stabilization 
as well as improved systolic function of the heart [201]. Prolonged release of VEGF from a 
nanofibrous scaffold functionalized by heparin-binding domain sequence LRKKLGKA and self-
assembling peptide RADA16 promoted angiogenesis, reduced scar size, and improved cardiac 
function [202]. Sequential delivery of VEGF and TAT-HSP27 within 7 and 28 days, 
respectively, to the ischemic heart through a hybrid scaffold consisting of VEGF-loaded PLGA 
microspheres and TAT-HSP27-incorporated alginate reduced muscle degeneration and fibrosis 
and promoted new blood vessel formation in the ischemic site [203]. Sustained release of 
engineered VEGF and immobilized VEGF for myocardial repair through functionalized and 
biodegradable collagen cardiac patches decreased fibrosis and increased vasculature density in 
the infarction site [204, 205]. Sustained release of hepatocyte growth factor (HGF) alone and 
simultaneous release of HGF and IGF at the site of myocardial infarction through an injectable in 
situ forming alginate hydrogel led to significant improvements in angiogenesis post-infarction 
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[206]. Injection of collagen-chitosan hydrogel containing thymosin β4 (Tβ4) to myocardial 
infarcted rat models significantly reduced scar size and improved blood vessel density [207]. 
Reis et al. (2012) developed a thermoresponsive hydrogel made of chitosan conjugated with the 
angiopoietin-1 derived peptide, QHREDGS, and mixed with collagen type I; subcutaneous 
injection of the hydrogel with cardiomyocytes in the back of Lewis rats illustrated its ability to  
 
Table 1.5. Recent in vivo and in vitro studies on nano/ micro-particulate angiogenic factor 
delivery systems for myocardial infarction and ischemia repair. 
Delivery system Composition 
Angiogenic 
factor Type of study Study conclusion Ref. 
Liposome Anti-P-selectin-
conjugated 
VEGF In vivo (targeted 
delivery to rat 
infarcted 
myocardium) 
Improved 
systolic function  
[190] 
Core-shell lipid-
based nanoparticles 
Lecithin containing 
VEGF in core, 
Pluronic-127a in 
shell 
VEGF In vitro (aqueous 
solution at body 
temperature) 
Minimally 
improved 
vascularization 
compared to 
single gel only 
[191] 
Polymeric 
microsphere 
PLGA VEGF In vivo (ischemic 
rat model) 
Increased 
angiogenesis, 
arteriogenesis, 
greater left 
ventricle wall 
thickness 
[192] 
Polymeric Trehalose and rat VEGF In vivo Significant blood [193] 
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microsphere serum albumin in 
succinate buffer 
(subcutaneous 
injection into 
dorsal area of 
Wistar rats) 
vessel formation 
Functionalized 
polymeric 
nanosphere 
Heparin- chitosan 
and γ-PGAb 
FGF In vivo (human 
foreskin 
fibroblasts) 
Enhanced 
angiogenic tube 
formation  
[194] 
Hybrid microsphere Combined alginate 
gel and PLGA 
VEGF In vivo (hindlimb 
ischemia rat 
model) 
Enhanced 
angiogenesis 
[195] 
Functionalized 
nanosphere  
Heparin-
functionalized 
fibrin gel 
VEGF In vivo (rabbit 
model of hindlimb 
ischemia) 
Increased 
angiographic 
score  
[196] 
Nanospheres Dex-GMA and 
gelatine 
VEGF In vivo (rabbit 
model of hindlimb 
ischemia) 
Significant 
increase in blood 
perfusion and 
capillary density 
[197] 
Microsphere PLGA FGF and 
NRG1c 
In vivo (myocardial 
infarction rat 
model) 
Significant 
improvement in 
cardiac function 
[198] 
Nanosphere PLGA VEGF In vivo (mouse 
femoral artery 
ischemia model) 
Increased blood 
vessel volume 
[199] 
Microsphere Collagen VEGF In vitro Induction of 
capillary 
formation of 
human umbilical 
vein ECs 
[200] 
Hybrid microsphere PLGA and alginate Sequential 
delivery of 
PDGF and 
VEGF 
In vivo (myocardial 
infarcted rat 
model) 
Higher density of 
α-actin positive 
[201] 
apoly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide), bpoly(γ-glutamic acid), cneuregulin-1 
localize at the site of injection and retain cells [208]. The hydrogel was more suitable for the 
survival and maturation of transplanted cardiomyocytes in vitro compared to chitosan-collagen 
hydrogel alone. 
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1.6.1.3. Micro-patterning of bioactive ligands 
Micro-patterning and bioprinting offer the possibility to organize cells and bioactive molecules 
in three dimensions in vitro with desired density, functionality, and shape. Considering that an 
intermediate density of ECM components (100-500 ng/cm2) can significantly promote EC tube 
networks (within 1-2 days) [209], it is very important to precisely control the density and 
geometry of ECM-coated substrates for stimulation of vascularization. Micro-patterning of self-
assembled monolayers of alkanethiolates to form islands of fibronectin with various geometries 
on gold led to formation of EC tubular structures on 10-µm wide lines of fibronectin [210]. 
Micro-patterning of chitosan and gelatine also resulted in capillary morphogenesis of ECs on 20-
µm lines of gelatine [210]. In other studies, poly(ethylene glycol) diacrylate hydrogels 
incorporated with various cell adhesion ligands (e.g., Arg-Gly-Asp-Ser (RGDS)) were used for 
two-dimensional and 3D micropatterning of these ligands using photolithographic techniques to 
guide cell adhesion and migration [210-214]. Based on HUVEC adhesion on 50- and 200-µm 
wide hydrogel laser-printed strips, micro-patterning of various concentrations of poly(ethylene 
glycol)-RGDS indicated that tubular formation significantly increased at 100 µg/cm2 after one 
day [209]. Patterned micro-scale regions of poly(ethylene glycol) hydrogels covalently bound 
with RGDS and VEGF accelerated tubulogenesis, forming EC tubes with lumens within two 
days, whereas tubule-like structures formed in two days on RGDS-only control patterns and had 
no observable lumens [215]. Quantification of the effect of pattern size on tubule formation 
revealed that all patterned strips smaller than 35 µm promoted tubule formation; however, the 
percentage of patterns that promoted tubule formation decreased as the pattern size increased 
[215]. 
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1.6.2. Prevascularization and inosculation strategies 
Although widely investigated, angiogenesis is a time-consuming process, as slow as ~5 µm/h 
[216]; thus, angiogenesis-only strategies are unable to prevent the death of cardiomyocytes in the 
center of infarcted myocardium in the initial days after implantation. This pivotal issue has led to 
the emerging field of engineering preformed microvascular networks within injectable or 
implantable scaffolds. Prevascularization of cardiac scaffolds or injectable hydrogels can be 
performed by either in vitro or in vivo approaches. For in vitro prevascularization, different 
combinations of ECs, EPCs, pericytes, smooth muscle cells, and stem cells along with 
angiogenic factors and ECM compounds are incorporated within injectable hydrogels or 
implantable scaffolds to form EC tubular structures in the scaffolds or hydrogels within several 
days to weeks of culturing in vitro. Microvascular networks and branching patterns of ECs can 
be micropatterned using bioprinting within cardiac patches prior to implantation. For in vivo 
prevascularization, both the arteriovenous loop method and avascular grafts in peritoneal cavity 
have been used to vascularize scaffolds prior to explanation and transferring to the defect site.  
The prevascularization approach offers the major advantage of anastomosis of a preformed 
microvascular network to the existing blood vessels of the host tissue in the defect area after 
implantation. This process is termed inosculation and can significantly accelerate vascularization 
of the implanted or injected scaffold in the infarcted and ischemic myocardium. 
1.6.2.1. In vitro spontaneous microvascular network formation 
Coculture of ECs with other cell types, such as pericytes, smooth muscle cells, mural cells, and 
even stem cells, in relevant ECM and angiogenic factors results in the formation of a 
spontaneous capillary-like network [217-220]. In vitro microvascular network formation in 
injectable hydrogels and cardiac patches can increase the chance of inosculation after 
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implantation. Zimmerman et al. (2002) developed a preformed microvascularized and functional 
cardiac hydrogel by seeding cardiac myocytes within collagen type I mixed with Matrigel [221]. 
Anastomosis with host tissue vasculature was accelerated when a fibrin hydrogel containing 
fibroblasts was prevascularized with HUVECs, leading to rapid perfusion and enhanced cell 
proliferation within the transplant [222]. Comparing the abilities of HUVECs and cord blood 
EPC-derived ECs (EPC-ECs) to form a microvascular network and inosculation within fibrin gel 
revealed the better potential of EPC-ECs to anastomose with host vasculature [222]. Co-culture 
of pericytes and a higher density of fibroblasts also accelerated inosculation [222, 223]. Stevens 
et al. (2009) developed cardiac patches containing hESC-derived cardiomyocytes, HUVECs, and 
stromal mouse embryonic fibroblasts that led to the formation of a human EC network 
resembling a vascular plexus [224]. The microvascularized disc-shaped patches formed 
significantly larger cardiomyocyte patches that contained more microvascular networks 
compared to cardiomyocyte-only patches, suggesting the clinical potential of human 
cardiomyocyte microvascularized patches for myocardial infarction repair.  
1.6.2.2. In-vivo prevascularization 
Because spontaneous microvascular formation methods demand complex and time-consuming 
cell isolation, seeding, and cultivation procedures and might not necessarily lead to 
interconnected functional microvessels, in vivo prevascularization has been introduced. This 
approach involves multiple surgeries or an arteriovenous loop to exploit the natural angiogenic 
potential of an organism to vascularize cardiac scaffolds or patches within the body. The scaffold 
is implanted into a well-vascularized host tissue or next to an artery, inducing a random ingrowth 
of microvessels from the host tissue to the scaffold due to angiogenesis that results in functional 
blood-perfused microvessels in the scaffold. The explanted scaffold is then transferred to the 
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defect area for faster inosculation. Using this approach, a 2-mm thick cardiac patch made of 
alginate and proangiogenic factors was implanted on the omentum to generate a microvascular 
network within the scaffold in vivo [225]. The vascularized patch was then explanted after 3 
weeks and implanted onto infarcted myocardium. In another study, the same approach was used 
to generate cardiac patches without the use of exogenous biomaterials [226]. In a recent study, 
Laschke et al. (2011) demonstrated that short-term cultivation of in situ prevascularized scaffold 
accelerated inosculation of preformed microvascular networks after implantation into the host 
tissue [227]. They prevascularized a hydroxyapatite/ poly(ester-urethane) scaffold for 20 days by 
implanting the scaffold in the flank of transgenic mice followed by fractionally destabilizing the 
preformed microvessels for 3 and 10 days by cultivating the prevascularized scaffold in 
Dulbecco’s modified Eagle’s medium (DMEM). They then implanted the cultivated scaffolds 
into dorsal skinfold chambers of FVB/N wild-type mice for inosculation. Ten days after 
implantation, the scaffolds that were non-cultivated or cultivated for 10 days contained many 
preformed non-perfused blood vessels whereas the scaffold cultivated for only 3 days exhibited a 
dense network of red blood cell-perfused microvessels indicating good inosculation [227]. This 
experiment clearly indicated that short-term destabilization of preformed microvessels of the 
scaffold can lead to rapid inosculation with the host tissue. 
Alternatively, cardiac patches or scaffolds can be vascularized by implanting scaffolds into an 
isolation chamber containing an arteriovenous loop [228-230]. In a recent study, a vascular 
pedicle with intact vessels (or using a constructed arteriovenous loop) and flow-through chamber 
were placed into an isolated chamber containing a mixture of cells and hydrogel (Matrigel) 
followed by implantation of the chamber into the groin region of rats [230]. The arteriovenous 
loop was perfused by the femoral vessels for 4-6 weeks. Blood microvascular ingrowth from 
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surrounding tissues vascularized the chamber within 4-6 weeks of implantation [230]. This 
prevascularization approach facilitates the generation of a 2-mm thick vascularized cardiac 
construct with neonatal rat cardiomyocytes [229, 230]; however, the 3-4 day delay in 
establishing the new vascular network causes significant cell death immediately post-
implantation [229]. This issue has been addressed in rats using a flow-through chamber 
containing an intact vascular pedicle [231]. Due to the appropriate-sized inflow and outflow 
conduits (e.g., femoral vessels) for anastomosis, this vascularization approach is very attractive 
for myocardial infarction repair. One disadvantage is the multiple surgeries required for 
implantation, explantation, and re-implantation of the cardiac patch or construct.  
1.6.2.3. Modular assembly and microvascular fragments incorporation  
Modular tissue engineering is a bottom-up approach that aims to create building blocks of tissues 
to then recreate larger tissues. Self-assembled aggregation, micro-patterning of cell-laden 
hydrogels, and direct bioprinting of tissues are different methods of bottom-up tissue 
engineering. The building blocks created are assembled into larger tissues by random packing, 
stacking of layers, or direct assembly. The random packing approach has been used for 
assembling tissue modules to create capillary networks. Microtissues composed of cell-
embedded hydrogels (e.g., collagen) are prepared and confluent layers of ECs are grown on the 
module surface [232]. The tissue modules are packed together to form a macrotissue with 
interconnected tortuous channels, allowing for blood flow in a perfusion bioreactor while 
confluent ECs perform as antithrombogenic factors to prevent clotting [232-234]. The 
interconnection of confluent ECs of modules eventually results in a perfusable and non-
coagulative tissue to be used for implantation [232]. Although modular tissue assembly allows 
for quick assembly of a working microvessel network from a premature vascular network, the 
 37 
initial vasculature is unstable and demands extensive remodeling of parenchymal cells within the 
tissue to stabilize the vessels [235]. Kunz-Schugart et al. (2006) developed 3-D spheroids 
containing fibroblasts and ECs as building blocks to create a microvascular network [236]. The 
packed bed of the spheroids resulted in a complex 3-D network of EC tubular structures with 
extensions of up to 400 µm, lumen formation, pinocytotic activity, and tight junctions [236]. 
Kelm et al. (2010) demonstrated the feasibility of biofabrication of engineered vascularized 
grafts from the tissue spheroids [237]. In a recent attempt to accelerate prevascularization and 
inosculation, vital microvascular fragments (as the biological building blocks of vascular tissue) 
isolated from adipose tissue and seeded onto scaffolds under dynamic conditions significantly 
increased functional microvessel density and interconnections with the host tissue after 
implantation [238]. This finding indicates that vascularization and inosculation of cardiac 
patches and injectable hydrogels can be markedly improved by incorporation of microvascular 
fragments. 
1.6.2.4. Tubulogenesis micro-patterning and micro-fluidic microvessels   
To further control the assembly of building blocks of microvascular networks, omnidirectional 
printing has been used to construct 3-D microvascular networks composed of hierarchical and 
branching topology with microchannel diameters ranging from 200 to 600 µm [239]. A scaffold-
free approach has been also used for assembling tissue spheroids with precisely controlled 
diameter in tubular structures. In this approach, straight agarose rods and uniform multicellular 
spheroids were initially deposited layer-by-layer with a wall thickness of 300 µm [240]. Once the 
tubular structure was assembled, multicellular spheroids can fuse within 5-7 days, resulting in a 
fused tubular structure. The branched pattern of 300 µm spheroids and 0.9-1.2 mm branch 
diameter fused after 6 days of deposition [240]. Although this approach provides accurate control 
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of tube diameter and wall thickness, the absence of a functional endothelium was a shortcoming. 
In another study, ECs embedded within collagen and micro-patterned into 100-µm wide and 50- 
to 100-µm high strips self-assembled into tubular structures that anastomosed with host 
vasculature within 3 days of implantation [241]. The microvessel structures that were initially 
immature with open lumens recruited pericytes and stabilized 28 days post-implantation [242]. 
Microgroove patterns between an explanted artery and a vein with culturing cardiac cells on the 
top of the capillary bed have been used to direct capillary sprouting and generate a beating 
cardiac sheet [243]. Combining photocrosslinking and self-assembled monolayer-based cell 
deposition techniques, a robust 3-D hydrogel scaffold composed of endothelialized hollow 
vascular structures was produced [244]. The endothelialized microchannels provide shear 
conditions associated with flow in the hollow vascular structure that can promote endothelium 
sustainability [245]. Furthermore, anastomosis points can be well defined in the construct to 
enhance the connection between the hollow vascular structures and blood microvessels at the 
implantation site. Thus, micro-fluidic networks designed to mimic human vascular networks 
show promise for rapid in vivo integration with the host tissue.  
Control over spatial patterns of vascular networks using microfabrication techniques allows for 
precise design of anastomosis points, microvascular geometry, tubular diameters, and branching 
direction and angle in fabricated cardiac scaffolds for rapid inosculation. In addition, co-culture 
of parenchymal cells embedding vascular cells in precisely defined patterns has been performed 
using a layer-by-layer biofabrication technique in a tissue engineered construct with limited 
interactions between the populations of the two cell layers [246]. Fabrication of prevascularized 
and functional cardiac constructs and patches by bioprinting techniques allows for rapid 
inosculation of the construct after implantation for effective myocardial infarction repair. Table 
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1.6 highlights the advantages, disadvantages, and challenges associated with vascularization 
strategies in tissue engineering. 
1.7. Challenges  
Despite intense efforts to improve cardiac tissue vascularization, the ability to achieve 
vascularized cardiac scaffolds to provide mature, stable, and functional microvascular networks 
capable of rapid integration with the host tissue remains a major challenge. Sophisticated 
methods based on stimulation of angiogenesis have been developed; however, angiogenesis is a 
time-consuming process and cardiac cells survival relies on rapid blood supply, so these 
approaches alone may not prevent the death of cardiac myocytes in the initial days after 
implantation.  
Recent studies indicate that, in many cases of prevascularized scaffolds, inosculation is observed 
within 4 days of implantation while the ingrowth of new blood vessels into large tissue 
engineered scaffolds can take several weeks via angiogenesis alone. Despite the fact that 
prevascularization promotes inosculation, even this approach is incapable of providing adequate 
blood perfusion to prevent the death of cardiomyocytes in the initial days after implantation 
[265, 266]. This is most likely due to the fact that effective inosculation can only occur when 
preformed microvessels of the implanted scaffold and the pre-existing blood vessels of the host 
tissue simultaneously grow toward each other to form interconnections. Therefore, directed 
sprouting in both the scaffold and the host tissue has a pivotal role in accelerating inosculation 
after implantation. To achieve directed cardiac tissue regeneration and vascularization, 
spatiotemporal control over biochemical and microstructural characteristics of the cardiac patch 
is very crucial. 
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Table 1.6. Advantages, disadvantages, and challenges associated with common tissue 
engineered scaffold vascularization strategies. 
Vascularization 
approach 
Pros Cons Challenges Ref. 
Delivery of pro-
angiogenic factors  
• Well and widely 
investigated 
• Profound effects of 
VEGF alone on 
angiogenesis  
• Significant 
vascularization using 
multiple angiogenic 
factor delivery 
• Minimally invasive 
delivery through 
injectable hydrogels 
into the ischemic 
region 
• Clinically efficient 
and cost effective via 
transendocardial 
hydrogel injection 
• Overdose of 
angiogenic factors 
(e.g., VEGF) can lead 
to aberrant vessels 
and hemangiomas 
• Short half-life of 
angiogenic factors 
dramatically reduces 
their efficacy and 
retention in the target 
zone 
• Microenvironmental 
dose is critical and 
delivery of a single 
angiogenic factor is 
not always the best 
strategy 
• Characterization of 
optimal release kinetics 
and profiles, and dose of 
vital angiogenic factors  
• Development and 
optimization of 
sophisticated delivery 
systems to provide 
sequential and spatio-
temporally controlled 
release of multiple 
angiogenic factors 
• Determination of the most 
effective angiogenic factor 
combinations  
[247-
250]  
Injection of 
transfected cells and 
EPCs within 
hydrogels 
• Genetic alterations 
could improve the 
effectiveness of cell 
transplantation 
• Over-expression of 
angiogenic factors 
can cause 
destabilized 
• Optimization of quantity/ 
number of cells injected to 
the ischemic area 
• Isolation of subsets of 
[247, 
251-, 
255] 
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• Expressions of 
multiple angiogenic 
factors improve 
vascularization 
• Transfected MSCs 
support their survival 
in addition to  
angiomyogenic 
response post-
transplantation 
• Released angiogenic 
factors from 
transfected cells 
facilitate angiogenesis 
• The ability of EPCs to 
differentiate into ECs 
and to initiate new 
vessel formation 
• EPCs can also secret 
angiogenic factors 
and differentiate into 
cardiomyocytes 
• ECs can form 
complex vascular 
network 
vascularization or 
massive blood vessels 
(tumor) 
• Uncontrolled 
angiogenic factor 
release by the 
transfected cells after 
injection 
• EPC-mediated 
vasculogenesis 
essential for 
malignant growth of 
tumours 
• Apoptosis rate of ECs 
in injected gels is 
high 
• Limited proliferative 
potential of mature 
ECs reduces the 
clinical applicability 
EPCs due to the lack of 
consensus on EPC-
defining markers and 
standardized protocols for 
their detection 
 
Functionalized and • Stimulating vessel • Slow vascularization • Sophisticated delivery [201, 
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injectable scaffolds ingrowth into 
scaffolds in vivo 
• Synergistic effect of 
multiple factors 
including biomaterial 
support, GFs, ECM 
components promote 
angiogenesis in vivo 
due to endogenous 
angiogenesis-only 
• Slow inosculation 
• Loss of GF biological 
functionality if GFs 
remain unprotected in 
the scaffold 
systems are required to 
regulate dose, timing, 
sequence, and profile of 
GF release 
231, 
235, 
236]  
Spontaneous 
vascularization in 
biomaterials of 
injectable scaffolds 
and cardiac patches 
• The most close-to-
nature vascularization 
• Functional 
anastomosis based on 
numerous studies 
• Easy to play with 
scaffold/ hydrogel 
composition for 
optimization 
• Ability to use co-
culture of multiple 
cells (e.g., ECs with 
fibroblasts) 
 
• Reduced EC-to-EC 
connections 
• Formation of fibrous 
tissues during 
scaffold degradation 
• Potential host 
inflammatory 
reactions to the 
scaffold polymer/ 
monomers 
• Extremely difficult to 
control due to many 
factors (e.g., multiple 
angiogenic factors, 
scaffold ingredients, 
type of cells) 
involved 
• Vasculogenesis 
mechanism controls the 
vascularization and is not 
well understood 
• Identifying the subsets of 
EPC leading to effective 
vascularization 
• Vessel maturation 
followed by tubular 
formation 
• Adjusting scaffold 
porosity for oxygen 
transfer in bioreactor 
[149, 
221, 
222, 
256-
258] 
Modular tissue • A prominent • Randomized vascular • Presence of ECs alone [235, 
259, 
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assembly  engineering approach 
for vascularization 
• Easily scalable 
• Structurally controlled 
endothelium assembly 
 
networks  
• Lack of components 
for immediate 
anastomosis 
• Extensive tissue 
remodeling essential 
for successful 
engraftment 
• Isolated tissue 
modules may be 
problematic for 
contractive cardiac 
muscle regeneration 
leads to a significant 
vessel regression due to 
immune response 
• Long inosculation time 
(~20 days) to integrate 
with host tissue 
 
260] 
In vivo 
prevascularization 
• Prevascularization of 
thick (2 mm) cardiac 
patches 
• Fast inosculation 
• Fully functional 
vascular network 
formation 
• Multiple surgeries 
required 
• Cardiac cell death 
due to delay in new 
vessel network 
formation (3-4 days) 
• Large and thick scaffolds 
(cms) require appropriate 
anatomical sites on the 
patient 
• Large scaffolds leave 
wound behind on the 
patient after 
vascularization 
[227-
230] 
Tubulogenesis micro-
patterning  
 
• Organized ECs, 
SMCs, and molecules 
in scaffold 
• ECs can self-organize 
into tubular structures 
• Microvessels have 
initially immature 
structures with open 
lumens 
• Weak mechanical 
• Tubular channels need to 
rapidly evolve into stable 
vascular networks 
• Efficient bioreactors to 
accelerate tissue 
[240, 
241, 
261-
263] 
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in 2 days 
• Desired local cell 
density and 
anatomical shape  
• Defined topology and 
tubular structure  
• Promoting 
angiogenesis 
properties of 
microvessel networks 
maturation are required 
• Micro-patterning of 
combinational cells (ECs, 
pericytes) to improve 
vascular maturation  
3D-Bioprinting and 
micro-fluidic 
microvessels 
• Precisely controlled 
geometry of 3D 
complex vasculatures 
in micron 
• Ability to create 
complex hierarchical 
macro- to micro-
vascular trees 
• Forming confluent 
linings 
• Lower chance of 
contaminating 
substrates due to 
contactless printing 
• Defined anastomosis 
points for fast 
inosculation 
• Resolution lower than 
microfluidic 
technique 
• Cell damage due to 
high shear stress 
during ejection and 
the impact of fluid 
drops  
• Potential changes in 
bioactive molecules 
during the inkjet 
delivery process 
• Costly 
• Weak mechanical 
properties of 
bioprinted constructs  
• Potential damage to 
cells and DNA during 
printing 
• Retention of biological 
activity of printed bioinks 
• Retention of printed 
patterns over time 
• Biopaper removal after 
bioprinting 
• Scalability  
• Combinational printing of 
functional ECs, SMCs, 
and fibroblasts to mimic 
intima, media, and 
adventitia 
[256, 
263, 
264] 
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With rapid development in micro-fabrication technologies including bio-printing of engineered 
tissue scaffolds, it becomes increasingly possible to precisely fabricate 3D cardiac constructs 
with spatially well defined microstructural properties to provide physical and biochemical cues 
essential for guided vascularization and cardiac regeneration. To this end, spatiotemporal control 
of GF release is of critical importance and yet remains unachievable. Also, 3D-printing of 
cardiac patches made of soft hydrogels (>98% water) is challenging and needs to be optimized. 
Furthermore, due to low density and weak X-ray absorption coefficient of the hydrogels, 
conventional radiography and X-ray µ-CT provide little or no information of microstructural 
features of the implanted hydrogel-based cardiac patches; thus, development of non-invasive and 
quantitative imaging methods with no contrast agents for visualization and longitudinal 
assessment of the implanted hydrogel-based cardiac patches is strategic priority in cardiac tissue 
engineering.  
1.8. Research objectives  
In overall, this research aims to develop polymeric nanoparticle for regulating GF release and 
non-invasive quantitative imaging techniques for cardiac tissue engineering. Accordingly, 
specific objectives of this research are set as follows: 
• Optimization of nanoparticle fabrication variables that affect the size, polydispersity, 
loading capacity, zeta potential and morphology of the nanoparticles through  
comprehensive experimental and computational studies.  
• Regulation of the release of multiple growth factors to promote angiogenesis in fibrin 
matrix through the development of biologically active bi-layer nanoparticles for time-
delayed release and single polymer nanoparticles for zero-order release kinetics.  
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• Mathematical modeling of release behavior of bi-layer nanoparticles to have a better 
insight into the release mechanism and provide a powerful and efficient tool for 
developing nanoparticles for cardiovascular tissue engineering. 
• Development of a low-dose synchrotron-based in-line phase contrast computed 
tomography for non-invasive visualization and quantitative assessment of an implanted 
3D-printed hydrogel cardiac patch towards monitoring patch degradation as well as 
vascularization and cardiac regeneration guided by the nanoparticles in the patch in-situ. 
1.9. Organization of the dissertation  
The dissertation is organized into seven chapters, including this introductory chapter.  
A literature review on rate-programming of nanoparticulate delivery systems for bioactive tissue 
engineered constructs is presented in Chapter 2. GF release strategies in tissue engineering are 
reviewed, critical factors in release behavior of polymeric nanoparticles are discussed, and the 
role of mathematical modeling of controlled release for designing smart tissue engineered 
scaffolds is elaborated. Moreover, spatiotemporal control of GF release in tissue engineered 
scaffolds is introduced as a challenge in cardiac tissue engineering. 
Chapter 3 presents a comprehensive experimental study, along with the development of a novel 
Geno-Neural model, on the optimization of the nanoparticle fabrication variables, which affect 
nanoparticle characteristics including size, polydispersity, zeta potential, protein loading 
capacity, and morphology. Physical, morphological and release characteristics of the polymeric 
nanoparticles are evaluated at different fabrication conditions. Moreover, the effect of the 
fabrication variables on the structural integrity of the encapsulated protein is investigated.  
In Chapter 4, the development and characterization of bi-layer nanoparticles are explored, the 
structural integrity of the encapsulated protein in the bi-layer nanoparticles is examined, and the 
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performance of the nanoparticles to regulate simultaneous and sequential release of multiple 
angiogenic GFs is assessed in the context of angiogenesis in fibrin matrix hydrogel through an 
ex-vivo study. Furthermore, a validated hybrid computational approach is presented for pre-
programming of release rates of the nanoparticles.   
In Chapter 5, two novel mathematical modeling approaches which are validated by experimental 
data are presented to explore the release mechanisms of the bi-layer nanoparticles. The models 
are implemented to identify and predict critical parameters of the bi-layer nanoparticles involved 
in the polymer degradation and protein release mechanisms for time-delayed release patterns. 
The predictability of the models is discussed by comparing the estimated release parameters to 
measured values and those in literature.   
Chapter 6 presents a comprehensive study on the development of the synchrotron in-line PCI-CT 
that includes 3D-printing of a dual-component hydrogel-based cardiac patch, surgical and patch 
implantation procedure in a rat MI model. The optimum imaging parameters are presented and 
the procedure for lowering the radiation dose is given in details. The imaging performance of 
phase retrieved PCI-CT is compared to that of phase non-retrieved phase contrast imaging and 
magnetic resonance imaging (MRI) for the same sample. The visualized patch microstructural 
features are quantitatively compared to the measured values from stereomicroscope images. 
Moreover, image quality criteria of the developed low dose PCI-CT is evaluated and statistically 
compared to the standard PCI-CT to evaluate the potentials of the PCI-CT for cardiac tissue 
engineering studies.  
Finally, Chapter 7 presents the conclusions drawn from this research. The first section of Chapter 
7 concludes the achievements of this research associated with the development of the rate-
modulated nanoparticles as well as the presented computational models to design and pre-
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program polymeric nanoparticles for cardiac tissue engineering. The second section of Chapter 7 
presents the conclusion drawn from the development of the low-dose synchrotron-based PCI-CT 
for non-invasive quantitative visualization of implanted cardiac patch and cardiac tissues for 
cardiac tissue engineering studies. 
1.10. Contributions of the primary investigator  
The manuscripts included in this thesis are co-authored; however it is the mutual understanding 
of all authors that Mohammad Izadifar, as the first author, is the primary investigator of the 
research work. The contributions of other authors are greatly appreciated and acknowledged in 
this thesis.  
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CHAPTER 2 
RATE-PROGRAMMING OF NANO-PARTICULATE DELIVERY 
SYSTEMS FOR BIOACTIVE SCAFFOLDS IN CARDIAC TISSUE 
ENGINEERING 
“This chapter has been published as “M. Izadifar, A. Haddadi, X. B. Chen and M. Kelly, 2015, 
Rate-Programming of Nano-Particulate Delivery Systems for Smart Bioactive Scaffolds in 
Tissue Engineering, Nanotechnology, 26(1), 012001” According to the Copyright Agreement, 
"the authors retain the right to include the journal article, in full or in part, in a thesis or 
dissertation". 
2.1 Abstract 
Development of smart bioactive scaffolds is of importance in tissue engineering, where cell 
proliferation, differentiation and migration within scaffolds can be regulated by the interactions 
between cells and scaffold through the use of growth factors (GFs) and extra cellular matrix 
peptides. One challenge in this area is to spatiotemporally control the dose, sequence and profile 
of release of GFs so as to regulate cellular fates during tissue regeneration. This challenge would 
be addressed by rate-programming of nano-particulate delivery systems, where the release of 
GFs via polymeric nanoparticles is controlled by means of the methods of, such as 
externallycontrolled and physicochemically/architecturally-modulated so as to mimic the profile 
of physiological GFs. Identifying and understanding such factors as the desired release profiles, 
mechanisms of release, physicochemical characteristics of polymeric nanoparticles, and 
externally-triggering stimuli are essential for designing and optimizing such delivery systems. 
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This review surveys the recent studies on the desired release profiles of GFs in various tissue 
engineering applications, elucidates the major release mechanisms and critical factors affecting 
release profiles, and overviews the role played by the mathematical models for optimizing 
nanoparticulate delivery systems. Potentials of stimuli responsive nanoparticles for 
spatiotemporal control of GF release are also presented, along with the recent advances in 
strategies for spatiotemporal control of GF delivery within tissue engineered scaffolds. The 
recommendation for the future studies to overcome challenges for developing sophisticated 
particulate delivery systems in tissue engineering is discussed prior to the presentation of 
conclusions drawn from this paper. 
2.2 Introduction 
One goal of tissue engineering is to maintain, replace, restore or enhance the functionality of a 
damaged/degenerated tissue/organ by controlling its biological environment [1, 2]. Generally, 
tissue engineering strategies include (i) injection of functional cells into a non-functional tissue, 
(ii) implantation of three dimensional (3D) tissue structures, which are formed in bioreactors, to 
the damaged/degenerated tissue/organ; and (iii) scaffold-based cell delivery to defected tissues 
for an in-situ tissue regeneration. Furthermore, stem cells with tremendous potentials of 
differentiations are opening new avenues for tissue engineering applications [3].   
For all tissue engineering strategies, cellular differentiation, proliferation, and migration are all 
critical processes and must be well regulated. Such controls and regulations are performed by 
growth factors (GFs), which have pivotal roles in instructing specific cellular responses during 
the tissue regeneration process [4]. The specific cellular response trigged by GFs can result in a 
wide range of cell functions, depending on the dose, type, release rate and timing of GF 
presented. The role of GF release profile becomes more critical when multiple GFs are used for 
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regenerative therapy. As such, the dose, release rate, and concentration gradients of different GFs 
need to be spatiotemporally controlled by GF delivery systems to mimic the native release 
patterns of GFs. Particulate delivery systems can perform critical roles in controlling the GF 
presentation patterns. Achieving a successful controlled GF release demands particulate delivery 
systems being well-designed and even optimized. This requires one to understand the release 
mechanisms and critical factors involved, as well as their relationships with GF release profiles. 
This paper presents an overview on recent developments in the field of smart bioactive scaffolds 
and GF delivery strategies in tissue engineering with an emphasis on the rate-programmed nano-
particulate delivery systems in order to mimic natural presentation patterns of GFs. Factors that 
are critical to the rate-programming of nanoparticles are discussed, along with the role played by 
mathematical models for optimizing nano-particulate delivery systems.  This review reveals that 
actively controlled nano-particulate delivery systems, triggered by either external stimuli or 
internal microenvironment conditions, can be of importance in the rate-programming of GF 
release in scaffolds. Strategies for spatiotemporal control of GF release are presented, along with 
their challenges and opportunities for the development of sophisticated delivery systems in tissue 
engineering. 
2.3. Smart bioactive tissue engineering scaffolds 
Tissue engineering generally requires an artificial extra cellular matrix (ECM) to facilitate cell 
adhesion, mechanical stimuli and cell-cell signals for tissue regeneration. In addition, the 
presence of signalling molecules including GFs and cytokines in the microenvironment is 
essential. In fact, the success of cell proliferation, differentiation and migration, leading to tissue 
regeneration, relies on the functionality of the matrix scaffolding cells. Interactions between cell 
receptors (e.g. integrin) and scaffold components (e.g. GFs, ECM peptides, mechanical stimuli) 
 86 
lead to sequential biochemical cascades controlling gen expressions to regulate cellular activities. 
In this regard, the role of bio-functional scaffolds behaving as a natural microenvironment for 
cells in instructing cells for tissue regeneration is inevitable. The concept of smart scaffolds is 
referred to the functionality of biomaterial-based scaffolds to properly supply ECM components, 
deliver signalling molecules, and provide required electrical or mechanical stimuli to guide cells 
for tissue regeneration.  
Generally tissue engineered scaffolds can be made of natural or synthetic biomaterials. Although 
natural biomaterials possess some remarkable properties such as cell adhesion, biodegradability 
and biocompatibility, they suffer from several deficiencies including limited flexibility for 
customizing physical properties of scaffold (e.g. porosity, stiffness), sourcing and inconsistent 
properties from material supplies, antigenicity and possible disease transmission, processing and 
deterioration. In contrast, synthetic biomaterials provide customizable scaffolds with 
reproducible and controllable physical and mechanical properties, degradation time and 
microstructural characteristics that can be manipulated according to particular applications. 
Despite numerous advantages, the lack of cell recognition signals is the major disadvantage of 
synthetic biomaterials. In recent years, there has been a significant increase in the number of 
studies on combining synthetic biomaterials as the frameworks with cell-recognition sites and 
GFs, aimed to facilitate cell proliferation, differentiation, and migration for tissue regeneration.  
In addition, a new trend has emerged in scaffold design to combine different scaffold fabrication 
techniques and different biomaterials to provide cells with mechanical and biological cues at the 
micro- and nano-scales. Combination of these two strategies in development of bioactive 
biomaterials and micro-fabrication of electrically/mechanically cell-stimulating scaffolds can 
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lead to smart tissue engineered scaffolds mimicking the natural cellular environment for tissue 
engineering. 
Fabrication of bioactive scaffolds with properly designed mechanical properties and architecture 
mimicking natural ECM can be achieved using biofabrication techniques such as bioprinting, 
micro-fabrication, electro-spinning, self-assembly, and freeze drying methods. The scaffold 
characteristics are further improved to provide cell adherence properties, present signalling 
molecules, and deliver chemical cues to guide cells towards their proliferation, differentiation 
and migration.   In a recent study, using electro-spinning technique Schulte et al. (2014) 
fabricated a 3D scaffold made of functionalized fibers incorporated into hydrogel possessing cell 
adhesive and spreading properties to mimic ECM microenvironment [5]. Shevach et al. (2014) 
biochemically and mechanically manipulated a double sheet of peritoneum as a natural scaffold, 
which was then seeded with cardiac cells and populated with endothelial cells in order to achieve 
a functional and vascularized cardiac tissue patch [6]. The emerging modular approach, also 
called bottom-up approach, is based on the generation of microscale tissue building blocks that 
resemble micro- and nano-architecture of native tissue to be assembled to form a functional 
tissue. Adopting modular strategy, Lee et al. (2014) successfully printed alginate hydrogel 
containing adipocytes and chondrocytes into an ear tissue construct mimicking ear shape and 
composition allowing for both adipogenesis and chondrogenesis [7]. Using capillary force 
lithography, Kim et al. (2014) fabricated nanopatterned cell culture substrates for vascular tissue 
engineering, in which endothelial cells showed better attachment, rapid EC migration and tubular 
morphology compared to non-patterned substrates [8]. Galler et al. (2011) incorporated basic 
fibroblast GF (bFGF), transforming GF (TGF) and vascular endothelial GF (VEGF) into a cell 
adhesive and enzyme-cleavable hydrogel made of self-assembling peptide nanofibers to 
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encapsulate dental pulp stem cells for dental pulp tissue engineering [9]. Implantation of the 
scaffold led to the formation of a vascularized soft connective tissue similar to dental pulp [9]. 
Hussain et al. (2013) coated chitosan fibers with fibronectin to enhance cell adhesion and 
migration properties and then fabricated an electrospun chitosan scaffold resembling the scale 
and architecture of natural ECM for cardiac tissue engineering [10]. They demonstrated that the 
chitosan nanofibers in the presence of fibronectin resulted in good cellular attachment and  
spreading as well as spatial organization [10]. The biologically active chitosan scaffolds for 
regenerative medicine have been well reviewed by Jiang et al. (2008) and Hyashi et al. (2012) 
[11, 12]. Several studies have shown that degradation rate [13], pore gradient and 
interconnectivity [14] and surface topography [15] of scaffolds have significant regulatory 
impact on cell fates. In addition, the role of ECM components in the scaffold matrix is crucially 
important for regulating cell fates mainly through integrins, substrate-specific receptors on cell 
surface. Among ECM components, fibronectin, collagen type I, II, VI, laminin, vitronectin, and 
osteopontin are typically important ECM proteins which regulate cell proliferation, survival, 
differentiation, and migration within scaffolds by activating several intracellular signalling 
pathways and focal adhesion formation [16-18]. GFs are also critical signalling molecules that 
instruct cells during development. GF-based tissue engineering is an attractive field in tissue 
engineering aiming to control the tissue regeneration process by precise control of GF delivery in 
a local area within the scaffold. An overview on the recent developments of this field has been 
provided by Kangwon et al. (2011) [19]. Despite the important roles of GFs in instructing cells, 
these signalling molecules need to act systematically to exert spectrum effects for tissue 
regeneration. Furthermore, GFs have a short half-life once they are presented to the cellular 
microenvironment. Although most often the precursors of GFs are more stable than active 
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molecules, upon presentation and binding to ECM molecules, the GFs are activated and rapidly 
degraded with a biological half-life of minutes [20, 21].  
Although numerous studies have shown the potential of GF-based tissue engineering, there are 
several major issues that must be addressed before reliable human applications can be 
considered. Table 2.1 shows the most important GFs and the delivery approaches as well as the 
associated biopolymers used in tissue engineering. In the context of GF delivery, the control of 
dose remains one of challenging issues. For example, in a study in which a liposomal delivery 
system containing TGF and a fibrinogen/thrombin/TGF solution were added to porcine full-
thickness defects, liposomal TGF concentrations between 200 and 900 ng/ml stimulated 
chondrogenesis while concentrations above 900 ng/ml caused osteophyte formation [44]. In 
addition to dose, a precise control of sequence (co-delivery or sequential delivery) and timing of  
 
Table 2.1. Most commonly used polymers for GF delivery in tissue engineering. 
Regenerative 
therapy 
Delivered GF Polymer Delivery system Ref. 
Angiogenesis VEGF PLGA1 Scaffold [22] 
 VEGF and Ang-12 Collagen Scaffold [23] 
 VEGF PLGA Microparticles [24] 
 VEGF PCL  Scaffold [25] 
 VEGF and bFGF PLGA Nanoparticles [26] 
 VEGF PEG3  Scaffold [27] 
 VEGF Alginate  Scaffold  [28] 
 VEGF Collagen Microparticles [29] 
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 VEGF and bFGF PEG Scaffold [27] 
 VEGF and PDGF4 HA5/chitosan Nanoparticle [30] 
Bone TGF-β PLA scaffold [31] 
 PDGF Chitosan/ PLA Scaffold [32] 
 rhBMP-27 and rhIGF-
18 
PLGA Microspheres [33] 
 PDGF PCL9 Scaffold [34] 
Cartilage TGF-β Alginate Beads [35] 
 TGF- β Chitosan Scaffold [36, 37] 
 BMP and TGF- β Chitosan Hydrogel [38] 
Dermis EGF10 Gelatin Bilayer scaffold [39] 
 bFGF Chitosan Scaffold [40] 
Mesenchymal 
stem cell therapy 
BMP-2 Chitosan Microspheres [41] 
Ligament PDGF Fibrin Scaffold [42] 
Spinal bone rhBMP-7 HAC11 Hydrogel 
scaffold 
[43] 
1Poly(lactide-co-glycolide), 2angiopoietin-1, 3poly(ethylene glycol), 4platelet-derived 
growth factor, 5hydroxyapatite, 6poly(lactic acid), 7recombinant human bone morphogenetic 
protein-2, 8recombinant human Insulin-like growth factor-1, 9poly(ε-caprolactone), 
10epidermal growth factor,11hydroxyapatite carrier 
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release as well as local concentration gradient of GFs is significantly challenging. Although 
studies have shown that the delivery of multiple GFs can improve tissue regeneration [45], most 
studies have used single GF delivery because of extremely little knowledge about optimum 
sequence and concentration of delivered GFs. These types of information are essentially critical 
for designing and optimizing nano-particulate delivery systems. Table 2.2 summarizes some of 
recent studies on determination of desired release characteristics of GFs for angiogenesis, 
cartilage and bone tissue engineering. 
Despite of the rapid progress, further investigations in developing more sophisticated bioactive 
scaffolds are required. Improvements in smart scaffolds must include spatiotemporal control of  
 
Table 2.2. Desired doses and release profiles of GFs reported by some studies on 
angiogenesis, cartilage, and bone regeneration. 
Regenetive 
therapy 
Type 
of 
study 
GFs Total dose Desired Release 
profile 
Delivery 
system 
Ref. 
 
 
Angiogenesis 
 
 
in-vivo 
 
 
VEGF 
 
 
0.04 µg/g 
 
 
 
 
 
 
 
Alginate/ PLGA 
microspheres 
 
 
[46] 
 
 
Angiogenesis 
 
in-vivo 
& 
in-vitro 
 
 
VEGF 
 
 
0.1 µg/g 
 
 
 
 
 
 
Alginate hydrogel 
 
[47] 
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Angiogenesis 
 
 
 
 
in-vivo 
& 
in-vitro 
 
VEGF 
and  
S1P 
 
100 µg/ml 
and 
1.8 mg/ml 
  
Cellulose hollow 
fiber 
 
[48] 
 
Cartilage 
regeneration 
 
 
 
 
 
in-vitro 
 
TGF-β1 
and 
BMP-7 
 
10 ng/ml 
and 
22.7 ng/ml 
  
Chitosan 
hydrogel 
 
[38] 
 
 
Bone  
regeneration 
 
 
 
 
 
in-vitro 
 
bFGF 
and 
VEGF 
and 
BMP-7 
 
10 ng/ml 
and 
1 ng/ml 
and  
50 ng/ml 
 
 
Direct 
administration to 
the culture 
medium 
 
 
[49] 
review, important aspects of smart delivery systems for controlled release of GFs are 
overviewed. The emphasis will be placed on critical parameters in rate-programming of 
polymeric nanoparticles and potentials of externally triggerable nanoparticles to control GF 
release in tissue engineered scaffolds. 
2.4. GF release strategies in tissue engineering 
Strategies for GF delivery in tissue engineering can be generally classified into two categories: i) 
chemical immobilization of GFs into the scaffold biomaterial and ii) physical encapsulation of 
GFs in the delivery system. In the first delivery approach, GFs are first conjugated with the 
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scaffold biomaterial, which may be mixed with cells for the subsequent scaffold fabrication (Fig. 
2.1a). The presentation of the GFs is regulated based on the extent of binding of GFs to the 
scaffold biopolymeric matrix. The chemical binding and affinity interaction between the GFs and 
the scaffold biomaterial binding domains determine the release rate of GFs. The GF conjugation 
with the scaffold matrix can be either non-covalent or covalent, thereby affecting the release rate 
of GFs from the scaffold.  
In non-covalent incorporation, electrostatic (charge-charge) interaction or indirect interactions 
via intermediate proteins are the major mechanisms for immobilizing GFs in their place within 
scaffolds. Hydrogels containing intermediate proteins such as fibronectin, laminin, collagen, 
elastin or the glycosaminoglycans heparin sulphate, chondroitin sulphate, fibrin, and hyaluronic 
acid can be used to link GFs into the scaffold matrix [50-57]. Due to the affinity of GFs to 
heparin, the surface of extracellular matrix components has been modified by grafting heparin in 
 
Figure 2.1. Schematic diagram of direct GF incorporation into fabricating scaffolds (a) and 
pre-formed scaffold (b). 
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order to bind GFs to the scaffold matrix [55, 56]. Small oligopeptides (e.g. arginine–glycine–
aspartic acid (RGD)) exhibiting adhesion properties have been used for linking GFs to the 
scaffold matrix for prolonged delivery of GFs [57-59]. Covalent binding of GFs with the scaffold 
matrix can provide more prolonged release compared to the non-covalent incorporation. GFs are 
conjugated with the scaffold via functional groups [60]; however, there are some limitations 
including the specificity of functional sites that can be difficult to assign selectively and possible 
loss of bioactivity of GFs due to potential damage to functional groups during immobilization. 
Furthermore, although some GFs can be active in the bound state, some need to be cleaved to 
become active [39] such that enzymatic and hydrolytic reactions, which can potentially affect the 
conformation and biological activity of GFs, will be necessary. Since GFs are immobilized into 
the scaffold matrix, the GF delivery will be localized so that the delivery system will be unable 
to provide GF spatial concentration gradient as a cue to stimulate cell migration and 
proliferation.  
Contrary to the chemical immobilization approach, physical entrapment of GFs in the scaffold 
biomaterials is simple with more flexibility to control the release rate based on the biopolymer 
molecular weight (MW), hydrophobicity and porosity. The GF presentation pattern is regulated 
by the scaffold matrix degradation rate, diffusivity of GFs and the composition and structure of 
the scaffold. One of the simplest ways to physically incorporate GFs into or onto the scaffold 
biomaterials is the immersion of pre-formed scaffolds in a GF solution allowing for diffusion and 
entrapment of GFs into the scaffold matrix (Fig. 2.1b). With the aid of 3D micro-patterning 
technologies, the efficacy of GF delivery have been significantly enhanced by precisely 
controlling the spatial distribution of GF-containing biomaterials within a 3D scaffold. In 
addition, since GFs can diffuse through the scaffold pores, GF concentration gradients as 
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stimulating cues to guide cellular migration can be provided. The drawback of this method is 
associated with low loading capacity, long loading time, burst release, and tightly composition-
dependent release properties of GFs from the scaffold the property of which need to have been 
optimized mechanically, chemically and biologically. Since GFs are exposed to the scaffold 
microenvironment in this delivery approach, the loss of GF bioactivity due to oxidation, 
proteolysis, hydrolysis and enzymatic reactions occurring in the scaffold microenvironment 
remains one of the major issues. One of very prominent approaches to bypass the above 
limitations and also to improve the biofunctionality of the scaffolds is to employ nano-particulate 
delivery systems to modulate GF release profiles and to protect the bioactivity of GFs during the 
release process.  
Generally nanoparticles can be structurally divided into several classes of micelles, dendrimers, 
liposomes, solid-lipid nanoparticles, and polymeric nanoparticles (Fig. 2.2). Depending on 
applications, the size of the nanoparticles varies between 20 and 1000 nm. Among these 
particulate delivery vehicles, polymeric particles provide a wide range of particle size ranging 
from 40-1000 nm (nanoparticles) to 1-100 µm (microparticles). Polymeric nanoparticles offer 
several advantages over other types of nanoparticles including high stability, biodegradability, 
high flexibility in modulating the release rate of GFs, protection properties that significantly 
prevent bioactivity loss of GFs, high loading capacity, feasibility of incorporation of both 
hydrophilic and hydrophobic substances. These distinct characteristics make the polymeric 
nanoparticles very suitable delivery vehicles for controlling the release profile of GFs within the 
scaffolds. GF-loaded polymeric nanoparticles and cells are incorporated into biomaterials which 
are used to fabricate three dimensional tissue engineered scaffolds using bioplotter (Fig. 2.3).  
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Figure 2.2. Typical nanoparticles compared to biological elements. 
 
The release rate of GFs can be manipulated based on different release limiting factors attributed 
to the composition, structure, and architecture of the nanoparticles as well as the mechanisms 
governing the GF release from nanoparticles. Recent studies have successfully used polymeric 
nanoparticles for dual and multiple GF delivery for guiding tissue regeneration [61-63]. The 
advantages offered by polymeric nanoparticles suggest that nano-particulate delivery systems 
have high potentials for controlling GF presentation patterns within bioactive scaffolds.  
2.5. Rate-programming of nanoparticles to control GF release 
One of the most important characteristics of smart scaffolds is their ability to regulating the dose, 
timing and sequence of GF release in the ECM mimicking microenvironment. As mentioned 
earlier, polymeric nano-particulate delivery systems play an important role in protecting GF  
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Figure 2.3. Schematic diagram of incorporation of GF-loaded micro/nanoparticles into 
tissue engineered scaffolds for controlled delivery of GFs to cells. 
biological functionality and controlling GF release profiles within the scaffolds during tissue 
regeneration. The release profile of GFs from nano-particulate delivery vehicles can be either 
pre-programmed by manipulating physicochemical and structural characteristics of polymeric 
nanoparticles, or actively controlled by triggering the nanoparticles in-situ using external or 
internal stimuli. 
2.5.1. Critical factors in pre-programming of polymeric nanoparticles 
Physicochemical properties, architectural and structural characteristics and release mechanisms 
are the most important factors affecting the design of nano-particulate delivery systems to 
provide pre-determined GF release profiles.  
 98 
Chemical properties including polymer hydrophobicity, MW and inherent viscosity, cross-
linking and crystallinity as well as number of functional groups are critical factors affecting 
release kinetics of GFs from polymeric nanoparticles. Besides, pore size, porosity, tortuosity and 
packing density of the polymer matrix constituting the polymeric nanoparticle influence GF 
release profiles from the nanoparticles. Structural characteristics and architectural features such 
as average size, polydispersity, size distribution, zeta potential, number of shells and the type of 
polymer of the shell can significantly affect GF loading capacity and efficiency as well as release 
characteristics of GFs from polymeric nano-particulate delivery systems. These physical 
properties of polymeric nanoparticles are affected by fabrication conditions during the 
preparation of the nanoparticles. A recent study by the authors has revealed that the size, 
polydispersity, zeta potential and protein loading capacity of high MW PLGA nanoparticles are 
significantly (p-value<0.05) affected by the concentration of poly vinyl alcohol (PVA), polymer 
concentration, PVA:organic phase ratio, the interaction between the polymer and PVA 
concentrations, and the interaction between PVA concentration and PVA:organic phase ratio. 
The authors have developed a model to be used for designing PLGA nanoparticle structural and 
physical characteristics, protein loading capacity and efficiency, zeta potential, and optimizing 
the fabrication conditions of the nanoparticles. The number of shells, the thickness and the 
polymer of each shell can significantly contribute to the control of the rate of GF release from 
multi-shelled nanoparticles in which the core contains the GF and the shell(s) acts as a rate-
limiting barrier to delay the GF release. In addition, double-shelled nanoparticles encapsulating 
two GFs in the core and shell allow for sequential release of GFs in various stages to achieve 
synergistic effects of the GFs. Such delivery systems would be useful for the simultaneous or 
sequential release of multiple GFs for expediting GF driven tissue regeneration in tissue 
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engineering [64]. Recently, several triple-walled particulate delivery systems have been 
developed to control release profiles of multiple factors [65-70]. 
Another critical factor affecting the design of nano-particulate delivery systems is associated 
with the mechanism(s) governing GF release from polymeric nanoparticles. In order to design a 
nano-particulate delivery system to provide a pre-determined GF release profile, having a good 
understanding of release mechanisms and their relationship with physicochemical properties of 
polymeric structure of nanoparticles are essential. In general, major release mechanisms in 
polymeric nano-particulate delivery systems include diffusion-dissolution [71-73], erosion [73, 
74], osmotic pump [75], swelling [76], polymer relaxation [77], pore closure [78], and 
heterogeneous degradation, crack formation and collapse of polymer matrix [79-81]. In most 
scenarios, combinations of above mechanisms control the release rate of GFs from the polymeric 
nanoparticles. Diffusion-dissolution mechanism, which is involved in most of release 
mechanisms, is governed by GF solubility and diffusivity in water, porosity, pore size and 
interconnectivity, packing density, and tortuosity of the polymer matrix of nanoparticles. In 
addition, the nanoparticle structure including the thickness and number of shells of nanoparticles 
are the limiting factors influencing mass transfer rate and release rate of GFs in nanoparticles. 
Bulk and surface erosions due to enzymatic reaction, hydrolysis or disentanglement of the 
polymer chains [82, 83], are important mechanisms governing GF release processes in polymeric 
nanoparticles. Bulk erosion is the major release mechanism in PLA, poly(glycolic acid) (PGA), 
and PLGA nanoparticles, which are characterized by ester linkages in the backbone of the 
polymers [84]. Rate of water infusion into the polymer matrix, which is affected by crystallinity 
of the polymeric nanoparticle, porosity and interconnected pores of the polymer matrix, and the 
polymer degradability are the most critical factors controlling bulk erosion mechanism. Bulk 
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erosion is characterised by an initially small increase in GF release from nanoparticles attributed 
to the solubility of GFs at the particle surface followed by a S-shape release kinetics (Fig. 2.4). In 
this mechanism of release, water penetrates into the amorphous regions of the polymer while GF 
release remains low due to low porosity and low pore interconnectivity of the polymer matrix 
(Fig. 2.4b). Over time, polymer hydrolysis causes acidic conditions in water-filled pores 
catalyzing the degradation reactions leading to exponentially increasing pore size within the 
particle. The growth and coalescence of the pores increase the pore interconnectivity [85], which 
boosts GF release rate [86]. When most of the amorphous regions of polymer are degraded, the 
hydrolysis rate gradually decreases due to the remaining crystalline parts [85]. Beside bulk 
erosion, surface erosion is another main mechanism of release in polymeric nanoparticles that are 
made of polyanhydrides because of their low glass transition temperature that causes the polymer 
to rapidly respond to the water erosion [82, 83]. Contrary to bulk erosion, surface erosion 
provides zero order release kinetics. 
 
Figure 2.4. Schematic diagram of GF release during bulk erosion (a-e). 
 
 101 
Swelling that refers to an increase in the volume of a polymeric matrix due to hydration is an 
important release mechanism in which a phase transition in the polymer matrix takes place from 
swells, and performs as a moving front that separates the interior glassy region from the exterior  
glassy state to the rubbery state. In the glassy state, polymer resists water uptake and GFs remain 
immobile in the matrix; however, the superficial layer of the matrix gradually absorbs water, 
swollen part of the matrix. As the water penetrates to the matrix interior, GFs are dissolved in the 
water in the swollen layer enhancing GF release due to an enhanced GF diffusivity [87, 88]. If 
GF diffusivity in water is high, swelling rate will be the rate-limiting factor; however, 
dissolution-diffusion mechanism will control the release process if the GF diffusivity is low [89, 
90]. 
 A critical issue in designing and optimization of nano-particulate delivery systems is associated 
with burst release which is defined as the initial large bolus of GF release before the release rate 
reaches a stable profile. Burst release presents a high initial GF dose to the microenvironment 
and can effectively reduce the life-time of the delivery system [91] with potentially inverse 
therapeutic effects (e.g. massive vessel formation due to a large dose of VEGF [92, 93]. Burst 
release can be caused by minor damages to the shell of nanocapsules leading to serious leaks 
during nanoparticle degradation [94]. Burst release can occur in nanogels where high loading 
conditions increases the chance of trapping more GFs on the surface of nanospheres [95-97]. 
Low polymer MW [96, 98, 99], low polymer concentration [100], high solvent removal rate and 
high drying rate during freeze drying [101-103] contribute to burst release from polymeric 
nanoparticles. Double-shelled particulate delivery systems have exhibited significant reduction in 
burst release due to the rate-limiting role of the exterior shell of the particles [104, 105].  
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2.5.2. The relationship between critical factors and release patterns 
Table 2.3 provides typical release profiles associated with critical factors and release 
mechanisms involved in GF release process. While surface erosion and swelling can provide 
zero order release kinetics of GFs, other mechanisms provide nonlinear release profiles. Table 
2.3 also indicates that GF effective diffusivity and polymer characteristics including polymer 
MW, glassy state, and hydrophilic properties as well as GF effective diffusivity are the most 
influential factors affecting release profiles. A good understanding of the relationship between 
these factors and the GF release profiles (Table 2.3) contribute to the design and rate-
programming of polymeric nanoparticles to provide desired GF release profiles. 
Physicochemical properties and structural characteristics of the polymeric nanoparticles can be 
manipulated so that combined effects of different factors lead to the desired GF release profile 
from the nanoparticles. In fact, rate-programming and optimizing polymeric nanoparticles rely 
on our ability to mechanistically describe the release process based on the critical factors that are 
involved. In this context, mathematical models play very important role in designing 
nanoparticles, analyzing the sensitivity of release kinetics with respect to the physicochemical 
properties of nanoparticles, and rate-programming of GF release.  
The first mathematical models of controlled release systems were developed by Noyes and 
Whitney (1897) and Nernst and Brunner (1904); however, due to oversimplifications associated 
with neglected mass transfer in porous polymer, the models were unable to well describe the 
release process mechanistically. Higuchi (1961) presented a model based on a pseudo-steady 
state mass transfer in a porous matrix but the model was confined to slab shape delivery systems 
[119]. Koizumi and Panomsuk (1995) improved Higuchi model and described the release 
process for non-erodible spherical particles [120]. Recently, Wang et al. (2010) developed an  
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Table 2.3. Critical factors and typical release profiles associated with major release 
mechanisms. 
Release 
mechanism 
Critical factors Typical release profile Ref. 
Dissolution-
diffusion 
Polymer and GF MW↓⇒release rate↑ 
Particle size↓⇒release rate↑ 
Porosity↑⇒release rate↑ 
Tortusity↓⇒release rate↑ 
Polymer/solvent ratio↓⇒release rate↑ 
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[106- 109] 
Surface 
erosion 
Glassy point↓⇒release rate↑ 
Polymer MW↓⇒release rate↑ 
Fatty acid dimmer-sebacic acid 
fraction↑⇒release rate↑ 
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[109, 110, 
111] 
Surface 
erosion & 
dissolution-
diffusion 
Hydration rate↑⇒release rate↑ 
Porosity↑⇒release rate↑ 
Interconnected pores↑⇒release rate↑ 
Tortusity↓⇒release rate↑ 
Glassy point↓⇒release rate↑ 
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[109, 110, 
112, 113] 
Bulk erosion Crystalline/amorphous↓⇒release rate↑ 
Hydration rate↑⇒release rate↑ 
Polymer MW↓⇒release rate↑ 
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[114, 115-
117, 109] 
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Lactic:Glycolic↓⇒release rate↑  
Particle size↓⇒release rate↑ 
Bulk erosion 
& dissolution-
diffusion 
Effective diffusivity↑⇒release rate↑ 
Polymer and GF MW↓⇒release rate↑ 
Lactic:Glycolic↓⇒release rate↑  
Crystalline/amorphous↓⇒release rate↑ 
Particle size↓⇒release rate↑ 
Hydration rate↑⇒release rate↑ 
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[114, 118, 
109] 
Swelling Glassy point↓⇒release rate↑ 
Hydrophilic polymer↑⇒release rate↑ 
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analytical model of dissolution-diffusion with burst release for polymeric particulate delivery 
systems [121]. Sophisticated models include dissolution, diffusion, and erosion governing 
equations which are solved simultaneously to describe bulk and surface erosion mechanisms of 
release for different physicochemical characteristics of polymeric particles [118]. Rothstein et al. 
(2008) recently developed a system of partial differential equations taking into account pore 
formation, diffusion-reaction, hydration, polymer MW change, dissolution, and crystallinity of 
the polymer to describe erosion controlled release process [122]. Table 2.4 summarizes well-
known mathematical models of release process form polymeric particulate delivery systems.  
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2.5.3. The role of mathematical modeling of controlled release for designing smart scaffolds 
One of the challenges that smart bioactive scaffolds are facing to is spatiotemporal control of GF 
release to facilitate cellular fate regulation in-situ. GF-loaded polymeric nanoparticles with 
flexible release characteristics play a crucial role in designing smart scaffolds with 
spatiotemporal GF control capability. Development of such scaffolds requires precise design and 
optimization of structural, architectural and physicochemical characteristics of the GF-loaded 
nanoparticles for pre-programmed GF release profiles within the scaffolds. Mathematical models 
of controlled release of GFs are efficient and effective tools for designing and optimizing GF- 
Table 2.4. Well-known mechanistic models and limitations for controlled release from 
particulate delivery systems. 
Model name Model Limitation Ref. 
Noyes-
Whitney/ 
Nernst-
Brunner 
( )bsAB CCh
SD
dt
dM
−=  
No structural 
characteristics of the 
matrix involved 
Perfect sink condition 
required 
Inapplicable to 
spherical particles 
Constant 
concentration 
gradient during mass 
transfer process 
Unable to describe 
the transient period of 
GF transportation  
[123, 
124] 
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Invalid for polymeric 
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the transient period of 
GF transportation 
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concentration 
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release  
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concentration should 
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the GF solubility in 
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significant errors 
Perfect sink condition 
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High initial excess 
GF 
Constant GF 
diffusivity 
Unable to predict the 
transient period of GF 
transportation 
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Diffusion 
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Bessel 
functions) 
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M(t): Cumulative amount of released GF at time t 
M∞: Cumulative amount of released GF at infinite time 
k0: erosion rate constant  
C0: Initial GF concentration within the polymeric matrix 
r: The radius of sphere, cylinder, or half thickness of the 
slab polymer 
n: Shape factor (n=3, 2 and 1 for spherical, cylindrical 
and slab geometries, respectively) 
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ka: Radial erosion rate constant  
kb: Axial erosion rate constant  
a0, b0: Initial radius and thickness of the cylindrical 
geometry, respectively 
A general model for 
bulk erosion-
controlled release 
Takes into account 
radial and axial 
erosion 
Release rate can be 
well described when 
ka≅ ka  
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Csat:Saturation concentration 
D: Effective diffusivity 
KLero:Linear erosion rate constant for bulk erosion 
Kdis:Dissolution rate constant  
r: Distance from the surface of particle 
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KSero: “S” erosion rate constant for bulk erosion 
 
Amorphous part 
blocked by crystalline 
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-Degradation is 
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causing a release lag 
time  
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Cw: time-dependent water concentration 
Dw: diffusivity of water in the matrix 
k: degradation rate constant 
Mw: polymer MW 
Cs: saturation concentration 
kdis: intrinsic dissolution rate constant 
Csn: normalized solid GF in the polymer matrix 
Can: difference between aqueous agent concentration 
and its maximum solubility 
Cwn: normalized concentration of water 
t: time 
CA: GF concentration 
Unified model for 
both surface and bulk 
erosion-controlled GF 
release 
 
[122] 
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loaded particulate delivery systems to be used in smart bioactive scaffolds. Since the mechanistic 
models take into account GF release critical factors (see section 2.4.1), computational simulation 
of GF release can significantly contribute to the design and optimization of physicochemical and 
structural properties of nanoparticles leading to desired GF release profiles.  Furthermore, the 
models can be coupled with governing equations of nutrient transports and cell 
growth/proliferation/migration [129, 130] in order to not only predict spatiotemporal distribution 
of GFs and cell population within scaffolds but also to assess the efficacy of the smart scaffold 
characteristics for tissue regeneration.  
One of the most important applications of modeling of smart scaffolds can be defined in the 
context of vascularization of implanted scaffolds, which is recognized as a major challenge in 
tissue engineering in general, and in myocardial infarction repair in particular [131]. 
Vascularization of implanted scaffolds includes the formation of new blood capillaries from pre-
existing capillaries of the surrounding tissue and the ingrowth of the vessels into the implanted 
scaffolds. Briefly, endothelial cells of existing capillaries remain undifferentiated unless they 
detect VEGF and/or FGF gradient in the microenvironment where tip cells are formed. The tip 
cells lead the new vessel sprouting while a lumen is created by stalk cells trailing behind the tip 
cells [132]. A steep and directional VEGF gradient leads to a rapid and directional migration of 
tip cells while non-directional VEGF concentration gradient causes very slow tip cell migration 
and dilated blood vessels [133]. To induce blood vessel sprouting into an implanted scaffold 
surrounded by a vascularized tissue, the smart scaffold should not only exhibit ECM 
characteristics but also control VEGF concentration gradient spatiotemporally within the scaffold 
such that the steep and directional VEGF gradient is maintained across the scaffold. Stage-wise 
release strategy can provide a VEGF concentration gradient that gradually travels from the 
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scaffold-tissue interface (scaffold outer boundary) to the scaffold center in order to guide 
capillary growth in the scaffold. Figure 2.5 schematically illustrates an implanted scaffold 
composed of a stage-wise VEGF release system (a three-stage release) to guide tip cells from the 
surrounding tissue into the scaffold. As shown, the symmetric scaffold is composed of three 
zones that include three physicochemically and structurally different VEGF-loaded nanoparticles 
(i.e. low MW, high MW, double-shelled nanoparticles) (Figs. 2.5a-c). The release of VEGF in 
each zone occurs in a timely manner to provide a dynamic VEGF concentration gradient that 
gradually travels from the outer to the inner zone of the scaffold (Fig. 2.5d-f). As seen in Fig. 
2.5a, during the first stage of release, the capillary sprouting takes place from the tissue into the 
first zone of the scaffold due to the VEGF concentration gradient induced by the low MW 
polymeric nanoparticles loaded with VEGF (Fig. 2.5d). As the release rate of VEGF in the first 
zone decreases, high MW polymeric nanoparticles in the second zone start releasing VEGF 
where the induced VEGF concentration gradient directs the capillaries from zone I towards zone 
II of the scaffold (Figs. 2.5b, e). In the third stage of release, a delayed VEGF delivery provided 
by double-shelled nanoparticles occurs in the zone III where the induced VEGF concentration 
gradient guide the blood capillaries from zone II to zone III (Figs. 2.5c, f). Such a spatiotemporal 
release pattern relies on precise design and optimization of VEGF-loaded nanoparticle 
characteristics (e.g. MW, size, structure) that can be achieved using computational simulation of 
the stage-wise release of VEGF.  
Knowing that the average velocity of capillary growth is a function of VEGF concentration 
gradient [131], mathematical modeling of the stage-wise release can be used to predict the VEGF 
release process at different conditions. In general, the mechanistic model consists of a system of 
differential equations as: 
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Figure 2.5. Schematic illustration of stage-wise VEGF release to induce vascularization in 
an implanted smart bioactive scaffold. 
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where R is the release rate, VEGFC is VEGF concentration in the nanoparticle matrix, pd  is the 
average nanoparticle size, PDI is the polydispersity index, Γ is the shell numbers, VEGFC∇
r
 is 
VEGF concentration gradient, dVEGFk _  is the VEGF decomposition rate constant, fε is the 
porosity of the nanoparticle matrix, ψ is VEGF loading capacity, degk is the degradation rate 
constant of the nanoparticle polymer, wC is the water concentration in the nanoparticle, effD  is 
 113 
the effective diffusivity of water, polymerC  is the polymer concentration of the nanoparticle, β is 
the crystallinity index, and ϑ is the hydrophilicity index of the polymeric nanoparticles. The rate-
programming procedure of the VEGF-loaded nanoparticles includes the determination of design 
parameters of the nanoparticles leading to the desired stage-wise release (see Fig. 2.5) of VEGF 
in the scaffold. Figure 2.6 illustrates the procedure for predicting the design parameters of the 
nanoparticles. The design parameters of the nanoparticles including pd , PDI, Γ , dVEGFk _ , ψ , 
polymerC , β , and ϑ are defined and assigned as the inputs to the mechanistic model (Eq. (2.1)). 
The governing equations are solved numerically to simulate the VEGF release process and 
predict spatiotemporal VEGF concentration variations within the scaffold (Fig. 2.6). The results  
 
Figure 2.6. Computational procedure to predict optimum design parameters of 
nanoparticles for a smart bioactive scaffold using a mechanistic model of controlled release 
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from the simulation are then compared to those of the desired VEGF release profile(s), which 
can be determined from experimental studies (see Table 2.2) or estimated based on the average 
rate of vascularization in response to VEGF concentration gradient [131]. If the discrepancy 
between the predicted and desired values is greater than a tolerance, the design parameters will 
be refined based on an optimization algorithm, and the numerical simulation and prediction 
assessment will be performed again. This computational process will continue until the 
simulation results converge to the desired spatiotemporal variation of VEGF release profile 
where the optimum design parameters of the VEGF-loaded nanoparticles are obtained (Fig. 2.6).  
2.6. Actively controlled GF release from nanoparticles 
The concept of actively controllable nanoparticles owes to the behaviour of responsive polymers 
that can undergo large conformational changes in response to environmental stimuli such as 
temperature, pH, particular chemicals, and enzymes. The environmentally induced changes in 
nanoparticle polymeric structure and physicochemical properties affect the mechanisms of 
release involved in GF release process. Thus, external and internal stimuli can be used to 
manipulate GF release characteristics of polymeric nanoparticles performing as actively 
controlled particulate delivery systems in smart tissue engineered scaffolds. Most important 
triggering systems that can be used for modulating the release rate of GFs from triggerable 
nanoparticles are magnetic field resonance, radio frequency and microwave, ultrasound, 
radiation, enzyme-substrate interaction, ion-substrate interaction, and cellular metabolites. The 
externally controlled GF release systems are provided in this section. 
2.6.1. pH-responsive delivery systems 
Acidic and basic conditions caused by cellular activities or enzymatic reactions in biological 
microenvironment can be used for triggering the release of bioactive compounds in tissue 
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engineering. When the microenvironmental pH reaches a certain level, pH responsive polymers 
of delivery systems undergo conformational changes leading to the release of GFs that are 
entrapped or encapsulated by the polymeric particles. These polymeric delivery vehicles are 
stable in physiological pH but their stability declines due to protonation or deprotonation of 
polymer functional groups in acidic and basic microenvironments, respectively. Also, the 
sensitivity of swelling and de-swelling characteristics of these polymers is an important factor 
contributing to actively controlling the release rate of bioactive compounds in response to the 
local pH [134]. Matsusaki and Akashi (2005) successfully used a pH-sensitive biopolymer 
composing of poly(gamma-glutamic acid) and sulfonated gamma-poly(glutamic acid) with 
variable de-swelling properties  at a pH ranging between 2.0 and 6.0 to regulate the release rate 
of bFGF [135]. Kim et al. (2009) developed a thermo/pH sensitive sulfamethazine oligomer-
poly(epsilon-caprolactone-co-lactide)-poly(ethylene glycol)-poly(epsilon-caprolactone-co-
lactide) (SMO-PCLA-PEG-PCLA) that could respond to basic microenvironment (pH=8.0) by 
transforming from gel to sol at 37°C [136]. Poly(acrylic acid), poly(methacrylic acid), poly(2-
ethyl acrylic acid), and poly(2-propyl acrylic acid) are the most investigated pH-responsive 
polyacids [137, 138], and poly(N,N-dimethyl aminoethyl methacrylate), poly(N,N-diethyl 
aminoethyl methacrylate), poly(4-vinylpyridine), and poly(vinyl imidazole) are the most studied 
pH-responsive polybases [139].  
2.6.2. Temperature-triggered delivery systems 
Temperature has been one of the most important triggering stimuli in triggerable controlled 
release systems. The triggering mechanism is based on characteristics of thermo-responsive 
polymers that undergo a significant phase separation at a critical temperature called lower critical 
solution temperature (LCST) and an upper critical solution temperature (UCST), below and 
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above which, respectively, the thermosensitive polymers are completely miscible in the 
hydrophilic microenvironment [122]. Table 2.5 presents well-known thermo-responsive 
polymers with their LCST and biocompatibility, biodegradability and toxicity characteristics  
Table 2.5. Biocompatibility, biodegradability, cytotoxicity, and LCST characteristics of well-
known thermo-responsive polymers [144]. 
 Biocompatibility Biodegradability Biotoxicity LCST(°C) 
PNIPAAm Lack High Unknown 32-37 
PEG-PPO-PEO1 Unknown High Low 5-30 
PEG-PLGA-PEG2 High High Unknown 30-35 
PMPA3 Unknown Unknown Unknown 50.6 
PNVCL4 High High Low 32-34 
EPG5 High Unknown Low 32-42 
PLGA-PEG-PLGA6 High High Unknown 37 
1Poly(ethylene oxide-b-propylene oxide-b-ethylene oxide), 2poly(ethylene glycol-b-(lactic acid-co-glycolic 
acid)-b-ethylene glycol), 3poly(methyl 2-propionamidocrylate), 4poly(N-vinylcaprolactam), 5Eudragit RS and 
polyethylene glycol blend, 6poly(lactic acid-co-glycolic acid-b-ethylen glycol-b-lactic acid-co-glycolic acid) 
[140]. Among these  polymers, poly(N-isopropylacrylamide) (PNIPAAm) is a highly popular 
thermo-responsive polymer which can be modulated for different LCST close to body 
temperature (32-39°C); however, low biocompatibility and potential cytotoxicity of the 
monomers has been drawbacks for using this polymer in tissue engineering. Figure 2.7 
schematically illustrates the conformational changes in a thermo-responsive polymeric particle 
loaded with a bioactive compound. Upon increasing the temperature above LCST, the particle 
shrinks due to the polymer precipitation leading to a positive internal pressure in pores pumping 
the entrapped GFs to the surrounding environment (Fig. 2.7).  
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Figure 2.7. Schematic diagram of temperature-triggered release of GFs from a thermo-
responsive polymeric particle. 
Magnetic resonance (MR), radio frequency (RF) wave, microwave (MW), and ultrasound are 
typically external triggering systems to induce temperature rise in thermo-responsive particulate 
delivery vehicles to trigger GF release within implanted tissue scaffolds (Fig. 2.8a-c). In brief, 
the energy associated with MR, RF (500 kHz, 500 MHz), MW (>3 GHz), and ultrasound (20-
100 kHz) energy is partially absorbed by the polymeric particles while propagating in the tissue. 
Energy absorption agents such as superparamagnetic materials (10-20 nm) (e.g Fe3O4 (ferrite) 
and γ -Fe2O3 (maghemite)) for MR heating and 1.4 nm gold nanocrystals for RF/MW heating are 
incorporated in the core of the thermo-sensitive particulate delivery systems to promote the 
efficiency of the energy absorption by the particulate delivery vehicles (Fig. 2.8d). The energy 
absorption in the core induces temperature rise in the thermo-sensitive polymeric particles that 
undergo conformational changes and release GFs when the temperature exceeds LCST (Fig. 
2.8d).  
Such triggering systems can be used for coordinating multiple GF release from particulate 
delivery systems that include thermo-responsive polymers with different LCST. As shown in 
Fig. 2.8e, three types of thermo-sensitive polymeric particles loaded with GFs can release three 
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Figure 2.8. Ultrasound (a), RF/MW (b) and MR (c) triggering strategies, and schematic 
diagrams for thermo-responsive delivery vehicle behaviour (d), stage-wise GF release (e), 
and temporal control of GF release (f). 
different types of GFs in a stage-wise fashion when the temperature of particles reaches their 
associated LCST with time. Furthermore, in a scaffold with a thermo-responsive polymeric 
particulate delivery system, the release of a GF can be temporally controlled by oscillating the 
external stimuli (MR, RF/MW, ultrasound) leading to fractional release of GF during tissue 
regeneration within the scaffold (Fig. 2.8f). Experimental and computational studies on RF-
induced heating of chitosan scaffolds for controlling spatiotemporal temperature distribution 
within implanted scaffolds have been recently done by Izadifar and Chen (2012) [141]. The heat 
transfer simulation results from their study suggest that periodic RF heating of chitosan scaffolds 
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can be potentially used to temporally trigger GF release from thermo-responsive polymeric 
particulate delivery system in the scaffolds.  For some particular tissue engineering applications 
where the release of a large dose of GF (e.g. VEGF) must be prevented, the temporally 
controlled release fashion allows for regulating the dose of GFs in-situ.      
2.6.3. Light-triggerable delivery systems 
Ultraviolet (UV) and visible lights can be used for externally controlling GF release from 
nanogels within tissue scaffolds. UV radiation can induce phase transition in the gels 
accompanied by reversible volume changes that can be used for releasing GFs entrapped within 
the nanogels [142]. Also, embedding light-absorbing chromophores in the core of nanogels 
makes the polymeric nanoparticles visible-light responsive. Depending on the intensity of the 
light, chromophores generate heat and increase the gel temperature altering nanogel swelling rate 
based on which GF release rate from the nanogels are controlled. The major drawbacks of light-
triggering are associated with low penetration depth of UV and visible light that are largely 
absorbed by the skin. In contrast, near-infrared (NIR) radiation has proven to be a promising tool 
for triggering nano-particulate delivery vehicles within 650-900 nm wavelength [143]. Gold  
nanorodes [144], gold nanoshells [145], and gold nanocages [146] are NIR-energy absorption 
agents that can be used for tuning NIR-induced heating of polymeric particulate delivery systems  
to release GFs within the implanted scaffolds. GF-loaded gold nanocages coated with a thermo- 
sensitive polymer (i.e. PNIPAAm) can entrap GFs inside the cage as the polymer closes the 
pores of the nanocage. After implantation of a tissue scaffold that includes the gold nanocages, 
the site of implantation is exposed to a predetermined dose and exposure time of NIR (Fig. 2.9) 
where gold nanocages absorb NIR radiation that generates heat and causes polymer precipitation  
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Figure 2.9. Light-triggering of GF release using NIR radiation and polymer coated gold 
nanocage. 
opening the nanocage pores leading to GF release into the scaffold microenvironment (Fig. 2.9). 
The applied power of radiation must be adjusted to avoid tissue damage. 
2.7. Spatiotemporal control of GF release in smart scaffolds 
The complex processes of cell migration, differentiation and proliferation typically rely on both 
the presence of particular GFs, and their time-dependent and spatial distributions. For example, 
the first step of angiogenesis demands VEGF, FGF and Ang-2 to destabilize pre-existing blood 
vessels, and to promote the proliferation and migration of endothelial cells to form new 
immature vessels. Next, Ang-1 and PDGF-BB stabilize these newly formed tubes to become 
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mature blood vessels [147, 148]. Sequential and simultaneous delivery of these GFs has been 
shown to enhance vascularization [149, 150]. Despite the significance of such GF delivery 
systems, designing and optimization of spatiotemporal delivery strategies in regenerative 
medicine remain a challenge that requires an interdisciplinary cooperation among cell biologists, 
biomaterial scientists, tissue engineers and clinicians. In this context, rate-programming of 
nanoparticles including pre-programmed polymeric nanoparticles or actively controlled delivery 
systems play a critical role in developing spatiotemporal control of GF release in the cellular 
micro-environments. 
A number of local delivery and spatial gradient systems have been developed for spatial control 
delivery of GFs; however, few studies met the challenge to construct tissue-engineered scaffolds 
to deliver spatial GF concentration gradient. A recently successful approach has been reported by 
Chen et al. (2007) who prepared several scaffolds composed of layered biomaterials 
incorporating different amounts of GFs to provide spatially localized and temporally controlled 
release of GFs [150, 151]. An important issue related to the scaffold-based GF release is 
associated with the release of GFs to the outside of defects that might induce unpredictable 
outcomes; thus spatial control of GF delivery should prevent or reduce the GF release into the 
surrounding healthy tissues [152]. 
Several approaches including direct adsorption of GFs to biomaterials, blending GF-loaded 
microspheres into the scaffolds, and covalently conjugating GFs to the scaffold polymers have 
been studied for controlling spatial distribution of GFs within tissue engineered scaffolds [153]. 
Burst release and low loading efficiency are the major disadvantages of direct adsorption while 
incorporation of GF-loaded particulate delivery system into the scaffold biomaterials provides 
more control over GF release because the release pattern can be controlled not only by the 
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scaffold degradation but also by rate-programming of nanoparticulate delivery system. Yilgor et 
al. (2009) incorporated  BMPs-loaded nanoparticles into/on 3D fiber tissue engineered scaffolds 
made of chitosan and chitosan-poly(ethyleneoxide) (PEO), and found that BMPs retained their 
bioactivities and exhibited different release profiles by releasing the GF from the scaffold to fiber 
first, and then to media [154]. Kim et al. (2006) rate-programmed PLGA nanoparticles by 
conjugating heparin to PLGA nanospheres to achieve long-term, zero-order delivery of bFGF. 
The release of bFGF from the heparin conjugated nanospheres could be sustained for more than 
1 month when the nanospheres were suspended in fibrin gel; and the bFGF release from the 
fibrin gel was controllable by the fibrinogen concentration [155]. Recently, White et al. (2013) 
developed a novel particulate delivery system made of a hydrophilic PLGA-PEG-PLGA triblock 
copolymer with 50:50 and 85:15 PLGA to provide customisable, localised and controlled 
delivery with adjustable release profiles of BMP-2, PDGF and VEGF [156]. Rate-programming 
of the proposed delivery system was performed by mixing two different formulations in order to 
modulate the release kinetics of the GFs [156]. Li et al. al (2011) also developed a double-
layered collagen delivery system for spatiotemporal control over GF delivery [157]. A dense 
layer and a loose layer which incorporated bFGF-loaded chitosan-heparin nanoparticles enabled 
spatiotemporal control of release process such that the release of protein in undesired direction 
was lessened [157]. Furthermore, different release amounts of bFGF from the different layers of 
the membrane resulted in significant difference in cell proliferation when the cells were seeded 
on the different layers of the membrane in-vitro[157]. Rate-programming this type of double-
layered collagen membrane can be potentially used for controlling time-dependent and spatial 
distribution of GFs in regenerative medicine. Several fabrication methods for preparation of 
double and multi-layered particulate delivery systems have been reported [158-164]. 
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Furthermore, collagen structure, which can be influenced by preparation conditions such as 
freezing, drying and/ or cross-linking conditions [165, 166], can affect the release of loaded GFs. 
De Paoli Lacerda et al.  (2005) studied the release characteristics of fluorescent substances which 
bonded covalently with collagen, and found a clear correlation between the release profile and 
the structure of the collagen gels [167]. Therefore, the structure of collagen matrix can also be 
used as a factor for rate-programming the particulate delivery systems to provide a 
spatiotemporal control of GF during tissue regeneration. 
Recently, Ishizuka et al. (2014) developed a spatiotemporal method to control molecular function 
by using silica-based photodegradable nanoparticles [168]. They used a short-term light 
irradiation (20 s) to trigger the release of encapsulated molecules from the network of the 
nanoparticle gel [168]. The nanoparticles prepared under mild conditions can be useful to control 
the spatiotemporal release of GFs in tissue-engineered scaffolds containing the nanoparticles by 
adjusting the time and location of the light exposure to the scaffold.  Furthermore, stimuli 
responsive nanoparticles that have been increasingly gaining more attentions in the field of smart 
scaffolds can also be used to engineer signalling networks and spatial self-organization inside a 
cell environment. Recently, Hoffmann et al. (2014) conjugated magnetic nanoparticles to key 
regulatory proteins in order to spatiotemporally control the Ran/RCC1 signalling pathway that 
regulates the cell cytoskeleton [169].  RanGTP proteins conjugated to superparamagnetic 
nanoparticles were able to provide microtubules to assemble into asymmetric arrays of polarized 
fibres in the presence of a magnetic field [169].  
Rapid developments in 3D printing techniques for scaffold fabrication are opening a new 
window towards precisely controlled release of GFs within tissue engineered scaffolds. Different 
GFs can be pre-loaded into micro/nanospheres which are entrapped in dispensable hydrogels 
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(e.g. alginate) to be used in a 3D bioplotter for fabrication of scaffolds. Micro/nanoparticles, 
made of appropriately selected biopolymers and loaded with different amounts of multiple GFs, 
are entrapped into a hydrogel that will be precisely printed into a 3D scaffold layer-by-layer 
leading to spatially customized GF release profiles in each layer of the scaffold. The release 
characteristics can be modified by rate-programming of particulate delivery system according to 
physicochemical properties of the micro/nanoparticles. Also, when the GF-loaded particles are 
stimuli responsive, time-dependent and spatial GF release can be controlled using external 
stimuli (e.g. MR, light). Thus, if the size of nanoparticles is large enough to avoid diffusing away 
from one location to another, spatial and temporal presentation patterns of multiple GFs may be 
theoretically achieved [170].   
2.8. Challenges and future directions  
The ultimate goal of smart GF delivery systems is to mimic the biological release patterns of GFs 
to effectively orchestrate tissue regeneration in a tissue scaffold. However, the development of 
such delivery systems is facing significant challenges. The optimum dose and release profile of 
different GFs that are involved in various types of tissue regeneration have not been well 
characterized yet. Despite immense studies on GF-based tissue engineering, the number of 
systematic investigations focusing on characterization of optimum GF presentation patterns for 
various tissue regeneration therapies is very limited. Such information is essential to the rate-
programming of GF release profiles in tissue engineered scaffolds. Furthermore, due to the 
various types of GFs that require different release patterns in different issue regenerative 
applications, particulate delivery systems need to provide sufficient flexibilities in modulating 
the spatial and temporal release characteristics of GFs.  
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Spatially micro-patterning of 3D tissue engineered scaffolds incorporated with rate-programmed 
nanoparticles demands further investigation to promote the scaffold bio-functionality to closely 
mimic native ECM.  
A comprehensive characterization of physicochemical, architectural and structural characteristics 
of particulate delivery systems, and a good understanding of the relationship between release 
kinetics of GFs and the critical characteristics of polymeric nanoparticles are essential for 
optimization and development of smart GF delivery systems. In this context, development of 
sophisticated mathematical models, which are powerful and efficient tools for prediction and 
optimization of GF release patterns from nanoparticles, is of critical importance. Moreover, 
comprehensive experimental and computational studies need to be conducted for optimization of 
nanoparticle fabrication variables that influence physicochemical characteristcs of the 
nanoparticles. Furthermore, it is crucially important to develop biologically active nanoparticles 
that enable time-delayed release of GFs, which is essential for sequential release of multiple GFs 
for cardiac tissue regeneration and vascularization. Besides, along with the experimental studies, 
novel computational models are needed for pre-programming of GF release rates of 
nanoparticulate delivery systems incorporated with 3D-printable hydrogels for bioactive 
hydrogel-based cardiac constructs in myocardium tissue engineering. 
Also, further studies on the development of novel stimuli responsive biopolymers that possess 
high biocompatibility, no cytotoxicity and slow conformational changes upon stimulation are 
required. 
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CHAPTER 3 
OPTIMIZATION OF NANOPARTICLES FOR CARDIOVASCULAR 
TISSUE ENGINEERING 
“This chapter has been published as “M. Izadifar, M. Kelly, A. Haddadi and X. B. Chen, 2015, 
Optimization of Nanoparticles for Cardiovascular Tissue Engineering, Nanotechnology, 26(1), 
235301” According to the Copyright Agreement, "the authors retain the right to include the 
journal article, in full or in part, in a thesis or dissertation". 
3.1. Abstract 
Nano-particulate delivery systems have increasingly been playing important roles in 
cardiovascular tissue engineering. Properties of nanoparticles (e.g. size, polydispersity, loading 
capacity, zeta potential, morphology) are essential to system functions. Notably, these 
characteristics are regulated by fabrication variables, but in a complicated manner. This raises a 
great need to optimize fabrication process variables to ensure the desired nanoparticle 
characteristics. This paper presents a comprehensive experimental study on this matter, along 
with a novel method, the so-called Geno-Neural approach, to analyze, predict and optimize 
fabrication variables for desired nanoparticle characteristics. Specifically, ovalbumin was used as 
a protein model of growth factors used in cardiovascular tissue regeneration, and six fabrication 
variables were examined with regard to their influence on the characteristics of nanoparticles 
made from high molecular weight poly(lactide-co-glycolide). The six-factor five-level central 
composite rotatable design was applied to the conduction of experiments, and based on the 
experimental results, a geno-neural model was developed to determine the optimum fabrication 
conditions. For desired particle sizes of 150, 200, 250 and 300 nm, respectively, the optimum 
conditions to achieve the low polydispersity index, higher negative zeta potential and higher 
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loading capacity were identified based on the developed geno-neural model and then evaluated 
experimentally. The experimental results revealed that the polymer and the external aqueous 
phase concentrations and their interactions with other fabrication variables were the most 
significant variables to affect the size, polydispersity index, zeta potential, loading capacity and 
initial burst release of the nanoparticles, while the electron microscopy images of the 
nanoparticles showed their spherical geometries with no sign of large pores or cracks on their 
surfaces. The release study revealed that the onset of the third phase of release can be affected by 
the polymer concentration. Circular dichroism spectroscopy indicated that ovalbumin structural 
integrity is preserved during the encapsulation process. Findings from this study would greatly 
contribute to the design of high molecular weight poly(lactide-co-glycolide) nanoparticles for 
prolonged release patterns in cardiovascular engineering. 
3.2. Introduction 
Cardiovascular diseases remain a critical health issue accounting for ~40% fatalities worldwide. 
Among them, myocardial infarction or heart attack stands out because the cardiac tissue is 
terminally developed and may fail to repair itself. Despite significant achievements in 
cardiovascular therapy, current therapeutic methods have failed to provide a definitive therapy 
for myocardial infarction repair. As such there has been a great interest in cardiovascular tissue 
engineering, which integrates cell biology, engineering, material science and medicine to provide 
a suitable environment for cardiac tissue regeneration and vascularization. One of critical issues 
in cardiac tissue engineering strategies is to carefully regulate the microenvironment by 
controlling the biological conditions in-situ in micro and nanoscale [1]. With recent advances in 
nanotechnology, it has been increasingly possible to rate-program nanoparticles to control the 
delivery of biologically signaling molecules instructing cellular fates for cardiac tissue 
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regeneration and stimulating neovascularization in the myocardial infarction area [2]. In this 
context, growth-factor (GF)-loaded polymeric nanoparticles have received considerable 
attentions [3].  
Among synthetic biopolymers, poly(D,L-lactide-co-glycolide) (PLGA) micro/nan-particles have 
significantly attracted attentions due to its attractive properties, which include (i) 
biodegradability and biocompatibility, (ii) Food and Drug Administration and European 
Medicine Agency approval, (iii) well described formulations and methods of production, (iv) 
protection of loaded substances from degradation, (v) possibility to modify surface properties to 
provide better interaction with biological materials, (vi) possibility to target nanoparticles to 
specific organs or cells, and (vii) commercially available with different physicochemical 
properties [4]. Recent studies have employed PLGA particulate delivery systems to tailor release 
profiles of GFs in the context of cardiovascular tissue engineering and brain regeneration, 
including the sequential delivery of vascular endothelial GF (VEGF) and TAT-HSP27 for 
angiogenesis therapy [5], sustained release of VEGF for neovascularization [6-8], co-delivery of 
VEGF and CoQ10 to improve angiogenesis in myocardial ischemia [9], and sequential delivery 
of GFs to stimulate brain tissue regeneration [10]. The GF release profiles are affected by the 
size, polydispersity index (PDI) and loading capacity of the nanoparticles, while the surface 
charge of the nanoparticles influences the interaction between the nanoparticles and the extra 
cellular matrix components as well as the tissue scaffold components in-situ. Since these 
nanoparticle characteristics are mainly affected by the fabrication conditions, it is very crucial to 
identify the significant fabrication variables and optimize them for desired nanoparticle 
characteristics.  
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Lamprecht et al. [11, 12] studied the effects of bovine serum albumin (BSA) concentrations, 
PLGA concentration, amount of surfactant, volume of the external aqueous phase, and duration 
of homogenization on encapsulation efficiency and the size of PLGA nanoparticles. However, in 
their studies the coupling effects of variables were not investigated [11, 12]. Berchane et al. [13] 
characterized the effect of mean diameter and PDI of PLGA microspheres on release profiles,  
but did not investigate the effects of fabrication conditions on microparticle size and size 
distribution. Jimenez et al. (2010) used a 3-factor 2-level full factorial design to analyze the 
effect of lactic acid ratio and other conditions on the size, zeta potential and encapsulation 
efficiency of methyl trypsin-loaded PLGA particles [14]. While Igartua et al. (1998) reported 
that harsh conditions induced by dichloromethane and ultrasound energy had no significant 
effects on BSA encapsulation in the first emulsification step [15], the observations by Kang and 
Singh (2003) [16] and Bilati et al. (2005) showed that sonication time is a crucially important 
variable affecting the protein loading efficiency and stability [17]. Feczkó et al. (2011) studied 
the influence of fabrication process parameters on the efficiency of BSA encapsulation and 
particle size in 50:50 PLGA nanoparticles based on a 5-factorial 3-level Box–Behnken type 
experimental design; however, they did not analyze the effects of preparation conditions on PDI, 
zeta potential and yield [18]. They observed that the effect of surfactant concentration on protein 
encapsulation efficiency was insignificant and PLGA concentrations above 4% (w/v) decreased 
the protein loading efficiency. Using 3-factor central composite design, Zhou et al. (2013) 
studied the effects of PLGA concentration, surfactant concentration and solvent removal rate on 
encapsulation efficiency and particle size of L-DOPA loaded PLGA nanoparticles [19]. Taken 
together, the aforementioned studies illustrate that nanoparticle characteristics such as their size, 
PDI, surface charge, and loading capacity can be related to the fabrication variables in 
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complicated manners. This raises a great need of multi-objective weighted variable optimization 
approaches in order to determine the optimum fabrication conditions based on desired 
nanoparticle characteristics for cardiovascular engineering applications. Typically, the desired 
nanoparticle size varies from ~100 nm for intravascular applications to ~500-1000 nm for 
scaffold-based cardiac tissue regeneration; while the PDI of the nanoparticles is desired to be less 
than 0.3 for uniform size distribution in all applications. Higher negative surface charge of the 
nanoparticles is more desirable due to the cytotoxicity associated with cationic nanoparticles. 
Also, higher negative zeta potential can enhance the dispersion of the nanoparticles in water and 
physiological systems (e.g. PBS, blood). Higher loading capacity directly increases the loading 
efficiency can provide higher dose. Furthermore, since prolonged release of growth factors is 
generally desired for myocardial regeneration and neovascularisation, the molecular weight 
(MW) of PLGA is an important factor as well.  
The main objectives of this study was to (1) analyze the effects of six fabrication variables on the 
nanoparticle characteristics based on 6-factor 5-level central composite rotatable design (CCRD), 
(2) develop a generalized Geno-Neural hybrid model to predict the nanoparticle fabrication 
outcomes, (3) identify and experimentally validate optimal fabrication conditions to provide 
desired nanoparticle characteristics with preserved structural integrity of the encapsulated 
protein, (4) assess the effects of the fabrication variables on the burst release of the protein from 
the PLGA nanoparticles. High MW PLGA with L:G ratio of 75:25 that contributes to prolonged 
release patterns was used in this study. Ovalbumin (OVA) that has a similar MW as VEGF, 
insulin-like GF (IGF), and transforming GF (TGF) was used as a protein model for 
characterization of loading properties of the nanoparticles. Response surface equations were 
derived and an artificial neural network (ANN) was developed to predict the nanoparticle 
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characteristics of size, PDI, zeta potential and OVA loading capacity with respect to fabrication 
variables. The generalization of the ANN was tested, and then a Geno-Neural hybrid model was 
developed by coupling the ANN with genetic algorithm to search for optimum fabrication 
conditions leading to desired nanoparticle size (150, 200, 250, 300 nm), low PDI (<0.3), high 
negative zeta potential (<-20 mV) and high loading capacity. The predicted optimum conditions 
were experimentally evaluated and the morphology of the nanoparticles was characterized using 
scanning electron microscopy (SEM).  
3.3. Materials and methods 
3.3.1. Materials 
High MW (66,000-107,000 Daltons) ester-terminated PLGA (75:25) with an average inherent 
viscosity of 0.67 dL/g (in chloroform at 30°C) was received from DURECT (DURECT Co., 
Cupertino, CA), and lyophilized OVA (MW: 44,287 Daltons), PVA (MW: 31,000-50,000 
Daltons), phosphate-buffered saline (PBS), and HPLC grade chloroform were the product of 
Sigma (Sigma-Aldrich, MO).    
3.3.2. Fabrication of OVA-loaded PLGA nanoparticle 
PLGA nanoparticles were prepared by a double emulsion-solvent evaporation technique at room 
temperature [20]. Briefly, 125 µl of OVA solution (1.1-9.4% w/v) in PBS (pH 7.4) as the inner 
aqueous phase was added to 1 ml chloroform containing PLGA at variable concentrations 
between 1.6-6.4% (w/v). OVA solution was emulsified in the organic phase for 50 s at 20% of 
total input power (~40 W, 40 kHz) using a probe sonicator (Branson Ultrasonics Co., Ltd., 
Shanghai, China) in an ice bath to obtain the first water-in-oil (W1/O) emulsion system. The 
W1/O emulsion was then added into aqueous PVA solutions (0.25-7% w/v) varying between 1 
and 7 ml as the external aqueous phase followed by sonication for 19-91 s at 40% of total input 
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power (~80 W) to obtain water-in-oil-in-water (W1/O/ W2) double emulsion. Then the 
chloroform was allowed to evaporate under magnetic stirring at different stirring rates between 
93 and 804 rpm for 4 hours. Nanoparticles were then separated by ultracentrifugation (Optima L-
Series, Becman Coulter Inc., Palo Alto, CA) for 20 min at 15,000 rpm. Particles were re-
suspended in double distilled water, washed twice and dried by freeze-drier (LABCONCO, MO) 
at -80°C for 48 h before being used for physical, morphological and loading capacity 
characterization. 1% sucrose solution was used as cryoprotectant to reduce the coalescence of 
nanoparticles during freeze drying. 
3.3.3. Characterization of physical, morphological and encapsulation properties   
The size, PDI, size distribution and zeta potential of nanoparticles were measured by a Dynamic 
Light Scattering technique (Zetasizer, Nano ZS3000; Malvern Instruments, Malvern, UK) based 
on backscattering detection at a scattering angle of 173° at 25°C. Morphology of the 
nanoparticles were characterized by scanning electron microscopy (SEM) where the 
nanoparticles were mounted on stubs, coated with a thin layer of gold with Sputter Coater 
(S150B, Edwards, Crawley, UK) and then were examined under a field-emission scanning 
electron microscope (JSM-6010 LV, JEOL, Ltd., Tokyo, Japan) at 15 kV. 
Loading capacity of the PLGA nanoparticles was measured by extracting and quantifying OVA 
from the nanoparticles. Briefly, nanoparticles were dispersed in 0.1 M sodium hydroxide 
containing 5% of sodium dodecyl sulphate which was incubated at room temperature overnight 
in an orbital shaker. The supernatant was collected by centrifugation at 15’000 rpm for 10 min. 
BCA assay kit (Sigma-Aldrich, MO) was used and OVA concentration was quantified by 
reading the absorbance of the samples at 562 nm using a UV spectrophotometer (Synergy HT, 
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BioTek Instruments, Inc., Winooski, VT). Loading capacity and loading efficiency were 
calculated as follows, respectively: 
NP
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C
C
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100
,
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OVAi
OVAa
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C
η                          (3.2) 
where ψ is the loading capacity (mg OVA/mg nanoparticles), Ca,OVA is the actual OVA 
concentration from direct extraction of the nanoparticles (mg OVA/ml), CNP is the concentration 
of nanoparticles used for the OVA extraction (mg nanoparticles/ml), Ci,OVA is the initial OVA 
concentration used for loading of OVA into nanoparticles (mg OVA/ml), and η is the loading 
efficiency. 
3.3.4. Experimental design 
The main experiments were designed based on six-factor five-level CCRD using statistical 
analysis software (SAS Institute Inc., Cary, NC). The CCRD is ideal for sequential 
experimentation, well suited for fitting quadratic surface for optimization, and can provide 
reasonable amount of information for testing the lack of fit while reducing unusually large 
number of design points [21-25]. A CCRD consists of two-level factorial design points, axial 
points, and center points such that the effects of independent variables are studied at five levels 
of factors coded as -α, -1, 0, 1, +α, where the value of α is calculated to fulfill the rotatability 
and orthogonality in the experimental design. Table 3.1 presents the coded and the corresponding 
actual experimental levels designed using SAS. The CCRD design matrix includes a total 
number of 58 experiments consisting of 32 factorial points, 12 axial points, and 14 replicates at 
the center point for estimation of pure error of sum of squares. This experimental design allows 
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for deriving multiple regression equations including linear, quadratic and two-factor interaction 
terms. The coded variables in CCRD are converted to actual values as: 
Table 3.1. Coded and actual values of nanoparticle fabrication conditions used in CCRD. 
   Coded and actual experimental levels 
Independent variables Symbol  
-α  
(-2.37841) 
-1 0 1 α 
(+2.37841) 
PVA concentration (% w/v) CPVA  0.61 2.40 3.70 5.00 6.80 
PLGA concentration (% w/v) CPLGA  1.62 3.00 4.00 5.00 6.40 
OVA concentration (% w/v) COVA  1.1 3.50 5.30 7.00 9.40 
PVA volumetric phase ratio RPVA  1.97 3.00 3.75 4.50 5.53 
Sonication time (s) t  19 40 55 70 91 
Stirring rate (rpm) S  93 300 450 600 807 
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where ax )1(− and ax )1(+ are the actual low and high values corresponding to coded values of -1 and 
+1, respectively, codedix is the coded values of the design points in CCRD, and aix is the actual 
value corresponding to codedix . 
 3.3.5. Statistical analyses 
Analysis of variance (ANOVA) study was carried out using SAS in order to identify the 
variables having significant effect (p-value<0.05) on size, PDI, zeta potential, yield, and 
encapsulation capacity and efficiency of the nanoparticles. Multiple regression analyses was also 
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performed by SAS to evaluate two-factor interaction influences as well as the linear and 
quadratic effects of fabrication variables on the dependent variables at a probability of 
significance of <0.05. The predictability of the multiple regression equations was assessed based 
on coefficient of determination, mean prediction error, and distribution of residual prediction 
errors. 
3.3.6. Artificial neural network development 
Simulating human brain analytical function, ANNs have an inherent ability to learn and 
recognize nonlinear and complex relationships by experience. In an ANN, basically a neuron 
sums weighted inputs from input connections and then applies a transfer function from which the 
result propagates to the succeeding neurons through outgoing connections. Three distinct layers 
of neurons are input, intermediate and output neurons (Fig. 3.1) that receive signals from the real 
world, process the signals, and return the results, respectively [26, 27]. ANN training is based on 
adjusting synaptic weight and bias values using training and validating datasets in order to learn 
complex relationships between inputs and outputs. In this study, the experimental data collected 
from the CCRD were randomly divided into three datasets, training, validating and testing 
datasets containing 30, 8 and 7 samples, respectively.  
Based on the number of independent and dependent variables, 6 and 4 neurons were devoted to 
the input and output layers. Backpropagation training algorithm based on Bayesian 
Regularization (BR) algorithm combined with Levenberg–Marquardt was used for training the 
ANN model in MATLAB 7.4. The magnitudes of variables in the datasets were normalized 
between -1 and +1 to improve the training process. Since the number of intermediate layers and 
neurons depends on the complexity of the problem, sensitivity analyses were performed to 
determine number of intermediate neurons. The training and validating processes were allowed 
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Figure 3.1. Schematic diagram of the Geno-Neural model and the procedure for 
optimization of fabrication conditions of the nanoparticles. 
to execute until sum of squared error (SSE) and sum of squared weights (SSW) remained 
relatively unchanged and network parameters truly converged and SSE reached its global 
minimum value over iterations. The validating dataset was used to prevent overtraining the ANN 
model. Based on the sensitivity analyses a single hidden layer containing 6 intermediate neurons 
possessing tangent hyperbolic transfer function was used in the ANN. The generalization of the 
ANN model was assessed using a testing dataset, which was not involved in the training process.  
A mathematical representation of the developed ANN model was proposed to facilitate the use of 
the model through simple matrix arithmetic in any spreadsheet by general users as: 
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where iM and iq  are the i
th
 rows of the weight matrix of M and bias vector of q , respectively, 
associated with hidden neurons, N and r  are weight matrix and bias vector of the output layer, 
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O is the output vector normalized between -1 and +1, and P is the input vector containing 
normalized values of the nanoparticle fabrication conditions as: 
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The predicted values ranging between -1 and +1 are converted to the real values of the 
nanoparticle characteristics as: 
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where maxO and minO are vectors containing the upper and lower limits, respectively, of the 
measured values of size, PDI, zeta potential and loading capacity. 
3.3.7. The Geno-Neural hybrid model for optimization of fabrication conditions  
Based on principles of biological concepts of evolution and genetics, genetic algorithm is 
essentially an iterative, population based and parallel global search algorithm. In this study, the 
ANN model was coupled with genetic algorithm to establish a Geno-Neuro model to search for 
optimum fabrication conditions of OVA-loaded PLGA nanoparticles. Figure 3.1 illustrates the 
Geno-Neuro system in which the ANN model predicts the outcomes of the genes (fabrication 
variables) in the current generation which undergo crossover, mutation, selection and elitism 
(genetic operators) and then evaluated by a fitness function in order to generate the next 
generation. The genes of the new generation undergo the same evolving process until a stopping 
criterion (e.g. termination generation) is met. In the present study, Genetic Algorithm for 
Optimization Toolbox (GAOT) in MATLAB was used for developing the Geno-Neuro system. 
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Initial population was randomly generated and a pre-specified number of generations were 
assigned as the evolution stopping criterion. The ANN model preformed as a predictor of particle 
size, PDI, zeta potential, and loading capacity corresponding to PVA, PLGA and OVA 
concentrations, PVA volumetric ratio, sonication time, and solvent removal rate representing the 
genes of the individuals in the current generation. The fitness of the genes of the individuals 
were then evaluated based on a weighted multi-objective fitness function as:  
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where f  is the fitness function, TpD is the desired size (nm), TPDI is the desired PDI, and w1, w2,  
w3 and  w4 represent the weights associated with the importance of each term in the fitness 
function for optimization. The variables were normalized between 0 and +1 in order to scale the 
terms in the fitness function into the same range of magnitude. The weights of 0.35, 0.35, 0.1, 
and 0.2 were assigned to w1, w2, w3 and w4 associated with the terms of size, PDI, loading 
capacity and zeta potential, respectively, in Eq. (3.7). The initial population of 5000, number of 
generations of 100, selection rate of 0.08, mutation rate of 0.05, and crossover rate of 0.6 were 
determined by performing sensitivity analyses, and then applied to the Geno-Neural model to 
search for optimum fabrication conditions by maximizing the fitness function (Eq. (3.7)). 
3.3.8. Release kinetics   
The release kinetics of OVA from the high MW PLGA (75:25) nanoparticles was characterized 
in-vitro based on a fractional factorial design corresponding to the CCRD axial points (-α and 
+α) (Table 3.1) including PVA, OVA and PLGA concentrations, and sonication time at an 
external aqueous phase ratio of 4 and stirring rate of 450 rpm. Pre-weighed OVA-loaded 
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nanoparticles were added to PBS solutions in vials for release measurements at 9 time points (0, 
1, 3, 5, 9, 14, 17, 20 and 24 days) under standard tissue culture conditions (37°C, 5% CO2). BCA 
protein assay (Sigma-Aldrich, MO) was used to determine OVA concentrations at each time 
point based on the absorbance of the solution at 562 and 572 nm using UV spectrophotometer. 
Time-dependent changes in OVA cumulative concentration were used to analyze the OVA 
release profiles from the nanoparticles prepared at different fabrication conditions. Minimizing 
sum of squared residuals, the modified Weibull function [28] was fitted into the experimental 
release data in order to estimate the initial burst release of OVA corresponding to the fabrication 
conditions: 
( ))exp(1)( βϑtXtX burst −−+=                        (3.8) 
where )(tX  is the fraction of OVA released at time t, burstX  is the fraction of OVA released due 
to the initial burst effect, ϑ  is a scale factor corresponding to the apparent rate constant, t is time, 
and β is a shape factor. After the values of initial burst release associated with the fabrication 
variables were determined, ANOVA study was carried out to identify the fabrication variables 
having significant effects (p-value<0.05) on OVA burst release. 
 3.3.9. Circular dichroism (CD) spectroscopy   
CD spectra were recorded using Chirascan Plus CD Spectrometer (Applied Photophysics Ltd, 
Surrey, UK) to assess the structural integrity of OVA during the loading and release processes at 
the nanoparticle fabrication conditions proposed by the Geno-Neural model. CD data were 
collected from 205 to 260 nm at a scan time of 0.5 s per point with a step size of 1 nm at 20°C 
using a quartz cell with 0.1 cm path length. Data were averaged over 5 scans and expressed as 
millidegrees. OVA solution (9% w/v) in PBS was used as the reference for CD spectroscopy.  
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Since the burst release is attributed to the dissolution of non-encapsulated protein molecules on 
the surface or from the cracks of the nanoparticles [29], the OVA released by the burst effect is 
less likely affected by PLGA bulk degradation, and its secondary structure during the fabrication 
process can remain in the same state during the burst release. As such, if the OVA collected from 
the burst release is denatured; its secondary structure has been affected by the nanoparticle 
fabrication conditions rather than PLGA bulk degradation. Therefore, OVA samples from the 
burst release (within the first 18 hours according to the release profile) were used for CD 
spectroscopy to evaluate the effect of nanoparticle fabrication conditions on the structural 
integrity of OVA. Furthermore, OVA samples were collected after 15 days to be assessed for the 
structural integrity during the release process based on an optimum fabrication condition 
proposed by the Geno-Neural model. Samples were concentrated at room temperature using a 
vacuum concentrator (LABCONCO., MO), filtered using filter syringe (0.45 µm), and degassed 
at 560 mmHg and 25°C for an hour before they were used for CD spectroscopy. CD Spectra 
Deconvolution software Ver. 2.1 (Gerald Böhm, Germany) was used for deconvolution of the 
CD spectra in order to estimate the percentage of alpha-helix, anti-parallel and parallel beta 
sheet, beta-turn and random coil of the secondary structure of ovalbumin of the samples. The 
recorded CD spectra and the deconvolution results of the samples were compared to those of the 
standard to evaluate changes in the secondary structure of OVA samples.  
3.4. Results and discussion 
Preliminary experiments were performed with chloroform and dichloromethane at the same 
fabrication conditions and the results showed that chloroform could result in smaller particle 
size. In the second screening experiment with chloroform, three solvent evaporation times (2, 4, 
6 hours) were applied to the solvent extraction/evaporation process performed in 30 mL and 100 
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mL of water as the solvent extraction/evaporation medium at 400 rpm and room temperature. 
The two-hour evaporation time with water volume of 30 mL led to a relatively high PDI and low 
loading capacity, which could be attributed to insufficient polymer hardening time that can 
increase the chance of coalescence and collapse of the particles during ultracentrifugation. In 
contrast, a relatively low PDI with spherical geometries of nanoparticles and enhanced loading 
capacity were observed when the evaporation times of 4 hours and 6 hours at 100 mL stirring 
water (data not shown) were applied. As such, based on the preliminary screening observations, 
chloroform was used as the organic solvent, and a solvent evaporation time and water volume of 
4 hours and 100 mL, respectively, were applied to the double-emulsion solvent evaporation 
method for the entire study. 
3.4.1. CCRD-based measurements and significant fabrication variables 
Table 3.2 shows the measured values of size, PDI, zeta potential, yield and loading capacity of 
OVA-loaded nanoparticles corresponding to the fabrication conditions defined by the 6-factor 
CCRD. As for the pure error calculation, standard deviations of the response variables at the 
central point were 14.6 nm, 0.02, 0.06, 0.98 mV and 3 µg OVA/mg nanoparticle for size, PDI, 
yield and zeta potential, respectively, which are reasonably acceptable.  
For the statistical analyses, linear and quadratic effects of the fabrication variables as well as the 
linear interactions were taken into account to identify the factors having significant effects (p-
value<0.05) on the size, PDI, zeta potential, loading capacity, and loading efficiency. Results 
from ANOVA, as presented in Table 3.3, revealed that PVA concentration not only had linear 
and quadratic effects on nanoparticle size but also its linear interaction with PLGA concentration 
was significant. The linear interaction between sonication time and external aqueous phase 
volume ratio also significantly affected the size of particles. While the external aqueous phase 
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volume ratio had both quadratic and linear effect on PDI, OVA concentration only exhibited a 
quadratic effect. Interactions between sonication time and PVA concentration, OVA and PLGA 
concentrations, and PLGA and PVA concentrations significantly affected the variation of 
nanoparticle size during the fabrication process. Zeta potential was affected by PLGA 
concentration and its interactions with PVA concentration and PVA volume ratio. PVA 
concentration and its volumetric ratio as well as OVA concentration and its interaction with 
PLGA concentration significantly affected loading efficiency. The loading capacity is affected 
by PLGA concentration, and linear interactions between OVA concentration and PVA 
concentration as well as PVA volumetric ratio. ANOVA results (Table 3.3) indicate that unlike 
solvent removal rate that has no significant effect, PLGA and PVA concentrations are very 
important variables that either their linear/quadratic effects or their interactions with other 
variables significantly affect the size, PDI, zeta potential, loading capacity and encapsulation 
efficiency. The linear interaction between PVA volume ratio and PVA concentration had a 
significant effect on the nanoparticle fabrication  yield. 
Table 3.2. Measured values of size, PDI, zeta potential, yield and loading capacity of nanoparticles 
corresponding to the fabrication conditions defined in the 6-factor CCRD. 
CPVA 
(%) 
CPLGA 
(%) 
COVA 
(%) 
RPVA 
 
t 
(s) 
S 
(rpm) 
Dp 
(nm) 
PDI ξ  
(mV) 
Y 
(%) 
ψ  
(µg OVA/mg PLGA) 
2.4 3.0 3.5 3.0 40 300 340±20 0.45±0.05 -24.1±0.5 0.66 89±5 
2.4 3.0 3.5 3.0 70 600 341±11 0.41±0.04 -23.1±0.7 0.66 105±5 
2.4 3.0 3.5 4.5 40 600 304±12 0.45±0.06 -19.9±0.9 0.67 107±2 
2.4 3.0 3.5 4.5 70 300 292±27 0.41±0.04 -21.3±0.8 0.64 94±2 
2.4 3.0 7.0 3.0 40 600 315±22 0.35±0.07 -22.7±0.9 0.73 97±1 
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2.4 3.0 7.0 3.0 70 300 267±7 0.29±0.04 -23.5±0.4 0.66 87±5 
2.4 3.0 7.0 4.5 40 300 290±10 0.31±0.03 -19.8±2.8 0.64 144±5 
2.4 3.0 7.0 4.5 70 600 304±8 0.31±0.04 -20.2±1.1 0.60 133±13 
2.4 5.0 3.5 3.0 40 600 535±20 0.59±0.11 -27.0±1.8 0.67 42±1 
2.4 5.0 3.5 3.0 70 300 355±16 0.48±0.03 -28.9±0.3 0.79 55±1 
2.4 5.0 3.5 4.5 40 300 402±18 0.53±0.08 -22.4±0.8 0.75 65±2 
2.4 5.0 3.5 4.5 70 600 387±14 0.48±0.06 -23.3±0.7 0.52 49±2 
2.4 5.0 7.0 3.0 40 300 541±34 0.51±0.01 -25.9±1.2 0.79 67±1 
2.4 5.0 7.0 3.0 70 600 445±20 0.46±0.04 -26.6±0.5 0.63 65±2 
2.4 5.0 7.0 4.5 40 600 430±6 0.39±0.02 -23.6±0.5 0.44 76±2 
2.4 5.0 7.0 4.5 70 300 332±15 0.42±0.03 -23.2±0.5 0.67 80±2 
5.0 3.0 3.5 3.0 40 600 275±34 0.40±0.12 -16.4±1.1 0.70 90±3 
5.0 3.0 3.5 3.0 70 300 208±33 0.35±0.07 -16.1±1.5 0.61 117±7 
5.0 3.0 3.5 4.5 40 300 225±5 0.29±0.02 -14.8±1.0 0.56 102±2 
5.0 3.0 3.5 4.5 70 600 248±8 0.35±0.02 -13.4±0.4 0.60 101±4 
5.0 3.0 7.0 3.0 40 300 233±2 0.29±0.03 -17.4±0.1 0.61 138±7 
5.0 3.0 7.0 3.0 70 600 220±6 0.31±0.04 -16.3±1.0 0.67 145±13 
5.0 3.0 7.0 4.5 40 600 230±6 0.28±0.04 -14.5±0.4 0.70 130±8 
5.0 3.0 7.0 4.5 70 300 199±4 0.23±0.03 -13.5±0.4 0.56 168±7 
5.0 5.0 3.5 3.0 40 300 331±11 0.52±0.03 -18.8±1.2 0.65 65±1 
5.0 5.0 3.5 3.0 70 600 307±7 0.46±0.02 -19.2±0.8 0.46 64±2 
5.0 5.0 3.5 4.5 40 600 313±36 0.44±0.12 -15.7±1.0 0.52 61±1 
5.0 5.0 3.5 4.5 70 300 257±5 0.34±0.03 -17.3±0.5 0.63 63±2 
5.0 5.0 7.0 3.0 40 600 330±3 0.38±0.03 -19.1±1.1 0.50 87±3 
5.0 5.0 7.0 3.0 70 300 242±7 0.28±0.03 -20.4±0.5 0.65 86±1 
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5.0 5.0 7.0 4.5 40 300 241±3 0.23±0.02 -15.8±0.6 0.59 84±2 
5.0 5.0 7.0 4.5 70 600 224±4 0.28±0.04 -17.0±1.0 0.40 99±4 
0.6 4.0 5.3 3.8 55 450 700±99 0.59±0.03 -22.4±1.1 0.64 103±3 
6.8 4.0 5.3 3.8 55 450 255±15 0.38±0.06 -18.3±0.7 0.57 107±1 
3.7 1.6 5.3 3.8 55 450 243±15 0.41±0.08 -19.5±1.1 0.56 147±2 
3.7 6.4 5.3 3.8 55 450 456±29 0.56±0.07 -20.3±0.7 0.70 53±1 
3.7 4.0 1.1 3.8 55 450 292±15 0.41±0.08 -21.4±0.5 0.52 40±1 
3.7 4.0 9.4 3.8 55 450 278±6 0.30±0.03 -22.1±0.3 0.59 137±1 
3.7 4.0 5.3 2.0 55 450 365±16 0.34±0.01 -19.8±0.4 0.77 93±2 
3.7 4.0 5.3 5.5 55 450 231±7 0.23±0.02 -21.3±0.4 0.54 133±3 
3.7 4.0 5.3 3.8 19 450 420±1 0.52±0.09 -19.8±1.3 0.64 119±6 
3.7 4.0 5.3 3.8 91 450 268±10 0.43±0.01 -20.4±1.2 0.50 124±5 
3.7 4.0 5.3 3.8 55 93 299±15 0.47±0.05 -21.3±0.9 0.15 88±5 
3.7 4.0 5.3 3.8 55 807 280±42 0.45±0.08 -17.3±0.7 0.60 80±4 
3.7 4.0 5.3 3.8 55 450 297±20 0.45±0.03 -17.6±0.9 0.62 105±5 
3.7 4.0 5.3 3.8 55 450 328±11 0.44±0.02 -17.1±1.0 0.65 108±2 
3.7 4.0 5.3 3.8 55 450 304±8 0.48±0.02 -16.5±0.8 0.67 103±1 
3.7 4.0 5.3 3.8 55 450 315±26 0.45±0.01 -17.9±0.6 0.72 97±2 
3.7 4.0 5.3 3.8 55 450 311±15 0.48±0.05 -18.4±1.5 0.67 97±2 
3.7 4.0 5.3 3.8 55 450 325±16 0.48±0.03 -17.0±0.9 0.72 100±7 
3.7 4.0 5.3 3.8 55 450 320±21 0.47±0.04 -17.6±1.4 0.52 111±2 
3.7 4.0 5.3 3.8 55 450 353±10 0.46±0.05 -18.5±1.3 0.57 95±3 
3.7 4.0 5.3 3.8 55 450 311±25 0.50±0.14 -17.2±1.8 0.70 106±3 
3.7 4.0 5.3 3.8 55 450 319±28 0.48±0.09 -16.9±1.5 0.74 101±3 
3.7 4.0 5.3 3.8 55 450 299±20 0.45±0.05 -18.9±1.1 0.70 98±3 
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3.7 4.0 5.3 3.8 55 450 299±22 0.47±0.10 -18.5±1.0 0.72 104±3 
3.7 4.0 5.3 3.8 55 450 304±11 0.44±0.12 -20.4±1.5 0.77 99±2 
3.7 4.0 5.3 3.8 55 450 327±3 0.40±0.04 -18.3±1.7 0.62 110±3 
 
3.4.2. Multiple regression analysis and response surface equations 
Multivariable regression analysis to fit regression surface to the experimental results provided 
response surface equations, as given in Table 3.4, applicable for predicting the response variables 
with respect to the fabrication conditions. The mean deviations of ~8% and coefficient of 
determination of >0.80 associated with the predicted values could be considered reasonable for 
estimating the size, PDI, and loading capacity of nanoparticles with respect to fabrication 
conditions. Although the coefficient of determination (0.78) associated with the zeta potential 
surface response equation is smaller than that of the other equations, the equation can be useful 
for sensitivity analysis of zeta potential of nanoparticles with respect to fabrication variables.  
3.4.3. Validation of response surface equations 
Figure 3.2 shows the relationship between the experimental results (Table 3.2) versus predicted 
values from the multiple regression equations (Table 3.4), and illustrates the distribution of 
prediction errors for nanoparticle size, PDI and encapsulation capacity. In Figs. 3.2a, c and d the 
upper and lower dash lines, which correspond to a deviation of ±5%, and the coefficients of 
determination of >0.80 show a reasonable agreement between the calculated values and 
experimental data for size, PDI and encapsulation capacity of the nanoparticles. Furthermore, as 
shown in Figs. 3.2b, d, and f, the residuals exhibit a random distribution indicating unbiased 
predictability associated with the response surface equations of size, PDI and loading efficiency 
of the nanoparticles. 
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Table 3.3. Summary of the fabrication conditions having significant effects on the response 
variables. 
Statistical significance (p-value) Response 
variable Dp (nm) PDI ξ  
(mV) 
ψ  
(µg OVA/mg NP) 
η  
(%) 
PVAC  <0.0001* 0.601 0.834 0.832 0.777 
PLGAC  <0.0001* 0.088 <0.0001* <0.0001* 0.246 
OVAC  0.102 0.09 0.814 0.335 <0.0001* 
PVAR  0.991 <0.0001* <0.0001* 0.989 0.378 
2
PVAC  <0.0001* 0.618 0.638 0.795 0.804 
2
PVAR  0.378 <0.0001* 0.907 0.912 0.329 
2
OVAC  0.081 <0.0001* 0.578 0.286 0.008* 
2
PLGAC  0.204 0.183 0.089 0.093 0.005* 
tCPLGA ×  0.001* 0.820 0.508 0.456 0.471 
tCPVA ×  0.068 0.005* 0.763 0.346 0.505 
PVAPVA RC ×  0.508 0.079 0.619 0.735 0.007* 
OVAPLGA CC ×  0.215 <0.0001* 0.957 0.537 0.039* 
PVAPLGA RC ×  <0.0001* 0.403 <0.0001* 0.750 0.324 
PVAOVA RC ×  0.105 0.521 0.091 <0.0001* 0.996 
PVARt ×  0.027* 0.837 0.624 0.346 0.350 
PVAPLGA CC ×  0.006* 0.018* <0.0001* 0.750 0.927 
PVAOVA CC ×  0.095 0.141 0.084 0.001* 0.996 
*significant effect (p<0.05) 
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Table 3.4. Multiple regression equations applicable for prediction of size, PDI, zeta potential and 
loading capacity of the PLGA nanoparticles. 
Surface response equation Mean 
deviation  
R2 
tRRCCC
CCtCCD
PVAPVAPLGAPVAPVA
PVAPLGAPLGAPLGAp
684.0535.16818.104655.14
582.13048.1309.21326.172
2 +−−+
−−+=
 
7.8% 0.86 
PVAPLGAPVA
PVAOVAPLGAPVAOVA
CCR
RCCtCCPDI
00416.0448.0
064.001.00003.00061.02383.0 22
−+
−+−−−=
 
8.5% 0.81 
a
PVAPLGAPVAPVAPLGAPLGA RCRCCC 194.1532.3513.0613.7362.1 +−+−−=ξ  8.1% 0.78 
OVAPVAPVAOVAPLGA CCRCC 000884.000147.002216.01386.0 ++−=ψ  8.9% 0.81 
aAn additional zeta potential measurement for a water system (CPVA= CPLGA= COVA = RPVA = 
t=S=0) was performed and included in the multiple regression analysis.  
3.4.4. Effect of fabrication conditions on the size and PDI of nanoparticles 
Figure 3.3 depicts the variation of nanoparticle size with respect to different fabrication 
variables. As seen in Fig. 3.3a, the size of nanoparticles decreases with an increase in PVA 
concentration for all levels of PLGA concentration. PVA, which performs as the external 
aqueous phase in the second nano-emulsion system, is an amphiphilic compound undergoing 
self-assembly in water when PVA concentration exceeds a critical micelle concentration (CMC). 
By decreasing the PVA concentration (particularly below CMC), the emulsion nano-droplets 
become increasingly unstable so that the chance of coalescence of the nano-droplets increases; 
therefore larger nanoparticles are resulted (Fig. 3.3a). In contrast, for larger PVA concentrations, 
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Figure 3.2. Predicted values from response surface equations vs. measurements (a, c, d), 
and distribution of residual prediction errors (b, d, f) for size, PDI and OVA-loading 
capacity (L.C.) of the nanoparticles. 
PVA molecules align themselves at the interface between the water and organic phase and 
stabilize the produced nano-droplets leading to smaller nanoparticles. However, as shown in Fig. 
3.3a, as PVA concentration increases beyond 4%, the size of the produced nanoparticles does not 
further decrease significantly. This could be attributed to the reduced net shear stress [30] caused 
by the increase in the external aqueous phase viscosity due to high PVA concentration. The 
external ultrasound energy provides shear stress to the organic phase. The shear stress-induced 
turbulence is the predominant mechanism of the organic phase break-up into nanodroplets. The 
size of the nanodroplets is inversely correlated to the magnitude of the shear rate. Increasing the 
external ultrasound energy directly increases the shear stress in the organic phase resulting in 
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Figure 3.3. Variation of nanoparticle size with respect to fabrication conditions based on 
the nanoparticle size response surface equation at t=60 s, RPVA=4 (a); CPVA=4%, RPVA=4 
(b); CPLGA=5%, RPVA=4 (c). 
more efficient droplet breadown and reduction in nanodroplet size. At a constant external energy 
per unit total volume, an increase in the viscosity of the organic phase and/or aqueous phase 
opposes the shear rate and leads to nanodroplets. Reducing the viscosity, the viscouse force 
decreases, and the resultant higher net shear stress in the organic phase leads to smaller size of 
nanodroplets. Also, the size of nanoparticles increases with PLGA concentration (Fig. 3.3a) due 
to the increase in the viscosity of the organic phase. Higher PLGA concentration causes higher 
organic phase viscosity that resists for droplets to be broken down by sonication and leads to 
larger nanoparticles. However, at higher levels of PVA concentration (Fig. 3.3a), the effect of 
PLGA concentration becomes less significant at higher levels of PVA concentration at which the 
organic phase viscosity associated with the mass fraction of high MW PLGA in the system is 
reduced and the amount of PVA in the system becomes sufficient to stabilize the sonication-
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induced droplets. Figure 3.3b illustrates the variation of nanoparticle size with sonication time 
and PLGA concentration where the effect of sonication time becomes clearly more significant 
with an increase in PLGA concentration. At lower PLGA concentrations, sonication can more 
easily break down the droplets due to the lower organic phase viscosity that is caused by the high 
MW PLGA concentration; however, as the PLGA concentration increases, longer sonication 
time will be required to break down the droplets. As seen in Fig. 3.3b, the significance of 
sonication effect on nanoparticle size considerably increases at higher PLGA concentrations 
where the size of nanoparticles can drop from ~500 nm to ~230 nm by increasing the sonication 
time from 20 to 90 s. In contrast, the effect of low PVA concentration cannot be compensated by 
sonication time due to highly significant effect of PVA concentration on sonication-induced 
nano-droplet formation. As seen in Fig. 3.3c, the size of nanoparticles increases for all levels of 
sonication time when PVA concentration decreases below a certain level (~4.5%) such that even 
at a sonication time of 90 s, the size of nanoparticles can reach 700 nm at PVA concentration of 
1%. It should be noted that the relative motion between the nanodroplets results in their collision 
leasing to the droplet coalescence. With an increase in the sonication time, the chance for the 
droplet coalescence also increases; however, the higher PVA concentrations (>4%) improve the 
nanodroplet stability, which contribute to less chance of the coalescence.        
PDI that represents the relative variation of the particle size distribution is affected by fabrication 
variables as shown in Fig. 3.4. Generally, PDI<0.3 is considered a desired value for an 
acceptable narrow range of nanoparticle size. Figure 3.4a shows that PDI of the nanoparticles 
first increases with OVA concentration and PVA volume ratio followed by a decreasing trend 
such that PVA volume ratios greater than 5.3 results in PDI<0.3 at any OVA concentration. The 
lowest PDI value (0.08) is resulted at OVA concentration and PVA volume ratio of 9% and 5.5, 
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respectively (Fig. 3.4a). At higher PVA volume ratios, the availability of the external aqueous 
phase to the sonication-induced droplets will be sufficient enough to contribute to 
individualization and stabilization of the droplets by reducing the chance of random coalescence 
of the droplets. Furthermore, as shown in Fig. 3.4b, lower PLGA concentration at higher PVA 
volume ratio reduces PDI value such that PVA volume ratios greater than 5.3 will be sufficient 
enough for all levels of concentration of high MW PLGA (75:25) to reduce the random 
coalescence of droplets  and result in PDI<0.3 at a sonication time, PVA concentration and 
sonication power of 60 s, 4% and ~80 W. Similar trend can be seen in Fig. 3.4c where PDI 
 
 
Figure 3.4. PDI variation with fabrication conditions based on PDI response surface 
equation at t=60 s, CPVA=4%, CPLGA=5% (a); t=60 s, CPVA =4%, COVA =4% (b); t=60 s, 
COVA =4%, CPLGA=5% (d). 
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decreases with PVA concentration such that a PVA volume ratio greater than 5.1 will be 
sufficient enough to reduce PDI below 0.3 at any PVA concentrations larger than 4%. 
3.4.5. Nanoparticle zeta potential variations with fabrication conditions 
Figure 3.5a illustrates the variation of zeta potential with respect to PVA and PLGA 
concentrations. While the negative zeta potential of the nanoparticles clearly increases with 
PLGA concentration, the effect of PLGA concentration becomes less significant as the PVA 
concentration increases. As shown in Fig. 3.5b, both PVA concentration and volumetric ratio 
directly cause the negative zeta potential to decrease. The effect of PVA concentration and 
volumetric ratio can be attributed to the coating PVA layer that shield the surface charge of 
PLGA. Redhead et al. (2001) have also reported similar reduction in the zeta potential of PLGA 
nanoparticles after coating with amphiphilic polymers [31]. Furthermore, when lower PVA 
volume ratio is used for nanoparticle fabrication, the amount of residual PVA is relatively 
decreased so that less shielding and subsequently higher negative zeta potential of the 
nanoparticles are resulted (Figs. 3.5b). The zeta potential of PLGA nanoparticles is determined 
by the surface charge that is influenced by the fraction of uncapped end carboxyl groups of 
PLGA nanoparticles. Stolnik et al. (1995) reported that zeta potential of PLGA nanoparticles 
without any PVA in a neutral buffer is about -45 mV [32]. Since the high negative zeta potential 
is mostly associated with carboxyl-terminated (uncapped end) PLGA of the nanoparticles; thus 
the lower negative zeta potential values measured in this study (-13 mV<ξ <-29 mV) is attributed 
to the ester-terminated PLGA used for nanoparticle fabrication. 
3.4.6. Effect of fabrication variables on the loading capacity 
Since PVA performs as the external aqueous phase in the second emulsification, it plays no role 
in the first emulsification where the loading process takes place; however, the interaction 
 172 
 
Figure 3.5. Zeta potential versus PLGA and PVA concentrations (a) and PVA 
concentration and external aqueous phase volume ratio (b) based on zeta potential surface 
equation. 
between OVA and PVA concentrations can affect the loading capacity. Figure 3.6a shows a clear 
trend where the loading capacity increases with PVA concentration particularly for OVA  
concentrations above 4%. The influence of PVA on the loading capacity can be likely associated 
with the increased viscosity of the external aqueous phase at higher PVA concentrations that 
increases the difficulty of OVA to partition across the interface from the internal water phase to 
the external aqueous phase enhancing the retention of OVA in the particle. Figure 3.6b illustrates 
the variation of loading efficiency with PLGA and OVA concentrations. A clear trend where the 
loading efficiency decreases with increasing OVA concentration for all levels of PLGA 
concentration can be seen. The decreasing trend of the loading efficiency is attributed to the low 
entrapment capacity of the nanoparticles particularly at high PLGA concentrations which 
increase packing density of PLGA nanoparticles. The multiple regression equation of loading 
capacity (Table 3.4) confirms this effect where PLGA concentration has a negative 
relationship with loading capacity. The lower PLGA concentration decreases packing density of 
the PLGA nanoparticles providing sufficient entrapment capacity for OVA. The decreasing trend 
of OVA concentration leads to a higher fraction of entrapped OVA out of the present OVA in the 
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aqueous system, as so the loading efficiency increases (Fig. 3.6b). Figure 3.6c illustrates the 
variation of loading efficiency with PLGA concentration and PVA volumetric ratio. The highest 
loading efficiency is attained at PLGA concentration of 2.6 % (w/v) while higher packing 
density of the high MW PLGA nanoparticles at higher PLGA concentrations leads to lower 
loading efficiency for all levels of PVA volumetric ratio. As seen in Fig. 3.6c, the loading 
efficiency is enhanced with PVA volumetric ratio. During the secondary sonication of the double 
emulsion, higher PVA volumetric ratio contributes to the reduction of ultrasound power density 
per unit volume of the medium resulting in lower breakdown of the inner aqueous phase of the 
 
 
Figure 3.6. Loading capacity versus PVA concentration and OVA concentration at 
CPLGA=5%, RPVA=4 (a), loading efficiency versus PLGA concentration and OVA 
concentration at CPVA=4%, RPVA=4 (b), and loading efficiency versus PLGA concentration 
and PVA concentration at COVA=5%, CPVA=5%  (c). 
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PLGA droplets containing OVA. As such the retention of OVA in the droplets is enhanced as 
PVA volumetric ratio increases. The influence of PVA volumetric ratio on OVA loading 
efficiency becomes less significant at higher PLGA concentrations that reduce nanoparticle 
loading capacity due to higher packing density of PLGA in the nanoparticle structure (Fig. 3.6c). 
3.4.7. Validation of the Geno-Neural model and optimal fabrication conditions 
Based on training and validating datasets, an ANN model constituting of 6, 6 and 4 input, hidden 
and output neurons, respectively, was trained and validated, and the generalization of the model 
was assessed using a testing dataset. Figures 3.7a-d illustrate the correlation between measured 
values and predicted results from the ANN model for the testing dataset within a 5% deviation 
 
Figure 3.7. Measured values versus predicted results by the ANN model for the size (a), 
PDI (b), -zeta potential (c) and loading capacity (L.C.) (d) of the nanoparticles within 5% 
confidence limit. 
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limit. A mean prediction error of 4.9% and coefficients of determination of 0.96, 0.98, 0.97 and 
0.93 associated with size, PDI, zeta potential, and loading capacity values predicted by the ANN 
model for the testing dataset suggest that the ANN model possesses a very good predictability. A  
comparison between the ANN model and the multiple regression equations (see Table 3.4) in 
terms of the mean error of predictions and coefficients of determination indicates that the ANN 
model has a better predictability (R2>0.92, prediction error<5%) compared to the multiple 
regression equations (R2<0.86, prediction error>7.5%). Thus, the ANN model can be used for 
optimization of the fabrication process of the nanoparticles. The neural network synaptic 
matrices ( M , N ) and vectors ( q , r ) to be used for evaluating Eq. (3.4) to predict nanoparticle 
characteristics are provided in appendix A. The Geno-Neural model, based on the ANN model 
and genetic algorithm (see Fig. 3.1), was used to search for optimum conditions within 100 
generations. Figure 3.8a illustrates the variation of the best fitness values of generations during 
the optimization process. The best fitness value increases with evolution of generations until it 
becomes relatively constant after 40 generations leading to optimum fabrication conditions that 
result in the desired particle size (250 nm) (Fig. 3.8b), PDI<0.3 (Fig. 3.8c), lower zeta potential 
(<-20 mV) (Fig. 3.8d) and loading capacity>0.15 mg OVA/mg PLGA (Fig. 3.8e). Table 3.5 
shows the optimum fabrication conditions corresponding to desired particle sizes of 150, 200, 
250 and 300 nm. Applying the optimum conditions proposed by the Geno-Neural model to the 
actual experiments, the nanoparticles were prepared, characterized and compared with the Geno-
Neural model predictions. Comparing the experimental results to the predicted values, except for 
the desired size of 150 nm, a good agreement between the measurements and predictions can be 
observed (Table 3.5). 
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Figure 3.8. Variation of the best fitness values (a), and evolving values of nanoparticle size 
(b), PDI (c), -zeta potential (d), and loading capacity (e) with generations for a desired 
particle size of 250 nm. 
3.4.8. Surface morphology of the nanoparticles 
Surface morphology of the nanoparticles was assessed based on SEM images. As shown in Figs. 
3.9a-c, the nanoparticles are spherical although adhered to each other after being re-suspended in 
water following freeze drying. A comparison between Figs. 3.9a and b shows that the presence 
of 1% sucrose solution during freeze drying can slightly improve the re-suspension of the 
nanoparticles in water. As seen in Fig. 3.9c, it seems that there are no large pores on the surface 
of the nanoparticles. The lack of cracks on the surface of the nanoparticles contributes to slower 
release properties benefiting prolonged release of growth factors (e.g. VEGF) in cardiovascular  
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Table. 3.5. Optimum conditions proposed by the Geno-Neural model and corresponding 
experimental results and predicted values of nanoparticle characteristics. 
Optimum conditions  Geno-Neural model 
predictions 
 Experimental results 
CPVA 
(%) 
CPLGA 
(%) 
COVA 
(%) 
RPVA t 
(s) 
S 
(rpm) 
 Dp 
(nm) 
PDI ξ  
(mV) 
ψ 
 Dp 
(nm) 
PDI ξ  
(mV) 
ψ 
 
2.9 1.6 9 3.92 90 400  150 0.21 -24 0.15  192 0.18 -19 0.15 
2.6 1.6 9 4.1 57 400  200 0.26 -23 0.16  214 0.20 -20 0.15 
2.3 1.6 9.4 4.1 40 400  250 0.28 -24 0.16  247 0.27 -21 0.14 
2.2 2.1 9.0 3.9 42 401  300 0.29 -23 0.16  315 0.23 -25 0.16 
 
 
 
Figure 3.9. SEM images of high MW PLGA nanoparticles at PLGA concentration of 4%, 
PVA concentration of 3.7%, PVA ratio of 3.8, sonication time of 55 s, and stirring rate of 
450 rpm in the absence (a, c) and presence of 1% sucrose (b) during freeze drying. 
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tissue engineering. Figure 3.9c also well depicts the spherical shape of the nanoparticles and 
shows that the predicted particle size is well comparable with that observed by SEM. 
3.4.9. OVA release 
Figure 3.10 illustrates in-vitro release profiles of OVA from the nanoparticles fabricated at 
different fabrication conditions. An initial rapid OVA release lasting for 24-36 hours of 
incubation can be observed for all the OVA-loaded nanoparticles prepared at different 
fabrication conditions; however, as seen in Fig. 3.10, depending on the fabrication conditions, 
the extent of the burst effect can vary from ~9% to ~38%. Following the initial burst release, 
OVA release rate decreases to a stable and low level. The release rate lasts about 14 days 
followed by an increase in release rate for the nanoparticles fabricated at a PLGA concentration 
of 1.6%. In contrast, the level of OVA release rate remains relatively low within 24 days for the 
OVA-loaded nanoparticles prepared at a PLGA concentration of 6.4% (Fig. 3.10). Comparing 
the OVA release pattern from the nanoparticles prepared at 1.6% PLGA to that reported by Zhao 
and Rodgers (2006) [33], who also visualized time-dependent bulk degradation/erosion of PLGA 
(75:25) microparticles, the enhanced release rate of OVA after 14 days can be attributed to the 
onset of the bulk degradation/erosion of PLGA matrix of the nanoparticles. Since the release of 
OVA in the second phase of release is mainly affected by hydration rate and PLGA degradation 
of the nanoparticles, a lower PLGA concentration (1.6%), which causes a lower packing density 
(higher porosity) of the PLGA matrix, contributes to a higher water absorption and PLGA 
degradation. The onset of PLGA bulk degradation/erosion improves OVA effective diffusivity  
 [2, 33] that enhances OVA diffusion rate through the eroding nanoparticle matrix and leads to 
an increased OVA release rate after 14 days (Fig. 3.10). On the other hand, the higher polymer 
concentration of 6.8% causes a lower porosity with higher tortusity in the PLGA matrix of the 
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nanoparticles reducing the hydration rate with slow PLGA degradation that causes a relatively 
low OVA release rate within 24 days (Fig. 3.10). 
3.4.10. The effects of fabrication variables on OVA burst release 
Table 3.6 presents the percentage of OVA burst release (Xburst) estimated by fitting the modified 
Weibull function (Eq. (3.8)) into the experimental OVA release data using the least squares 
method. The sum of squared residual of ≤0.001 (with a coefficient of determination of >0.97)  
between experimental release data and predicted values indicate a reliable curve fitting for 
estimation of burst release corresponding to the fabrication variables. As shown, the burst release 
varies from 8.9% to 37.8% depending on the nanoparticle fabrication conditions. ANOVA 
analysis at a significance level of 0.05 revealed that concentrations of PVA and PLGA had 
 
 
Figure 3.10. Release profiles of OVA from high MW PLGA (75:25) nanoparticles 
corresponding to eight different fabrication conditions. 
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significant effects (p-value<0.05) on the burst release while OVA concentration (p-value=0.08) 
and sonication time (p-value=0.2) had no significant effects on the burst release. Figure 3.11 
illustrates the effects of concentrations of OVA, PVA and PLGA on the burst release. As shown, 
OVA burst effect can be significantly decreased if higher concentrations of PVA and PLGA are 
used for fabrication of the OVA-loaded nanoparticles (Fig. 3.11). The effect of higher PVA 
concentration on reducing the burst release can be attributed to the higher viscosity of the 
external aqueous phase hindering the diffusivity of the encapsulated OVA in the external 
aqueous phase during the second emulsion. As such, the increased difficulty for OVA to diffuse 
to the surface of the nanoparticles contributes to more entrapped OVA within the interior of the 
Table 3.6. Burst release of OVA associated with different nanoparticle fabrication 
conditions at a stirring rate of 450 rpm and external aqueous phase ratio of 4. 
Fabrication variables   
COVA (%) CPVA (%) CPLGA (%) t (s)  Burst release (%) SSR* 
9.4 0.6 1.6 42  37.8 0.001 
9.4 0.6 6.4 42  23.2 <0.001 
9.4 6.8 1.6 92  21.1 <0.001 
9.4 6.8 6.4 92  12.3 0.003 
1.1 6.8 1.6 42  11.7 <0.001 
1.1 6.8 6.4 42  8.9 0.001 
1.1 0.6 1.6 92  30.1 0.001 
1.1 0.6 6.4 92  15.0 <0.001 
*Sum of squared residual for estimation of burst release using Eq. (3.8). 
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nanoparticles. In contrast, a low PVA concentration can result in less stable nano-emulsion with 
higher diffusivity of OVA in the external aqueous phase facilitating OVA mass transfer outward, 
causing more loosely associated OVA at the nanoparticle exterior that leads to a higher burst 
effect during the release process. 
The higher burst effect at lower PLGA concentration can be attributed to the higher porosity 
(lower packing density) and lower tortusity caused by lower polymer concentration within the 
PLGA matrix, particularly at the nanoparticle exterior. The higher porosity coupled with lower 
tortusity results in a higher mass transfer surface area and enhanced effective OVA diffusion at 
the surface of the OVA-loaded nanoparticles contributing to an initially rapid release rate during 
 
 
Figure 3.11. Effects of OVA, PLGA and PVA concentrations on the burst release of OVA 
from high MW PLGA (75:25) nanoparticles at a significance level of 0.05 (∗ indicates 
significant effect). 
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the release process. In contrast, a higher PLGA concentration can improve the entrapment of 
OVA at the nanoparticle matrix exterior due to a higher packing density leading to a lower burst 
effect. As shown in Fig. 3.11, although a lower OVA concentration (1.1%) can reduce the burst 
release, the effect of OVA concentration on the burst release is statistically insignificant (p-
value=0.08). Apparently, with an increase in the amount of OVA loading, a larger protein 
concentration gradient from the nanoparticle interior toward the release medium is expected to 
form to enhance OVA diffusion rate; however, the concentration gradient associated with the 
OVA concentration of 9.4% (compared to that of 1.1%) may have been insufficiently high to 
cause a significant effect on OVA burst release in this study.  
3.4.11. CD spectroscopy analyses of OVA structural integrity 
Figure 3.12 illustrates CD spectra and the relative proportion of α-helix, β-sheets and random 
coil of the secondary structure of OVA for the standard OVA solution in PBS (150 µg/ml), the 
released OVA after 20 days, and the OVA encapsulated under four optimum fabrication 
conditions that were suggested by the Geno-Neural hybrid model (see Table 3.5). The CD 
spectra and the percentage of α-helix and β-sheets were consistent with the measurements (~36% 
α-helix and ~38% β-sheets) reported by Perkins et al. (1992) [34, 35]. As seen in Fig. 3.12a, the 
CD spectra of the OVA released after 20 days and the OVA encapsulated under the four 
optimum fabrication conditions have similar patterns as the CD spectrum of the standard OVA 
sample. The differences in the height of the valleys of the spectra can be attributed to the 
different OVA concentrations of the OVA samples. Furthermore, α-helix, β-sheets and random 
coil of the  secondary structure of OVA of the samples have similar proportions (Fig. 3.12b). To 
evaluate any statistically significant difference between the secondary structure of OVA of the 
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Figure 3.12. CD spectra (a) and the percentage of α-helix, β-sheets and random coil of the 
secondary structure of OVA standard, encapsulated OVA at four optimum nanoparticle 
fabrication conditions, and released OVA after 20 days. 
samples and that of the standard OVA solution, an independent sample t-test was performed in 
SPSS at a significance level of 0.05 and the relative proportions of α-helix, β-sheets and random 
coil of the OVA samples were compared to those of the standard. The results from the t-test 
revealed that the optimum fabrication conditions (Table 3.5) and the release process within 20 
days had no significant effect (p-value>0.05) on the structural integrity of OVA.  
3.5. Conclusions 
In this study, OVA was used as a protein model for VEGF, IGF and TGF, which are considered 
as the main regulating GFs in cardiovascular tissue engineering. Fabrication conditions need to 
be determined and optimized in order to achieve desired nanoparticle characteristics, as required 
in cardiovascular tissue engineering. Investigation was carried out to assess the effects of six 
major fabrication variables on size, PDI, zeta potential, loading capacity, loading efficiency and 
yield of high MW PLGA nanoparticles. 
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Statistical analyses revealed that PLGA and PVA concentrations were influential variables and 
that their interactions with other variables could significantly affect the nanoparticle properties of 
size, PDI, zeta potential, loading capacity and encapsulation efficiency. Multiple regression 
equations with reasonable standard prediction errors were derived and used for sensitivity 
analyses of response variables. Higher and lower PVA and PLGA concentrations, respectively, 
were generally beneficial to improve loading efficiency and achieve lower size and PDI of the 
high MW PLGA nanoparticles. Both PVA concentration and volumetric ratio directly caused the 
negative zeta potential to decrease. The effect of PVA concentration and volumetric ratio can be 
attributed to the coating PVA layer that shield the surface charge of PLGA. Attributed to the 
ester-terminated PLGA used for nanoparticle fabrication in this study, the highest negative zeta 
potential of -29 mV, was smaller than that of -45 mV reported by Stolnik et al. (1995). Most 
likely, due to the increased viscosity of the external aqueous phase at higher PVA concentrations, 
the OVA loading capacity increased with PVA concentration. Since lower concentrations of high 
MW PLGA can decrease the packing density of the polymer matrix of the nanoparticles, higher 
OVA loading capacity was resulted from lower PLGA concentrations. During the secondary 
sonication of the double emulsion, higher PVA volumetric ratio that contributes to the reduction 
of ultrasound power density per unit volume of the medium, results in enhanced loading 
efficiency due to lower breakdowns of the inner aqueous phase of the PLGA droplets. 
An ANN model was developed and its generalization was assessed using a testing dataset. The 
mean prediction error of <5% and coefficients of determination of 0.96, 0.98, 0.97 and 0.93 
corresponding to the size, PDI, zeta potential, and loading capacity indicated that the model had 
a good predictability. The ANN model parameters (see Appendix A) were compiled into Eq. 
(3.4) to be used in spreadsheets for general users. A Geno-Neural hybrid model was successfully 
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developed by coupling the ANN model with Genetic Algorithm to be used as an optimization 
tool to search for optimum fabrication conditions. The optimum conditions leading to PDI<0.3, 
higher negative zeta potentials and loading capacity for four desired sizes of 150, 200, 250, and 
300 nm were obtained and experimentally validated. Except for the size of 150 nm, the Geno-
Neural model could successfully predict the optimal fabrication conditions. Surface morphology 
assessment from SEM images showed spherical shapes of the fabricated nanoparticles that 
seemed to have no large pores or cracks on the surface and had sizes comparable with predicted 
values. Also SEM images revealed that for high MW PLGA nanoparticles, the use of 1% sucrose 
solution as a cryoprotectant can improve the re-suspension of the nanoparticles in water after 
freeze drying. While OVA release rate remained relatively low and constant within 24 days for 
OVA-loaded nanoparticles, which were prepared at 6.4% PLGA concentration, the release rate 
was enhanced at the PLGA concentration of 1.6% after 14 days. PVA and PLGA concentrations 
significantly affected OVA burst release while the effects of OVA concentration and sonication 
time on the burst release were insignificant in this study. CD spectroscopical analyses revealed 
that the optimum nanoparticle fabrication conditions (Table 3.5) predicted by the Geno-Neural 
model had no significant effect (p-value>0.05) on OVA structural integrity. 
 
 
 
 
 
 186 
References 
[1] Izadifar M, Kelly EM, Chen XB 2014 Engineering Angiogenesis for Myocardial Infarction 
Repair: Recent Developments, Challenges, and Future Directions. Cardiovasc. Eng. Tech. 5 281-
307. 
[2] Izadifar M, Haddadi A, Chen XB, Kelly ME 2014 Rate-programming of nano-particulate 
delivery systems for smart scaffolds in tissue engineering. Nanotechnology 26 012001. 
[3] Zhang SF, Uludag H 2009 Nanoparticulate systems for growth factor delivery. 
Pharm. Res. 26 1561–1580. 
[4] Danhier F, Ansorena E, Silva JM, Coco R, Le-Breton A, Préat V 2012 PLGA-based 
nanoparticles: An overview of biomedical applications. J Control. Release 161 505–522. 
[5] Shin S H, Lee J, Lim K S, Rhim T, Lee S K, Kim Y H and Lee K Y 2013 Sequential delivery 
of TAT-HSP27 and VEGF using microsphere/hydrogel hybrid systems for therapeutic 
angiogenesis. J Control. Release 166 38-45. 
[6] Formiga FR, Pelacho B, Garbayo E, Abizanda G, Gavira JJ, Simon-Yarza T, Mazo M, 
Tamayo E, Jauquicoa C, Ortiz-de-Solorzano C, Prósper F, Blanco-Prieto MJ 2010 Sustained 
release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling 
in an acute myocardial ischemia-reperfusion model. J. Control. Release 147 30-37. 
[7] Golub JS, Kim YT, Duvall CL, Bellamkonda RV, Gupta D, Lin AS, Weiss D, Robert Taylor 
W, Guldberg R E 2010 Sustained VEGF delivery via PLGA nanoparticles promotes vascular 
growth. Am. J. Physiol. Heart Circ. Physiol. 298 H1959-65. 
[8] Geng H, Song H, Qi J, Cui D 2011 Sustained release of VEGF from PLGA nanoparticles 
embedded thermo-sensitive hydrogel in full-thickness porcine bladder acellular matrix. 
Nanoscale Res. Lett. 6 312. 
 187 
[9] Simón-Yarza T, Tamayo E, Benavides C, Lana H, Formiga F R, Grama C N, Ortiz-de-
Solorzano C, Kumar M N, Prosper F, Blanco-Prieto M J 2013 Functional benefits of PLGA 
particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia. Int. J. Pharm. 454 
784-790. 
[10] Wang Y, Cooke M J, Sachewsky N, Morshead C M, Shoichet M S 2013 Bioengineered 
sequential growth factor delivery stimulates brain tissue regeneration after stroke. J. Control. 
Release 172 1-11. 
[11] Lamprecht A, Ubrich N, Hombreiro Pérez M, Lehr C M, Hoffman M, Maincent P 1999 
Biodegradable monodispersed nanoparticles prepared by pressure homogenization-mulsification. 
Int. J. Pharm. 184 97–105. 
[12] Lamprecht A, Ubrich N, Hombreiro Pérez M, Lehr C M, Hoffman M, Maincent P 2000 
Influences of process parameters on nanoparticle preparation performed by a double emulsion 
pressure homogenization technique. Int. J. Pharm. 196 177–182. 
[13] Berchane N S, Carson K H, Rice-Ficht A C, Andrews M J 2007 Effect of mean diameter 
and polydispersity of PLG microspheres on drug release: Experiment and theory. Int. J. Pharm. 
337 118–126. 
[14] Jimenez N, Galan J, Vallet A, Egea M A, Garcia M L 2010 Methyl trypsin loaded poly(d,l-
lactide-coglycolide) nanoparticies for contact lens care. J. Pharm. Sci. 99 1414–1426. 
[15] Igartua M, Hernández R M, Esquisabel A, Gascón A R, Calvo M B, Pedraz J L 1998 
Stability of BSA encapsulated into PLGA microspheres using PAGE and capillary 
electrophoresis. Int. J. Pharm., 169 45–54. 
 188 
[16] Kang F, Singh J 2003 Conformational stability of a model protein (bovine serum albumin) 
during primary emulsification process of PLGA microspheres synthesis. Int. J. Pharm. 260 149–
156. 
[17] Bilati U, Allemann E, Doelker E 2005 Strategic approaches for overcoming peptide and 
protein instability within biodegradable nano- and microparticles. Eur. J. Pharm. Biopharm. 59 
375–388. 
[18] Feczkó T, Tótha J, Dósac G, Gyenis J 2011 Optimization of protein encapsulation in PLGA 
nanoparticles. Chem. Eng. Process. 50 757–765. 
[19] Zhou Y Z, Alany R G, Chuang V, Wen J 2013 Optimization of PLGA nanoparticles 
formulation containing L-DOPA by applying the central composite design. Drug Dev. Ind. 
Pharm. 39 321-330. 
[20] Panyam J, Dali M M, Sahoo S K W M, Chakravarthi S S, Amidon G L, Levy R J, 
Labhasetwar V 2003 Polymer degradation and in vitro release of a model protein from poly(d,l-
lactide-co-glycolide) nano- and microparticles. J. Control. Release 92 173–187. 
[21] Montgomery D C 1996 Design and analysis of experiments Wiley, New York. 
[22] Sahu JN, Acharya J, Meikap B C 2009 Response surface modeling and optimization of 
chromium (VI) removal from aqueous solution using tamarind wood activated carbon in batch 
process. J. Hazard. Mater. 172 818–825. 
[23] Özer A, Gürbüz G, Çalımlı A, Körbahti BK 2009 Biosorption of copper(II) ions on 
Enteromorpha prolifera: application of response surface methodology (RSM). Chem. Eng. J. 146 
377–387. 
 189 
[24] Moghaddam SS, Alavi Moghaddam MR,Arami M 2010 Coagulation/flocculation process 
for dye removal using sludge from water treatment plant: optimization through response surface 
methodology. J. Hazard. Mater. 175 651–657. 
[25] Myers R H, Montgomery DC 2002 Response surface methodology: process and product 
optimization using designed experiments Wiley, New York. 
[26] Izadifar M 2005 Neural network modeling of trans isomer formation and unsaturated fatty 
acid changes during oil hydrogenation. J Food Eng 66 227–232. 
[27] Izadifar M, Abdolahi F 2006 Comparison between neural network and mathematical 
modeling of supercritical CO2 extraction of black pepper essential oil. J. Supercrit. Fluids 38 37–
43. 
[28] D’Souza S S, Faraj J A, DeLuca P P 2005 A model-dependent approach to correlate 
accelerated with real-time release from biodegradable microspheres. AAPS Pharm Sci Tech 6 
E553–564. 
[29] Wang J, Wang B M, Schwendeman SP 2002 Characterization of the initial burst release of a 
model peptide from poly(d,l-lactide-co-glycolide) microspheres. J. Control. Release 82 289–307. 
[30] Budhian A, Siegel SJ, Winey KI 2007 Haloperiodol-loaded PLGA nanoparticles: systemic 
study of particle size and drug content. Int. J. Pharm. 336 367-375. 
[31] Redhead HM, Davis SS, Illum L 2001 Drug delivery in poly (lactide-co-glycolide) 
nanoparticles surface modified with copoloxamer 407 and poloxamine 908: in vitro 
characterization and in vivo evaluation. J. Control. Release 70 353–363. 
[32] Stolnik S, Garnett MC, Davies MC et al. 1995 The colloidal properties of surfactant-free 
biodegradable nanospheres from poly (b-malic acid-co-benzyl malate)s and poly (lactic acid- co-
glycolide) Coll. Surf. 97 235-245. 
 190 
[33] Zhao A, Rodgers VG J 2006 Using TEM to couple transient protein distribution and release 
for PLGA microparticles for potential use as vaccine delivery vehicles. J. Control. Release 113 
15-22. 
[34] Perkins SJ, Smith KF, Nealis AS, Haris PI, Chapman D, Bauer CJ, Harrison RA 1992 
Secondary structure changes stabilize the reactive-centre cleaved form of SERPINs. A study by 
H nuclear magnetic resonance and Fourier transform infrared spectroscopy. J. Mol. Biol. 228 
1235–1254. 
[35] Koseki T, Kitabatake N, Doi E 1988 Conformational Changes in Ovalbumin at Acid pH. J. 
Biochem. 103 425-430. 
 
 
 
 
 
 
 
 
 
 
 191 
CHAPTER 4 
REQULATION OF SEQUENTIAL RELEASE OF GROWTH FACTORS 
USING BI-LAYER POLYMERIC NANOPARTICLES FOR CARDIAC 
TISSUE ENGINEERING 
“This chapter has been submitted as “M. Izadifar, M. Kelly, and X. B. Chen, 2016, Regulation of 
Sequential Release of Growth Factors using Bi-layer Polymeric Nanoparticles for Cardiac Tissue 
Engineering, Nanomedicine (Under Review)” According to the Copyright Agreement, "the 
authors retain the right to include the journal article, in full or in part, in a thesis or dissertation". 
4.1 Abstract 
Cardiac tissue engineering aims to develop engineered constructs for myocardial infarction 
repair, where a challenge is the control of sequential release of growth factors (GFs). Bi-layer 
polymeric nanoparticles composed of a GF-encapsulating core surrounded by an adjustable shell 
thickness have been developed for sequential GF release. The bi-layer nanoparticles featured low 
burst effect, structural integrity of the encapsulated protein and time-delayed release patterns. 
Allowing for adjusting the timing of release, preconditioned nanoparticles demonstrated 
bioactive in the context of angiogenesis. The bi-layer nanoparticles successfully regulated 
sequential release of platelet-derived GF following co-release of vascular endothelial GF and 
basic fibroblast GF, and significantly promoted angiogenesis in fibrin matrix. Moreover, a novel 
Geno-Neural model was developed and validated for rate-programming of the nanoparticles. 
4.2. Introduction 
Myocardial infarction (MI) is the most common cause of heart failure. Current therapies can only 
slow down the progression of heart failure, but not tackle the progressive loss of cardiomyocytes 
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after heart attack [1-3]. Cardiac tissue engineering aims to develop implantable constructs (e.g., 
cardiac patches) that provide physical and biochemical cues allowing for myocardium 
regeneration [4, 5]. To this end, spatiotemporal control of growth factor (GF) release is of critical 
importance and yet remains unachievable [6]. GF immobilization and non-covalent 
encapsulation, which have been used in previous studies [7-14], suffer from limited control over 
the release rate and the possible loss of GF bioactivities due to covalent bonding and cleaving 
reactions for immobilization and release, respectively [14, 15]. Recent advances in polymeric 
particulate delivery systems enable improvements over the control of GF release [14]. Among 
various polymers, the use of poly(lactide-co-glycolide) (PLGA) and poly(L-lactide) (PLLA) 
stands out due to their biocompatibility, biodegradability, and approval for use by the Food and 
Drug Administration and European Medicine Agency [16]. Recent studies have employed PLGA 
microparticles to control GFs for improving angiogenesis in myocardial ischemia [17-21]. The 
commonality in these studies is the use of single polymer microparticles, which are severely 
undermined by several limitations including the initial burst effect, difficulty in achieving zero-
order release kinetics, and lack of time-delayed release pattern.   
To overcome the above limitations, we present a polymeric nano-particulate delivery system 
including bioactive bi-layer nanoparticles for simultaneous and/or sequential release of multiple 
GFs, such as vascular endothelial GF (VEGF), basic fibroblast GF (bFGF), and platelet derived 
GF (PDGF). The core-shell composition, structure, surface morphology, protein localization, 
release kinetics and physical properties of the nanoparticles are characterised, and the structural 
integrity of the encapsulated protein are assessed over 70 days of release. The bioactivity of the 
nanoparticles is assessed using rat aortic ring bioassay. A combination of PLGA and bi-layer 
nanoparticles are employed to regulate three release scenarios of VEGF release only, co-release 
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of VEGF and bFGF, and sequential release of PDGF following VEGF and bFGF, which are 
statistically compared in the context of angiogenesis in fibrin matrix of a cardiac patch. 
Furthermore, a predictive Geno-Neural model is developed, validated and applied for pre-
programming of release rates of the polymeric nanoparticles to provide pre-determined release 
patterns of interest. The predictability of the model is statistically assessed using the 
experimental data from release kinetics study and the measured values of physical and polymeric 
characteristics of the nanoparticles. 
4.3. Materials and methods 
Capped and uncapped PLGA with an average inherent viscosity of 0.2 and 0.65 dL/g (in 
chloroform), respectively, and capped PLLA with an average inherent viscosity of 0.9 dL/g (in 
chloroform) were purchased from DURECT (DURECT Co., Cupertino, CA). Ovalbumin 
(OVA), polyvinyl alcohol (PVA) (MW=31,000-50,000), phosphate-buffered saline (PBS), 
bovine serum albumin (BSA), sodium bicarbonate, HPLC grade dichloromethane (DCM), 
MEM-10x, and Bicinchoninic acid (BCA) protein assay kits were received from Sigma (Sigma-
Aldrich, MO). OVA Texas Red® Conjugate, human recombinant VEGF, bFGF, PDGF, and 
gentamicin were purchased from Life Technologies Thermo Fisher Scientific Inc. (Life 
Technologies, Grand Island, NY). Fibrinogen and thrombin were received from Baxter 
Healthcare Corporation (Westlake Village, CA) and essential basal medium (EBM) was 
purchased from Lonza (Lonza, Allendale, NJ). Sodium hydroxide and sodium dodecyl sulphate 
(SDS) were the products of Life Technologies Thermo Fisher Scientific Inc. (Life Technologies, 
Grand Island, NY). 
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4.3.1. Fabrication of bi-layer and single polymer nanoparticles 
A water-in-oil-in-oil-in-water (W/O/O/W) double emulsion solvent extraction technique was 
modified to fabricate the bi-layer nanoparticles. PLLA and PLGA polymers were separately 
dissolved in DCM at concentrations of 16.6, 20, and 23.5% (w/v). The internal aqueous phase 
(IAP), consisting of OVA (20 µg/mL), sucrose (10%), and sodium bicarbonate (6.7%) in PBS, 
was added to the PLGA organic phase followed by sonication for 50 s at 40 W. The emulsion 
was gently mixed with PLLA solution on a vortex mixer to obtain a uniform cloudy solution. 
The mixture was then sonicated at 40 W for 120 s. PVA was added to the emulsion, which was 
subsequently sonicated at 70 W for 120 s. The emulsion was added drop-wise to a DCM-
saturated PVA solution (0.5%) stirring at 450 rpm. After 24 h, the nanoparticles were collected 
by ultracentrifugation (Optima L-Series, Becman Coulter Inc., Palo Alto, CA) at 15,000 rpm for 
30 min, and washed three times with de-ionized water. Nanoparticles were re-suspended in de-
ionized water containing sucrose (1%) as the cryoprotectant and then stored at -20 °C. The above 
procedure was applied to the preparation of angiogenic factor-loaded bi-layer nanoparticles 
where human recombinant VEGF, bFGF, and PDGF in sterile 0.2% BSA solution were used 
instead of OVA with sodium bicarbonate and sucrose as buffering and stabilizing agents in the 
IAP. 
To be able to cross section the core-shell structures and assess the internal structure and 
morphology, bi-layer microspheres were also prepared by adding the IAP to a PLGA solution 
that was subsequently homogenized at 3000 rpm for 1 min. The emulsion was added to the 
PLLA solution and homogenized at 5000 rpm for 3 min followed by adding the emulsion to the 
stirring PVA solution. The microparticles were collected after 24 h by centrifugation at 8000 rpm 
for 10 min. The collected microparticles were washed with de-ionized water, freeze-dried, and 
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then stored at -20 °C. For protein localization assessment using fluorescence microscopy, OVA 
Texas Red® Conjugate was used as the encapsulated protein. 
Single polymer (PLGA) nanoparticles were prepared using a water-in-oil-in-water (W/O/W) 
double emulsion method. Polymers with different lactide to glycolide (L:G) ratios were 
dissolved in DCM at total concentrations of 3, 7, and 9% (w/v). The IAP was added to the 
organic phase followed by sonication at 20 W for 50 s. The external aqueous phase was then 
added to the W/O emulsion and sonicated for 120 s at 40 W followed by adding the emulsion to 
a PVA solution (0.5%) that was allowed to stir for 24 h at 450 rpm at room temperature. Six 
experimental conditions featuring different polymer characteristics were used to prepare the 
single polymer and bi-layer nanoparticle groups compared in this study (Table 4.1). 
Table 4.1. Polymer characteristics of the experimental groups.  
Experimental Group Characteristics 
A B C D E F 
PLGA concentration (%) 4.0 7.0 9.0 16.6 16.6 16.6 
PLLA viscosity (dL/g) n/a n/a n/a 0.9 0.9 0.9 
PLGA viscosity (dL/g) 0.20 0.65 0.20 0.65 0.65 0.65 
Terminal group Acid Ester Ester Ester Ester Ester 
L:G ratio 50:50 50:50 75:25 50:50 50:50 50:50 
PLLA/PLGA mass ratio 0 0 0 1 2 3 
 
4.3.2. Preparation of nanoparticle-incorporated fibrin matrix 
Nanoparticle-incorporated fibrin gel was prepared at fibrinogen concentrations of 1 and 4 
mg/mL. Three hundred µg of nanoparticles were re-suspended in 800 µL of PBS on the vortex 
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mixer. Then, 50 and 200 µL of a fibrinogen solution (40 mg/mL) in calcium chloride were mixed 
with the PBS solution containing the nanoparticles, resulting in 2 and 8 mg/mL fibrinogen 
solutions, respectively. Addition of thrombin (2 U/mL) to the fibrinogen solutions initiated 
polymerization, resulting in fibrin gels at final fibrinogen concentrations of 1 and 4 mg/mL. 
Immediately after mixing with thrombin, the fibrinogen solutions were transferred into a disk-
shaped mold and incubated at 37 °C to allow for complete polymerization. The nanoparticle-
incorporated fibrin matrices were used for surface morphology assessment. 
4.3.3. Structural characterization and morphological analyses 
The size, polydispersity index (PDI), and zeta potential of the nanoparticles were measured using 
Dynamic Light Scattering (Zetasizer, Nano ZS3000; Malvern Instruments, Malvern, UK) based 
on backscattering detection at a scattering angle of 173° at 25 °C. Scanning electron microscopy 
(SEM) was used to examine the surface morphology of the nanoparticles. Freeze-dried 
nanoparticles were re-suspended in distilled water followed by placing one droplet of the 
suspension on a carbon tape attached to SEM stubs, which were subsequently allowed to dry for 
24 h at room temperature. The samples were coated with a thin layer of gold with a Sputter 
Coater (S150B, Edwards, Crawley, UK) and then examined using a field-emission scanning 
electron microscope (JSM-6010 LV, JEOL, Ltd., Tokyo, Japan) at 5-15 kV.  
To visualize and characterize the internal core-shell structures, bi-layer microspheres were 
suspended in a solution of gelatine (20%) and glycerine (5%) for 8 h at room temperature. The 
suspension was then transferred into a cryostat mold and frozen at -80 °C for 1 h. The mold was 
placed over liquid nitrogen and then the gelled suspension removed and sectioned at a thickness 
of 8-14 µm using a cryostat at -30 °C. The sections were mounted on carbon tape attached to 
SEM metal stubs, dehydrated for 24 h, coated with g
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Morphological analyses of the nanoparticle-incorporated fibrin matrix were performed at two 
final fibrinogen concentrations of 1 and 4 mg/mL and a thrombin concentration of 1 U/mL. After 
preparation of the nanoparticle-incorporated fibrin, an appropriate size of the gel was cut using a 
scalpel blade, placed on a carbon tape attached to a stub, and then freeze dried at -80 °C for 24 h. 
The freeze-dried sample was gold-coated and imaged using SEM (JSM-6010 LV, JEOL, Ltd., 
Tokyo, Japan) at 5 kV.     
4.3.4. Identification of core and shell polymeric compositions 
Under an inverted phase contrast microscope, cross-sectioned bi-layer microparticles were 
viewed to visualize core-shell structures. An ethyl acetate assay [22] based on the different 
solubilities of PLLA and PLGA in ethyl acetate was applied to determine the core and shell 
polymeric composition. The microscope slides holding the microparticle cross sections were 
immersed in ethyl acetate for 12 h, and then the remnants of the core-shell structure were 
visually characterized under the microscope. Because the solubility of PLGA (580 mg/mL) in 
ethyl acetate is much higher than PLLA (0.1 mg/mL) [23], a hollow structure (ring shape) or 
solid core of the remnant would indicate that PLLA mainly constituted the shell or core, 
respectively. The experiment was performed at different PLLA and PLGA mass ratios to 
evaluate the effect of polymer mass ratio on the core-shell polymer orientation. The surface 
morphology of ethyl acetate-treated cross sections of PLLA shells was assessed at three solvent 
removal conditions that may affect PLLA-PLGA phase separation during particle preparation. 
SEM imaging and quantitative image analysis of PLLA shells using ImageJ software (National 
Institutes of Health, Bethesda, Maryland, USA) was employed to examine the uniformity of the 
shell texture. Pixel intensity standard deviation across an area of 0.01 mm2 was used as a 
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criterion to evaluate shell texture uniformity, on which the best solvent removal rate was 
determined and applied to the nanoparticle preparation procedure.    
4.3.5. Encapsulation capacity and release kinetics 
Measurement of the loading capacity of the bi-layer and single polymer (PLGA) nanoparticles 
was based on extracting and quantifying OVA from the nanoparticles. Nanoparticles were 
dispersed in 0.1 M sodium hydroxide containing 5% SDS, and incubated at room temperature 
overnight in an orbital shaker. The supernatant was collected by centrifugation at 15000 rpm for 
10 min. A BCA assay kit (Sigma-Aldrich, MO) was used and OVA concentration was quantified 
by reading the absorbance of the samples at 562 nm with a UV spectrophotometer (Synergy HT, 
BioTek Instruments, Inc., Winooski, VT). Loading capacity was then calculated as 
NP
OVA
C
C
=ψ                                      (4.1) 
where ψ is the loading capacity (mg OVA/mg nanoparticles), OVAC  is OVA concentration from 
the direct extraction (mg OVA/mL), and NPC is the OVA-loaded nanoparticle concentration 
(mg/mL). An in-vitro release study was conducted based on direct measurement of OVA 
released from the nanoparticles in the release medium. A given amount of nanoparticles was 
transferred into glass vials containing PBS. Vials were placed in a swinging sample holder 
mounted on an orbital shaker to provide rotational and axial shaking (200 rpm) at 37 °C. At 
predetermined time intervals over 70 days, 800 µL of the nanoparticle suspension were 
withdrawn from each vial and centrifuged at 10,000 rpm. Then 450 µL of the supernatant, 
subsequently replaced by 450 µL fresh PBS, were removed and the OVA concentration 
quantified. The nanoparticle pellet in the centrifugation tube was re-suspended in the fresh PBS 
on a vortex mixer and then the contents (800 µL) transferred into the corresponding vial on an 
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orbital shaker. The experiment was carried out in triplicate for all polymeric mass ratios. The 
concentration of OVA was measured based on the absorbance of the solution at 562 and 572 nm 
using a UV spectrophotometer (Synergy HT, BioTek Instruments, Inc., Winooski, VT). 
4.3.6. Localization of the loading protein in the double-layered structures   
To evaluate the protein distribution across core-shell structures, PLGA and bi-layer microspheres 
were loaded with fluorescent OVA (OVA Texas Red® Conjugate), cross sectioned, and 
observed using fluorescence microscopy. The microspheres, which were prepared at 
PLLA/PLGA mass ratios of 0, 1, 2, and 3, were embedded in resin, cross sectioned at 10 µm, 
and then observed using fluorescence and bright field phase contrast microscopy. Superimposed 
bright field and fluorescence microscopy images were used for protein distribution mapping 
across the core and shell. For each selected microparticle, the cross section with the largest 
diameter, which most likely represented the cross section at the center of the microparticle, was 
used for quantitative assessment of the protein distribution across the core and shell. Average 
fluorescence intensity profiles and the area under the curve associated with the composite images 
of the cross sections were determined in ImageJ software and used as measures for comparing 
protein distribution and encapsulation across the microparticles at different PLLA/PLGA mass 
ratios.  
4.3.7. Circular dichroism (CD) spectroscopy 
A Chirascan Plus CD Spectrometer (Applied Photophysics, Surrey, UK) was used to record CD 
spectra to assess the structural integrity of OVA during the release process from the bi-layer 
nanoparticles. CD spectra were collected at a scan time of 0.5 s per point with a step size of 1 nm 
from 205 to 260 nm at 20 °C using a quartz cell with a 0.1 cm path length. The recorded data 
were averaged over five scans and expressed as millidegrees. An OVA solution in PBS was used 
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as the control sample while the buffer (sucrose and bicarbonate in PBS) was used to compensate 
for noise in the spectroscopic analysis. OVA samples, which were collected within the first 18 h, 
were used to assess the effect of the fabrication conditions on the structural integrity of the 
encapsulated protein based on CD spectra analyses. OVA samples were also collected after 7, 25, 
and 50 days to assess the protein structural integrity during the release process from the single 
and bi-layer nanoparticles. Samples were filtered using a 0.45 μm filter syringe, and degassed at 
560 mmHg at 25 °C for 1 h before being subjected to CD spectroscopic analysis. Deconvolution 
of the CD spectra was conducted using CD Spectra Deconvolution software Ver. 2.1 (Gerald 
Böhm, Germany) to estimate the percentage of proteins in the samples featuring alphahelix, anti-
parallel and parallel beta sheet, beta-turn, and random coil structures. The recorded CD spectra 
and the deconvolution results were statistically compared to those of the controlled OVA sample 
to assess the structural integrity of the proteins. 
4.3.8. Ex vivo angiogenesis study for angiogenic factor-loaded nanoparticle bioactivity 
The rat aortic ring assay, which is considered a physiologically relevant angiogenesis model 
similar to that observed in vivo [24], was used to assess the bioactivity of angiogenic factor-
encapsulating nanoparticles and evaluate the performance of the nano-particulate delivery system 
with respect to providing simultaneous and sequential release of multiple angiogenic factors.  
Two-month old rats were euthanized by carbon dioxide and their thoracic/abdominal skin shaved 
and then disinfected using 70% ethanol. Each rat was pinned down in supine position on a 
dissection board covered with a sterile impermeable pad. From the shoulders downward medially 
to the lower abdomen, a Y-shape incision was made, the ribs cut to expose the thoracic cavity,  
and then the sternal plate displaced to the upper side of the animal with a haemostat (Fig. 4.1a). 
After cutting the diaphragm and displacing the abdominal organs, the thoracic aorta (yellow 
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arrow in (Fig. 4.1b) was exposed and a knot tied just below the diaphragm at the distal end of the 
aorta using a 2-0 silk suture (blue arrow in Fig. 4.1b) with a reverse cutting needle (green arrow 
in Fig. 4.1b). While holding the suture, the aorta was dissected and excised at the aortic arch as 
close as possible to the heart (white arrow in Fig. 4.1b) using sterile micro-dissection scissors 
and  forceps. The aorta was immediately transferred into EBM on ice. Attention was given to 
perform the procedure in less than 15 min, excluding the euthanasia time, and to hold the aorta 
only by the suture at all times to avoid damaging the endothelium. Submerged in EBM 
containing gentamicin, the isolated aorta was carefully cleaned of fibroadipose tissue, fat, and 
blood using sterile micro-dissection scissors and curved forceps under a dissection microscope 
(Fig. 4.1c). 
 
Figure 4.1.  The procedure for (a) dissection and (b)  excision of the rat aorta, (c) cleaning 
and (d) cutting the aorta into ~1.5 mm rings in EBM, and (e) transferring the rings into a 
24-well culture plate and (f) embedding the aortic rings in nanoparticle-incorporated fibrin 
matrix in MEM. 
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During the 60-min cleaning procedure, the aorta was transferred into a new petridish containing 
fresh EBM every 10 min. The aorta was cut into 1-1.5 mm rings using a scalpel blade (Fig. 4.1c). 
Excluding the rings from either end, the aortic rings were washed five times in EBM before 
being transferred into a 24-well tissue culture plate (Fig. 4.1d). VEGF, bFGF, and PDGF- loaded 
nanoparticles were added to 200 µL of MEM (10x) followed by shaking on a vortex mixer to re-
suspend the nanoparticles in the solution. The amount of nanoparticles was calculated based on 
the loading capacity and the desired release rate over the angiogenesis study as: 
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where Mnp is the estimated average amount of protein-loaded nanoparticles (mg), ∆X(ti) is the 
time-dependent cumulative (fractional) release, t is time (day), .dm  is the desired release rate 
(mg/day), and ψ is the loading capacity (mg/mg). The numerator represents the total delivered 
dose over the release time of 15 days. Based on Eq. (4.2), the mass of required nanoparticles was 
calculated to obtain total doses of ~30, ~60, and ~10 ng/day for VEGF, bFGF, and PDGF, 
respectively. 
Fibrinogen (200 µL) at 40 mg/mL in calcium chloride that contained 10 µg/mL of aprotinin was 
mixed with the nanoparticle-containing MEM solution. PBS was added to the mixture to obtain a 
total volume of 1 mL with a fibrinogen concentration of 8 mg/mL. Then, 60-µL aliquots of the 
fibrinogen solution were prepared and kept on ice. Aortic rings (three rings at a time) were 
transferred into the center of wells of a 24-well culture plate (Fig. 4.1e). Sixty µL of thrombin (2 
U/mL) were mixed with each 60-µL aliquot. The fibrin solution at a concentration of 4 mg 
fibrinogen/mL was then applied to embed each aortic ring in the culture plate wells, which were 
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then incubated at 37 °C for 30 min. After incubation, MEM-containing gentamicin with or 
without angiogenic factor-loaded nanoparticles was added to the wells (Fig. 4.1f).  
Because the release lag phase of the bi-layer nanoparticles was beyond the duration of the entire 
experiment, the time-delayed release was adjusted by pre-conditioning the angiogenic factor-
loaded bi-layer nanoparticles in MEM/PBS for 25 days before being used in the fibrin matrix and 
MEM. Single polymer (PLGA) and bi-layer nanoparticles, which were loaded with VEGF and/or 
bFGF and/or PDGF, were employed to provide simultaneous and sequential GF release 
compared to VEGF release alone. Saline-loaded nanoparticles were used as control samples in 
all experiments.  
The aortic rings were viewed and monitored under a phase-contrast inverted microscope each 
day. Sprouting microvessels were quantitatively (e.g., number of vessels, maximum sprout 
length, and sprouting rate of new microvessels) and qualitatively (colocalization of endothelial 
cells and pericytes, microvessel regression phase) assessed on a daily basis and statistically 
compared to the control sample at a significance level of 0.05. ImageJ software (National 
Institutes of Health, Bethesda, Maryland, USA) was used for image analyses. Experiments were 
conducted in six replications. 
4.3.9. Development of a Geno-Neural model for rate-programming of the nanoparticles  
A Geno-Neural model consisting of a trained artificial neural network (ANN) coupled with 
genetic algorithm (GA) was developed to predict optimum combinations of multiple physical 
and polymeric variables of the nanoparticles in order to achieve a pre-determined release 
pattern(s). GA is based on the principal of ‘survival of the fittest’ and biological concepts of 
genetics and evolution. In this study, the DNA of each individual consists of 7 genes which are 
defined as the nanoparticle physical and polymeric characteristics of PLGA concentration, 
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viscosity, G:L ratio, ester/carboxyl terminal group, and PLLA/PLGA mass ratio, nanoparticle 
size and PDI (Fig. 4.2). The ANN that simulate human brain analytical function consists of 
input, intermediate and output neurons which sum weighted inputs and apply a transfer function 
from which the results propagate to the succeeding neurons. The ANN is trained by adjusting the 
synaptic weights using training and validating datasets to learn the relationships between inputs 
and outputs. In this study, 80, 10, and 20% of the experimental data pool from the release study 
as well as the measurements of loading capacity, were randomly divided to training, validating, 
and testing datasets. Release information associated with bi-layer nanoparticles of group E was 
entirely transferred to the testing dataset to assess the predictability and generalization of the 
ANN. Eight variables including release time and nanoparticle characteristics were assigned to 
the input neurons, and cumulative release and loading capacity were considered as the outputs of 
the ANN.  
Inputs and outputs were normalized between -1 and +1 to improve the training process, and the 
ANN was trained using a Backpropagation training algorithm based on Bayesian Regularization 
combined with the Levenberg–Marquardt method in MATLAB 7.4 [25, 26]. Tangent hyperbolic 
and linear transfer functions were assigned to the hidden and output neurons, respectively (Fig. 
4.2). Synaptic weights (Appendix B) of the tested neural network architecture were compiled 
into a mathematical model expressing a relationship between nanoparticle physicochemical 
design parameters and the release characteristics:  
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Figure 4.2. Schematic diagram of the Geno-Neural approach for rate-programming of 
nanoparticles. 
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where nϑ  and nψ  are normalized values of predicted cumulative release and loading capacity 
(µg/mg), respectively; 41−M and 41−q  are the synaptic weights and bias vector, respectively, 
corresponding to the 1st to 4th neurons of the hidden layer; N and r  are the synaptic weights and 
bias vectors corresponding to the neurons of the output layer, respectively; and P is the input 
vector normalized between -1 and +1 and defined by eight physicochemical parameters of the 
nanoparticles as: 
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where CPLGA, µPLGA, and χG:L are PLGA concentration (%), inherent viscosity in chloroform 
(dg/L), and G:L ratio, respectively; χPLLA:PLGA is PLLA to PLGA mass ratio; ε is the PLGA 
terminal group (0 for carboxyl and 1 for ester); d is the average size of the nanoparticles (nm); ξ 
is PDI; and t is the release time (day). The normalized values of nϑ  and nψ are converted to the 
actual values of cumulative release and loading capacity using: 
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are the vectors of the upper and lower boundaries, respectively, of 
cumulative release and loading capacity corresponding to the training dataset. 
GA is coupled with the trained ANN in such a way the genes of the initial population, which are 
randomly generated, are assigned to the ANN, while the time variable is defined by the release 
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pattern of interest (desired release pattern) (Fig. 4.2). The ANN predicts the release profiles and 
loading capacity corresponding to the genes of the initial population, which are subsequently 
compared to the desired release profile to compute fitness values of the genes (Fig. 4.2). Through 
the genetic operators, genes are evolved to produce the next generation. The evolutions continue 
until the fitness function is maximized to return the fittest genes (nanoparticle characteristics) 
that satisfy the pre-determined release pattern of interest (desired release profile). An initial 
population of 1000, number of evolution of 500, selection rate of 0.08, mutation rate of 0.05, and 
crossover rate of 0.6 were assigned to the GA based on a preliminary sensitivity analysis.  
To assess the precision of the Geno-Neural approach, two arbitrary release patterns similar to 
release profiles of the experimental groups C and D were assigned to the Geno-Neural model and 
the predicted fittest genes were compared to the corresponding measured values. 
4.4. Results  
4.4.1. Structural and morphological assessments and localization of encapsulated protein  
The SEM image of a cross-sectioned bi-layer microsphere that was prepared at PLLA/PLGA 
mass ratio of 1 and polymer concentration of 16.6% clearly shows core-shell architecture (Fig. 
4.3a). Both core and shell exhibit porous structures but pores in the shell are relatively smaller 
than those in the core. Notably, no large pores or cracks can be identified on the surface of the 
bi-layer microsphere (Fig. 4.3a). Figure 4.3b depicts the bright field microscopy images of the 
cross-sections of bi-layer microspheres that were prepared at PLLA/PLGA mass ratios of 1, 3 
and 0.5. Applying ethyl acetate assay to the cross-sections resulted in hollow ring configurations 
and solid core remnant corresponding to PLLA/PLGA mass ratios ≥1 and <1, respectively (Fig. 
4.3c). Moreover, the ethyl acetate assay unveiled some pores on the shell that may be associated 
with the dissolution of scattered PLGA residues in the shell (Fig. 4.3c). Figure 4.3d depicts SEM  
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Figure 4.3. (a) SEM image of a bi-layer microsphere cross section (scale bar=100 µm). (b) 
Bright field microscopy images of cross sections of bi-layer microparticles at PLLA/PLGA 
mass ratios of 1 (left), 3 (middle), and 0.5 (right) before applying the ethyl acetate assay 
(scale bars=100 µm). (c) The hollow ring configurations and solid core remnant resulted 
from ethyl acetate assay for PLLA/PLGA mass ratios of 1 (left), 3 (middle), and 0.5 (right) 
(scale bars=100 µm). (d) Surface morphology of the ethyl acetate-treated cross sections of 
bi-layer microspheres prepared at three polymer concentrations and EAP of 23.5% in 100 
mL water (left), 20% in 50 ml of 0.5% PVA solution (middle), and 16.6% in 30 ml of DCM-
saturated 0.5% PVA (right) (scale bar=100 µm) (scale bar of magnified images=20 µm). 
images of the ethyl acetate-treated cross sections of the bi-layer microspheres that were prepared 
at different polymer concentrations and external aqueous phase (EAP) compositions. The SEM 
images revealed that the surface morphology of the ethyl acetate-treated shell may be improved 
when the polymer concentration and EAP are adjusted from 23.5% at 100 ml EAP of water (Fig. 
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4.3d, left image) to 20% at 50 ml EAP of 0.5% PVA (Fig. 4.3d, middle image), and 16.6% at 30 
ml EAP of DCM-saturated 0.5% PVA. The pixel intensity variation associated with the shell 
SEM images represents a quantitative measure of the shell texture uniformity that improves at 
the lower polymer concentration (16.6%) and the adjusted EAP (Fig. 4.3d). 
Figure 4.4a shows the surface morphology, geometry and agglomeration level of PLGA (top-left 
image) and bi-layer nanoparticles that were prepared at PLLA/PLGA mass ratios of 1 (top-right 
image), 2 (bottom-left image) and 3 (bottom-right image). Spherical geometry and low particle 
agglomeration of the nanoparticles that are featured with no large superficial pores or cracks can 
be noted from the SEM images (Fig. 4.4a). The surface morphology of the nanoparticle-
incorporated fibrin matrix at two levels of thrombin to fibrinogen ratio of 0.25 (left image) and 1 
U/mg (right image). Coarser fibers with higher apparent nanoparticle density per fiber at 
thrombin to fibrinogen ratio of 0.25 U/mg can be distinguished from fine fibers with small 
number of nanoparticles per fiber at thrombin to fibrinogen ratio of 1 U/mg (Fig. 4.4b). Figures 
4.4c-e illustrate the fluorescence microscopy images of cross-sections of bi-layer microparticles 
encapsulating labelled ovalbumin at different PLLA/PLGA mass ratios. The protein can be 
identified largely in the core at PLLA/PLGA mass ratios of 1 (Fig. 4.4c) and 2 (Fig. 4.4d); 
however, the fraction of protein in the shell relatively increases at PLLA/PLGA ratio of 3 (Fig. 
4.4e). By overlaying bright field and fluorescence microscopy images, the protein distribution 
over the shell and core was visualized at four PLLA/PLGA mass ratios of 1(Fig. 4.4f), 2 (Fig. 
4.4g) and 3 (Fig. 4.4h) and 0 (Fig. 4.4i). The composite images and the fluorescence intensity 
profiles revealed that the encapsulated protein was largely confined in the core of the bi-layer 
structures (Figs. 4.4f-h) but distributed across the entire PLGA microparticles (Fig. 4.4i). Figures 
4.4f-h indicate that the shell thickness of the bi-layer microparticles increases with PLLA/PLGA  
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Figure 4.4. (a) Nanoparticle surface morphology at PLGA/PLLA ratios of 0 (top left), 1 
(top right), 2 (bottom left), and 3 (bottom right) (scale bar=500 nm). (b) Surface 
morphology of nanoparticle-incorporated fibrin matrix at thrombin to fibrinogen ratios of 
0.25 (left) and 1 U/mg (right) (scale bar=10 µm) (scale bar of the magnified images=500 
nm). (c-e) Fluorescence microscopy images for protein localization assessment at 
PLLA/PLGA ratios of 1, 2, and 3, respectively (scale bar=50 µm). (f-i) Superimposed 
images of fluorescence and bright field microscopy with the fluorescence intensity profiles 
of cross-sections of microparticles at polymeric mass ratios of 1 (f), 2 (g), 3 (h), and 0 (i). 
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mass ratio while the area under the curve of the fluorescence intensity profiles, which represent 
apparent protein encapsulation  capacity, decreases with PLLA/PLGA mass ratio (Figs. 4.4f-i). 
Unlike the core-shell structures, a significant amount of surficial protein can be identified on the 
surface of PLGA microparticles (Fig. 4.4i). 
Table 4.2 presents the size range, loading capacity and PDI of the nanoparticles corresponding to 
polymer characteristics given in Table 4.1. PLGA nanoparticles offer significantly larger loading 
capacity than bi-layer nanoparticles with relatively more uniform size distribution represented by 
PDI. The measured values imply that the loading capacity of bi-layer nanoparticles decrease with 
PLLA/PLGA mass ratio (Table 4.2). 
4.4.2. Protein loading capacity, release kinetics and structural integrity assessment 
Figure 4.5a illustrates the kinetics of release of the nanoparticles corresponding to the polymeric 
characteristics given in Table 4.1. The nanoparticles with carboxyl terminal groups, which 
offered the highest loading capacity (Table 4.2), provided the most rapid protein release among 
the nanoparticles (Fig. 4.5a). The release rate decreased with an increase in the polymer 
concentration and L:G ratio. Notably, PLGA nanoparticles at polymer concentration of 9% and 
L:G ratio of 75:25 resulted in a sustained zero order release kinetics (Fig. 4.5a). Bi-layer 
nanoparticles provided a distinct time-delayed release pattern that can be clearly distinguished 
from the release kinetics of PLGA nanoparticles (Fig. 4.5a). The lag phase of protein release 
slightly increased with PLLA to PLGA mass ratio of bi-layer nanoparticles (Fig. 4.5a). 
Figures 4.5b-d illustrate CD spectra of the released protein after 1, 25 and 50 days of release, 
compared to the standard protein sample. Deconvolution of the CD spectra led to the percentage 
of α-helix, β-sheets and random coil of the secondary structure of the released protein and the 
control sample after 1, 25 and 50 days of the release, respectively (Fig. 4.5e-g). 
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Table 4.2. Physical properties of nanoparticles corresponding to the experimental groups.  
Experimental Groups   Characteristics 
A B C D E F 
Size (nm) 220±7 211±33 258±12 340±29 490±16 685±43 
PDI 0.21±0.02 0.18±0.04 0.30±0.03 0.32±0.08 0.38±0.05 0.46±0.04 
Loading capacity 
(µg/mg) 
1.3 0.9 0.2 0.05 0.02 0.01 
 
The CD spectra and the relative proportion of α-helix, β-sheets and random coil were consistent 
with the measurements reported in literature [27, 28]. It should be noted that the CD spectra of 
the protein that is released over the 1st day is mostly associated with the surficial protein 
dissolution, which is less likely affected by PLGA degradation. As such, any changes in the 
secondary structure of the protein within the first day of release can be attributed to the 
fabrication process. In contrast, changes in the secondary structure of the protein during a 
prolonged release (e.g. after 25 and 50 days) can be associated with the acidic microenvironment 
resulted from PLGA and PLLA degradation. 
4.4.4. Angiogenic bioactivity of the GF-loaded nanoparticles 
Figures 4.6a-d depict angiogenic response of aortic rings to saline-loaded (Fig. 4.6a) and 
angiogenic factor-loaded nanoparticles (Figs. 4.6b-d) in the fibrin matrix (0.25 U/mg). 
Angiogenic factor-loaded nanoparticles that were prepared at PLLA/PLGA mass ratios of 0, 1 
and 2 corresponding to the experimental groups of A (Fig. 4.6b), D (Fig. 4.6c) and E (Fig. 4.6d) 
significantly stimulated sprouting angiogenesis compared to a very limited angiogenic response 
of saline-loaded nanoparticles (Fig. 4.6a). Figure 4.6e depicts the time course of the sprouting 
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Figure 4.5. (a) Release kinetics of the nanoparticles corresponding to the polymeric 
characteristics of the experimental groups. (b-d) CD spectra and (e-g) secondary structure 
percentage of the releasing protein after 1 day (b, e), 25 days (c, f) and 50 days (d, g) of 
release compared to those of the control sample. 
angiogenesis at three different release scenarios over 8 days for VEGF release alone, 
simultaneous release of VEGF, bFGF and PDGF, and sequential release of PDGF after 5 days 
following co-delivery of VEGF and bFGF. Co-delivery and sequential release of the angiogenic 
factors apparently resulted in a higher microvessel sprout density after 8 days (Fig. 4.6e). Figures 
4.7a, b illustrate the number of sprouts and the maximum length of sprouts at different 
angiogenic factor release conditions compared to those of the control sample. Figure 4.6c 
illustrates the rate of new sprout formation over 9 days associated with the three release patterns 
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Figure 4.6. Angiogenic response of aortic rings to (a) saline-loaded nanoparticles, (b) 
VEGF-and bFGF-loaded PLGA nanoparticles, (c, d) bi-layer nanoparticles after 6 days 
(scale bar=500 µm). (e) Time course of sprouting angiogenesis for VEGF release alone, and 
simultaneous and sequential release of VEGF, bFGF, and PDGF over 8 days (scale 
bars=1000 µm). 
shown in Fig. 4.6e. In terms of average sprout diameter of microvessels which were measured 
over 3-mm distance from the aortic ring, a comparison between VEGF release alone, co-release 
of the angiogenic factors and PDGF sequential release indicated that simultaneous and sequential 
release of multiple angiogenic factors significantly (p-value<0.05) improved the average  
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Figure 4.7. Quantitative evaluation of sprouting angiogenesis stimulated by the angiogenic 
factor-loaded nanoparticles in fibrin matrix: variation of number of sprouts (a), maximum 
sprout length (b), sprouting regression phase (c) and the average sprout thickness (d) at 
three angiogenic factor release scenarios, and the maturing lumens composed of endothelial 
cell (white arrow), pericytes (green arrow), fibroblasts (red arrow), and tip cells (black 
arrow) after 5 days (scale bar=50 µm) (e) and 9 days (scale bar=100 µm) (f) for sequential 
PDGF release following co-release of bFGF and VEGF. 
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microvessel diameter (Fig. 4.7d). With sequential release of PDGF, the microvessels began to  
recruit pericytes surrounding endothelial cells as an indication of maturing lumen after 5 days 
(Fig. 4.7e) leading to anastomosis after 9 days (Fig. 4.7f). 
4.4.3. Predictability and sensitivity analyses of the ANN model 
Figures 4.8a illustrates the correlation between predicted and experimental data within 95% 
confidence level. The high coefficient of determination and low mean prediction error represent 
a good agreement between experimental release data and the predicted values from Eqs. (4.3)-
(4.5) associated with the testing data set. Moreover, the random distribution of the residual error 
represents unbiased predictability of the model (Fig. 4.8b). Figure 4.8c illustrates the 
experimental and predicted release kinetics associated with bi-layer nanoparticles of Group E, 
which was not involved in the training process of the model. The predicted release profile of bi-
layer nanoparticle demonstrated a very good agreement with the corresponding experimental 
data (Fig. 4.8c). Based on the predictability of the validated and tested model, the sensitivity of 
release profiles and loading capacity were analyzed with respect to different nanoparticle design 
parameters. The sensitivity analysis illustrates the variation of release profile with respect to 
PLGA concentration (Fig. 4.8d), PLGA viscosity (Fig. 4.8e), and glycolide to lactide ratio (Fig. 
4.8f) at the given nanoparticle design parameters. Besides, the model predicted that the fractional 
dose of the released protein over a certain period of time of interest (e.g. 15 days) can be 
regulated by adjusting PLLA/PLGA and G:L ratios of bi-layer nanoparticles (Fig. 4.8g), while 
the loading capacity is changed accordingly (Figs. 4.8h, i).  
4.4.4. The Geno-Neural model potential for rate-programming of the nanoparticles 
Figure 4.9a illustrates the variation of the best fitness value of populations over 500 generations 
in order to identify the fittest genes (nanoparticle characteristics) that provide the desired release  
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Figure 4.8. (a) The correlation between predicted and experimental values within 95% 
confidence limit, (b) Random distribution of the residual of prediction errors. (c) 
Agreement between predicted release profile and experimental data for bi-layer 
nanoparticles at PLLA/PLGA mass ratio of 2 (group E). (d-i) Sensitivity analyses of release 
and loading capacity with respect to the nanoparticle design parameters at (d) µPLGA=0.2 
dg/L, χG:L=1, χPLLA:PLGA=0, ε=1, d=220 nm, and PDI=0.21, (e) CPLGA=7%, χG:L =1, 
χPLLA:PLGA=0, ε=1, d=220 nm, and PDI=0.21, µPLGA, (f) CPLGA=7%, µPLGA=0.5 dg/L, 
χPLLA:PLGA=0, ε=1, d=250 nm, and PDI=0.21, (g) CPLGA=16.6%, ε=1, d=550 nm, and 
PDI=0.21, (h, i) µPLGA=0.2 dg/L, χPLLA:PLGA=0, ε=1, d=220 nm, and PDI=0.21. 
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patterns of interest (Fig. 4.9b). The fitness value significantly improves over 50 evolutions and 
then converges to the fittest value after 285 generations (Fig. 4.9a). Figure 4.9b illustrates the 
release patterns associated with the fittest nanoparticle characteristics proposed by the Geno-
Neural model (Fig. 4.9b). Notably, there is a very good agreement between the desired and 
predicted release profiles. 
Since the desired release profiles were very similar to those associated with experimental groups 
C and D, the nanoparticle characteristics of groups C and D were used as a reference to evaluate 
the predictability of the Geno-Neural model. Table 4.3 presents the nanoparticle characteristics 
proposed by the Geno-Neural model and those of experimental groups C and D. A comparison 
 
Figure 4.9. The evolution of the fittest individuals over 500 generations (a), and the release 
patterns associated with the fittest nanoparticle characteristics and the pre-determined 
release profiles (b). 
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Table 4.3. The nanoparticle characteristics associated with the fittest values proposed by 
the Geno-Neural model and the experimental groups C and D corresponding to the 
desired release patterns of zero-kinetics and time-delayed release.  
 Release patterns of interest 
Zero-order kinetics release  Time-delayed release Nanoparticle 
characteristics Experimental 
group C 
Geno-Neural 
model 
 Experimental 
group D 
Geno-Neural 
model 
CPLGA (%) 9 8.7  16.6 15.8 
µPLGA (dL/g) 0.2 0.2  0.2 0.2 
 χG:L 0.33 0.33  1 0.87 
 χPLLA:PLGA 0 0.18  1 1.1 
d (nm) 258 216  340 211 
PDI 0.3 0.31  0.32 039 
 
between the experimental and predicted characteristics of the nanoparticles indicates a very low 
discrepancy, suggesting that the Geno-Neural model is a reliable tool for pre-programming of the 
nanoparticles to achieve release rates of interest. 
4.5. Discussion   
The modified double emulsion solvent removal technique was successfully used to fabricate bi-
layer nanoparticles and microspheres with different structural and architectural characteristics. 
SEM images of the internal structures of bi-layer microparticles revealed porous core and shell 
where the pores represent the IAP that is entrapped in the polymeric network and sublimated 
during freeze-drying. Compared to small pores in the shell, the core featured larger pores, 
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indicating that a larger fraction of IAP was entrapped in the core rather than the shell (Fig. 4.3a). 
Since PLGA is the polymer that was primarily loaded with IAP during the first sonication, a 
larger fraction of entrapped IAP was expected to appear in PLGA, which mainly constituted the 
core. The scattered pores in the shell can be attributed to the second sonication (homogenization) 
during which the entrapped IAP in PLGA could be fractionally dispersed in PLLA. 
Although various PLLA/PLGA mass ratios resulted in bi-layer microparticles (Fig. 4.3b), the 
core and shell polymer composition was dependent on the polymer ratio. Based on the fact that 
PLGA has much higher solubility in ethyl acetate than PLLA [22], the hollow ring and solid core 
configurations from the ethyl acetate assay indicated that PLLA largely constituted the shell and 
core at PLLA/PLGA ratios of ≥1 and <1, respectively (Fig. 4.3c). A comparison between the 
cross-sections of the bi-layer microparticles before (Fig. 4.3b) and after (Fig. 4.3c) applying 
ethyl acetate assay suggests that some pores are appeared on the shell as a result of ethyl acetate 
dissolution. These pores could be attributed to PLGA residues in the shell due to incomplete 
polymer phase separation. Based on the fact that the polymer phase separation is a dynamic 
process occurred during solvent removal process at a critical polymer concentration, the solvent 
removal conditions may affect PLLA-PLGA phase separation. In case of incomplete phase 
separation, PLGA may appear in PLLA shell in a scattered pattern (Fig. 4.3c) that can 
consequently affect the rate-controlling characteristics of the shell. Since PLGA has a higher 
hydrolytic degradation rate than PLLA [14], the faster degradation of PLGA residues in the shell 
during the release process leads to the formation of scattered pores in the shell that increases the 
shell permeability and potentially causes impaired release of a bi-layer nanoparticle. 
Surface morphology assessment of ethyl acetate-treated shells revealed that the shell uniformity 
texture can be improved by adjusting the solvent removal rate and total polymer concentration 
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(Fig. 4.3d). Attempts were made to control the solvent removal rate by varying the EAP volume 
and composition, and polymer concentration in order to evaluate relatively high and low solvent 
removal rates at 100 ml of water and 30 ml of DCM-saturated 0.5% PVA solution, respectively. 
Examination of the cross-sectional surface morphology of ethyl acetate-treated shells confirmed 
that the size and distribution of PLGA-associated pores in the shell were reduced when the total 
polymer concentration decreased from 23.5 to 16.6% and the volume and composition of the 
EAP were changed from water (100 mL) to DCM-saturated 0.5% PVA (30 mL) (Fig. 4.3d). 
Pixel intensity standard deviation across an area of 0.01 mm2 was used to statistically evaluate 
the uniformity of the ethyl acetate-treated shell textures (Fig. 4.3d). The texture uniformity 
significantly (p<0.05) improved at a polymer concentration of 16.6% and EAP of DCM-
saturated 0.5% PVA (Fig. 4.3d, right image), which was applied to the preparation of bi-layer 
nanoparticles.   
Surface morphology assessment of single and bi-layer nanoparticles revealed spherical 
nanoparticles with no superficial cracks or large pores (Fig. 4.4a) but rather a smooth 
nanoparticle surface that would reduce the initial burst effect, which is often recognized as a 
significant defect of nano-particulate delivery systems. Notably, the nanoparticles exhibited a 
low agglomeration (Fig. 4.4a) which can be attributed to the use of 1% sucrose as the 
cryoprotectant for prevention of nanoparticle coalescence during freeze-drying. The presence of 
sucrose at the interface between freeze-dried nanoparticles also contributed to re-suspension of 
the nanoparticles in the fibrinogen solution due to high sucrose solubility in aqueous phase. SEM 
images also show that the size of the nanoparticles increased from ~200 to ~550 nm with 
PLLA/PLGA ratio (Fig. 4.4a), which is consistent with the measurements from dynamic light 
scattering (Table 4.2).    
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The nano-scale size, spherical geometry, smooth surface, reasonably low PDI (Table 4.2), and 
low agglomeration of the nanoparticles are the features that enhance surface area, bio-reactivity, 
and uniform distribution of the nanoparticles in the context of a fibrin matrix. With specific 
emphasis on the surface morphology of the nanoparticles on the fibers, SEM images showed that 
the fibers were coarser and less interconnected at the lower thrombin to fibrinogen ratio of 0.25 
U/mg compared to that at 1 U/mg (Fig. 4.4b); however, the nanoparticles exhibited a better 
distribution and coating over the fibers at the lower thrombin to fibrinogen ratio (Fig. 4.4b, left 
image). The effect of the fibrinogen-thrombin ratio on the fiber diameter may be explained by 
the higher rate of fibrin monomer formation at the higher thrombin per unit mass of the substrate. 
Although a thrombin to fibrinogen ratio of 1 U/mg could provide a larger surface area (Fig. 4.4b, 
right image), the fibrin matrix benefits an enhanced bio-reactive surface area at the lower ratio of 
0.25 U/mg due to better nanoparticle distribution over the fibers (Fig. 4.4b, left image). 
Localization of encapsulated protein in the core of the bi-layer nanoparticles is essential for 
achieving time-delayed release patterns with low initial burst effect. Fluorescence microscopy 
imaging revealed that the encapsulated proteins were largely confined in the core of the bi-layer 
microparticles at PLLA/PLGA ratios of 1 and 2 (Figs. 4.4c, d), while the encapsulated protein 
was identified in a scattered pattern in the shell at a PLLA/PLGA ratio of 3 (Fig. 4.4e). Given 
that the proteins exhibit greater affinity for the PLGA core, the scattered proteins in the shell 
may be attributed to incomplete PLGA core separation from PLLA shel at the higher 
PLLA/PLGA ratio of 3. The fluorescence intensity profile across the core and shell (Figs. 4.4f-h) 
indicated that the area under the curve declined with PLLA/PLGA mass ratio, indicating lower 
apparent encapsulation capacity of bi-layer nanoparticles at higher polymer mass ratios. In 
contrast, PLGA microspheres offered the highest protein encapsulation capacity but 
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demonstrated the highest amount of surficial protein which contributes to a higher initial burst 
effect. The observations from the composite images and fluorescence intensity profiles of the 
microspheres (Figs.4.4f-i) are consistent with measured values of protein loading capacity of the 
nanoparticles (Table 4.2). The fact that the loading capacity decreased with the PLLA/PLGA 
ratio of bi-layer nanoparticles (Table 4.2) suggests that, at higher PLLA/PLGA ratios, larger 
amounts of bi-layer GF-encapsulating nanoparticles would be required for a certain GF dose.  
In terms of release kinetics, bi-layer nanoparticles provided very low initial burst release (<7%) 
with a distinct time-delayed release pattern (~18-35 days) that was followed by zero order 
release kinetics (Fig. 4.5a). Ester-terminated PLGA nanoparticles (group C in Table 4.1) 
provided zero order kinetics following an initial release of ~20% whereas carboxyl-terminated 
nanoparticles (group A in Table 4.1) released nearly the entire payload within 10 days (Fig. 4.5a). 
Due to the fact that the carboxyl terminal group and lower L:G ratio at the reducced polymer 
concentrations increase hydrophilicity of the matrix, which subsequently enhance polymer 
degradability in an aqueous system, uncapped PLGA nanoparticles (4 and 7% w/v) at L:G ratio 
of 50:50 are more susceptible to bulk degradation than capped nanoparticles (9% w/v) at L:G 
ratio of 75:25. As such, uncapped PLGA nanoparticles at the lowest polymer concentration (4% 
w/v) lead to a rapid release profile with a high initial burst effect (Fig. 4.5a) that is attributed to 
the surficial protein attached to the surface (Fig. 4.4i). In contrast, bi-layer nanoparticles provide 
a very low initial burst effect of <7% (Fig. 4.5a), which is associated with the protein localization 
in the core and low surficial protein (Figs. 4.4f-h). The distinct lag phase that is provided by the 
bi-layer nanoparticles suggests that the shell can effectively control the protein release from the 
core (Fig. 4.5a). The zero order release kinetics following the lag phase indicates a progressive 
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bulk degradation of the shell that allows for steady diffusion of the protein from core to the 
surface.     
Given that PLGA and PLLA degradation leads to the generation of acidic products, the 
encapsulated protein is potentially susceptible to be denatured during the release process. 
Moreover, the fabrication process can also cause protein denaturation due to the large interface 
between aqueous and organic phases. These issues become more critical for bi-layer 
nanoparticles due to the fact that PLGA degradation acidic products can be accumulated in the 
core surrounded by PLLA shell. As such, it is crucially important to protect the protein during 
the release process and nanoparticle fabrication. Although the CD spectra of the releasing protein 
seem to slightly change after 25 and 50 days of release, compared to those of the control sample 
(Figs. 4.5c, d), an independent sample t-test at a significance level of 0.05 indicates no 
significant difference between the percentage of α-helix, β-sheets and random coil of the released 
protein and those of the standard sample (p-value>0.05) (Figs. 4.5e-g). Results from CD 
spectroscopy suggest that in the presence of sodium bicarbonate and sucrose, which were used as 
the buffering and stabilizing agents in IAP, the structural integrity of the encapsulated protein 
was preserved during nanoparticle preparation (Figs. 4.5b, e) and protein release (Figs. 4.5c, d, f, 
g). 
The rat aortic ring bioassay [24] revealed that the angiogenic factor-loaded nanoparticles were 
biologically active and significantly stimulated endothelial sprouting angiogenesis in the 
nanoparticle-incorporated fibrin matrix (Figs. 4.6a-d). Moreover, PLGA nanoparticles (group C) 
provided VEGF release only and co-release of VEGF, bFGF and PDGF (Fig. 4.6e). Particularly, 
a combination of bi-layer (group D) and PLGA nanoparticles (group C), which were loaded with 
PDGF and VEGF&bFGF, respectively, were successfully employed to provide sequential release 
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of PDGF after 5 days following co-release of VEGF&bFGF (Fig. 4.6e). While all of the pre-
designed release patterns improved angiogenesis compared to the control, the co-release and 
sequential release patterns provided significantly (p<0.05) larger number of sprouts and 
maximum sprout length than VEGF release alone (Figs. 4.7a, b). Moreover, the assessment of 
the rate of new sprout formation indicated that the sequential release of PDGF that followed 
simultaneous release of VEGF and bFGF may postpone the sprout regression phase that is 
represented by the negative sprouting formation rate (Fig. 4.7c). Furthermore, the sequential 
release of PDGF may improve the average sprout thickness, which appeared to be significantly 
larger than that of VEGF release alone (Fig. 4.7d). PDGF sequential release also resulted in 
morphologically maturing sprouts, which were characterized by the recruitment of pericytes 
surrounding endothelial sprouts and microvessel anastomosis after 5 and 9 days, respectively 
(Figs. 4.7e, f). The qualitative and quantitative assessments of the angiogenesis associated with 
different release scenarios suggest that the designed nanoparticles can be successfully used for 
regulation of simultaneous and sequential release of multiple GFs. In particular, pre-conditioning 
of the bi-layer nanoparticles in PBS for 30 days demonstrated effective in order to achieve an 
adjusted lag-phase for sequential release of PDGF after 5 days. As such, the bi-layer 
nanoparticles offer a great potential for temporal control of GF release.  
The fact that the release patterns rely on polymeric nanoparticle characteristics including 
polymer concentration, MW, terminal group, L:G ratio and PLLA/PLGA mass ratio (Fig. 4.5a) 
suggests that the release kinetics may be pre-designed by modulating these properties. The 
sensitivity analysis shows that the lag phase of release can be nonlinearly adjusted by tuning 
PLGA concentration from 10% to 16% w/v (Fig. 4.8d), the initial burst release can be reduced 
by increasing PLGA viscosity (Fig. 4.8e), and nearly zero order release profiles may be achieved 
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by adjusting G:L ratio between 0.33 and 0.65 (Fig. 4.8f). When a certain protein dose is required 
to be released within a pre-determined period of time, the right combination of PLLA/PLGA 
mass ratio and G:L ratio of the nanoparticles can satisfy the release conditions. For instance, the 
nanoparticles prepared at PLLA/PLGA ratio of 1 and G:L ratio of 0.67 can lead to a fractional 
dose of 11.6% after 15 days of release, while nanoparticles with G:L ratio of 0.4 would provide a 
fractional dose of 9.1%  (Fig. 4.8g). Excellent predictability (Figs. 4.8a, 4.9b), unbiased 
prediction residual error (Fig. 4.8b), and good agreement between predicted results and 
experimental dataset (Fig. 4.8c) (Table 4.3) suggest that the developed Geno-Neural model (Fig. 
4.2) can be a reliable tool to identify the optimum nanoparticle characteristics (Table 4.3) that 
result in desired release profiles; a process so call ‘rate-programming of the nanoparticles’. 
Moreover, the model can predict the nanoparticle loading capacity corresponding to the 
determined polymeric design parameters in order to estimate (Eq. 4.2) the total amount of the 
GF-loaded nanoparticles which will be required for a particular release pattern. The proposed 
Geno-Neural model offers a great potential for designing a nano-particulate delivery system that 
may require different designs of the nanoparticles to provide simultaneous and sequential release 
of multiple GFs.     
4.6. Conclusion 
We have developed bioactive bi-layer nanoparticles which are composed of protein-
encapsulating PLGA core that is surrounded by PLLA shell and featured low initial burst effect, 
time-delayed release and structural integrity of the encapsulated protein during a prolonged 
release. To the best of our knowledge, no other bioactive bi-layer nanoparticles have been 
reported for sequential GF release. The nanoparticle-incorporated fibrin matrix demonstrated 
bioactive to stimulate angiogenesis from embedded rat aortic rings (Figs. 4.6q-d). The bi-layer 
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nanoparticles provided time-delayed release patterns with very low initial burst effect, essential 
for sequential release of GFs. A combination of GF-loaded PLGA and bi-layer nanoparticles 
were successfully employed to provide different GF release scenarios as VEGF release only, 
VEGF, bFGF and PDGF co-release, and sequential release of PDGF following co-release of 
VEGF and bFGF (Fig. 4.6e). Quantitative analyses of the sprouting angiogenesis indicated a 
significant difference in angiogenic response between the three GF release scenarios (Fig. 4.7), 
suggesting that the nano-particulate delivery systems were able to regulate the pre-designed GF 
release patterns to promote angiogenesis in fibrin matrix of a cardiac patch.    
Based on the fact that the physical and polymeric characteristics of the nano-particulate delivery 
system can be adjusted to provide various release patterns, a predictive Geno-Neural model was 
developed, tested, and successfully employed to rate-program nanoparticles for achieving desired 
zero-order kinetics and time-delayed release of interest. There was an excellent agreement 
between the predicted and experimental values of the nanoparticle physical and polymeric 
characteristics resulting in the desired release patterns of interest. The proposed Geno-Neural 
approach offer a great potential for designing and optimization of PLLA/PLGA-based 
nanoparticles to facilitate pre-programming of various release profiles for different tissue 
engineering applications.   
Finally, the potential of the developed nanoparticles is not limited to temporal control of GFs. 
Using the proposed Geno-Neural model, the nanoparticles are rate-programmed and fabricated, a 
and then incorporated into a hydrogel (e.g. fibrin) which can be precisely micro-patterned into a 
3D cardiac patch with 3D-bioprinting technique to achieve spatiotemporal control over the 
release of GFs in the patch.      
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CHAPTER 5 
MODELING OF CONTROLLED RELEASE OF BIOACTIVE AGENTS 
FROM BI-LAYER NANOPARTICLES FOR TISSUE ENGINEERING 
“This chapter has been submitted as “M. Izadifar, M. Kelly, and X. B. Chen, 2016, Development 
of Bi-layer Nanoparticles for Temporal Control of Release of Bioactive Agents for Tissue 
Engineering: an Experimental and Computational Study, Journal of Biomechanical Engineering, 
(Under Review)” According to the Copyright Agreement, "the authors retain the right to include 
the journal article, in full or in part, in a thesis or dissertation". 
5.1. Abstract 
Spatiotemporal control of release of bioactive agents from nanoparticles is essential to many 
tissue engineering applications, yet remains a challenge due to its complicated behaviour. 
Notably, the release behaviour relies on the physical and chemical properties of the 
nanoparticles, which may be regulated and optimized for achieving desired release profiles. To 
this end, this paper presents two novel modeling approaches based on local volume averaging 
(LVA) and Geno-Mechanistic modeling to represent the controlled-release of bioactive agents 
from bi-layer nanoparticles. Differential mass transfer governing equations based on LVA 
method were derived and numerically solved to provide the insight on the transport and 
degradation properties of the nanoparticles. Also, a system of analytical governing equations of 
release of pseudo bi-layer nanoparticles was coupled with genetic algorithm to provide a hybrid 
model, so called ‘Geno-Mechanistic’ model, to predict volume-averaged release properties of the 
nanoparticles at various conditions.  Single polymer and bi-layer nanoparticles were fabricated 
from poly(lactide-co-glycolide) and poly(L-lactide) with varying fabrication conditions where 
ovalbumin was used as a protein model for the release study, loading capacity examination, and 
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protein structural integrity assessment over 70 days. The experimental data were used to assess 
the model predictability. The models presented in this study will be powerful, effective and 
efficient tools to predict and optimize the controlled release of bioactive agents from polymeric 
nanoparticles for many tissue engineering applications. 
5.2. Introduction 
Tissue engineering aims to develop functionally bioactive and viable constructs (e.g. cell-
incorporated cardiac patch) for damaged tissue/organ repair. Development of bio-functional 
constructs is quite challenging due to the fact that the biological events involved in tissue 
regeneration are really complex. Increasing level of complexity and functionality in the design of 
the constructs demands incorporation of sophisticated delivery systems allowing for temporal 
control over the sequential release of multiple growth factors (GFs) in constructs [1].  
Biodegradable polymeric nano-particulate delivery systems are increasingly gaining interest in 
the field of GF controlled release in tissue engineering. Specifically, bi-layer polymeric 
nanoparticles offer fundamental advantages over their conventional monolithic counterparts to 
provide sequential release of multiple GFs [2] and avoid antagonism effects of GFs, such as 
vascular endothelial GF (VEGF) and platelet-derived GF (PDGF) [3], by physically separating 
them in core-shell constructs and/or suppressing the initial burst effect [2]. Moreover, the nano-
scale GF-encapsulating polymeric devices enhance bio-reactive surface area of cardiac 
constructs, thereby improving cell-construct interactions.  
Physical, chemical, structural and architectural characteristics of the polymeric nanoparticles 
have profound effects on release behaviour. Mathematical models are powerful and efficient 
tools that facilitate the development and optimization of the GF delivery systems. Furthermore, 
mechanistic modeling combined with precise experimental evaluation of the nano-particulate 
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delivery systems improves the understanding of the mechanisms of GF release, and thus help to 
determine crucial parameters that regulate the release rate. Also, predictive models can reduce 
and even eliminate the need for experiments, thus saving time and the associated costs. 
Comprehensive reviews of release kinetics from biodegradable matrices including particulate 
delivery systems have been reported in the previous studies [1-5]. Some models consider initial 
burst release and bulk degradation of nanoparticles [6], while more complex models involve 
diffusion-dissolution mechanism combined with bulk/surface degradation to describe the release 
[7-9]. Another release modeling approach is based on the summation of three sequential 
mechanisms of burst release, relaxation-induced payload dissolution and diffusion [10, 11]. 
Monte Carlo-based simulation have been also employed to describe random chain scission 
process during polymer degradation in order to predict the corresponding drug release from 
polymeric delivery systems [12]. Despite numerous models for controlled release, there is no 
report on mechanistic models to elucidate governing mechanism and provide predictive means 
on release behaviour and parameters for bi-layer polymeric nanoparticles. Considering the great 
potential of GF-encapsulating bi-layer nanoparticles for sequential release of GFs in 
cardiovascular tissue engineering, it is crucial to develop mechanistic models of release for bi-
layer nanoparticles which are specifically composed of poly(lactide-co-glycolide) (PLGA) and 
poly(L-lactide) (PLLA) due to their biocompatibility and biodegradability, as well as the 
approval for use from the Food and Drug Administration and European Medicine Agency [13]. 
In this study, a mathematical model based on local volume averaging (LVA) approach and local 
equilibrium was developed and numerically solved for simulation of controlled release and 
identification of transport and degradation properties of the core and shell of a bi-layer 
nanoparticle. Also, a Geno-Mechanistic model consisting of a system of governing equations of 
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release coupled with genetic algorithm (GA) was developed to provide a predictive tool for 
estimation of crucial transport properties and release parameters from PLLA-PLGA bi-layer 
nanoparticles and their conventional monolithic counterparts. The nanoparticles were fabricated 
and their physical, chemical and structural parameters were characterized and applied to the 
models to predict release behaviours at various conditions for the verification of the developed 
models. The predictability of the models and estimation of release parameters were assessed 
based on experimental data collected from release study of the protein -encapsulating 
nanoparticles.  
5.3. Theory and experiments 
5.3.1. Development of the mechanistic model using LVA  
A polymeric nanoparticle is a matrix that can be described as a porous medium consisting of a 
solid phase (polymer) and the spaces which are filled with fluid phase (e.g. aqueous phase during 
the release) (Fig. 5.1a). Depending on the polymer packing density, the range of pore size may 
vary from molecular size ( Å) to several nanometres. When the polymeric matrix structure cannot 
be fully described within the pore size, a representative elementary volume (REV) (Fig. 5.1a) is 
typically used to describe the porous medium [14]. A differential volume as small as the size of a 
pore may not be a representative element to describe a porous medium property (e.g. porosity) 
but as the size of the differential volume increases the volume-averaged properties of the porous 
medium converges to a certain value (Figs. 5.1b, c). As such, the REV is defined as the smallest 
differential volume with a characteristic length (l) (Fig. 5.1a) and volume (VREV) (Figs. 5.1b, c) 
that results in statistically meaningful average properties of the porous medium as [15]:  
∫=〉〈
REVVREV
dV
V
φφ 1                (5.1) 
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Figure 5.1. A polymeric nanoparticle from a porous media point of view: (a) the linear 
dimension of a nanoparticle, the characteristic length of the REV, the pore size with respect 
to REV length, and the local volume averaged equilibrium at pores between the fluid phase 
and the solid phase; (b) the smallest differential volume with meaningful properties of the 
porous medium; (c) the effect of REV size on a matrix property such as porosity for 
determination of the characteristic length of REV; and (d) the local volume averaged mass 
flux and properties to set a differential mass balance over a REV of a polymeric 
nanoparticle. 
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where φ is a property of interest of the fluid or solid phase of the medium, and 〉〈φ represents the 
local volume averaged property. Development of transport governing equations based on 
conservation of mass, heat and momentum over the REV and local volume averaged properties 
is considered as the local volume averaging (LVA) approach. In general, LVA can be applied to 
a porous medium when the pore size (dp) of a polymeric matrix is smaller than REV, and the 
characteristic length of REV (l) is much smaller than the linear dimension (L) of the porous 
medium (Fig. 5.1a). Extending the concept of LVA to nano-scale (Fig. 5.1a), mass transport 
equations can be integrated over the REV based on LVA approach in a spherical nanoparticle 
where the dynamic equilibrium of a soluble species (e.g. protein) between the solid phase 
(polymeric matrix) and fluid phase (aqueous phase) in the REV can be also averaged over the 
REV. When a nanoparticle is exposed to an aqueous medium (e.g. water, hydrogel, physiological 
fluid), the protein molecules attached to the polymeric matrix reach a dynamic equilibrium with 
the aqueous phase filling the pores, which is defined by a partition coefficient of λ that relates 
the local volume averaged concentration of the protein in the solid phase ( sC〉〈 ) to that in the 
fluid phase ( fC〉〈 ) (Fig. 5.1a). However, the protein diffusion toward the nanoparticle surface is 
suppressed because of low porosity, high tortusity and non-interconnected pores of the matrix, 
while hydrolytic reactions begin to degrade the polymer and reduce the polymer molecular 
weight (MW). Depending on the degree of crystallinity, initial MW, terminal group (ester or 
carboxyl) of the polymer and nanoparticle structure, the polymer degradation rate varies, and 
subsequently the time for bulk degradation onset changes. As such, a lag phase (Td) between the 
hydration and the diffusional mass transfer-based release of the protein may be occurred.  
When the amorphous regions of the polymer matrix, which are degraded faster than the 
crystalline regions, are eroded, the pores begin to grow and enhance the protein diffusion across 
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the matrix where the dynamic local equilibrium is maintained. Figure 5.1d illustrates the 
schematic diagram of the polymeric nanoparticle differential volume with a thickness of ∆r and 
the corresponding input and output diffusional mass flows. Since the local volume averaged 
properties such as porosity, protein concentration and polymer molecular weight (MW) changes 
with time (Fig. 5.1d), the flux of the mass flow varies with both space and time. Applying local 
equilibrium and LVA method to the differential mass balance over the different REV results in 
the mass transport governing equation as: 
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where t is time (s), r is radius (m), degmˆ is the local volume averaged protein degradation rate 
(mgm-3s-1) due to protein denaturation associated with the acidic PLGA and PLLA degradation 
products, and effD is the effective diffusion coefficient (m2s-1) which can be defined by [10]: 
)()( tMW
KDtD ieff +=                                             (5.3) 
where Di is the initial effective diffusivity (m2s-1), MW is the polymer molecular weight (kDa) 
associated with the core and shell, and K is constant (m2s-1kDa). The effective diffusivity is 
related to the time-dependent porosity of the matrix as [14, 15]: 
ϑ
ε )()( 0 tDtDeff =               (5.4) 
where D0 is the protein diffusivity in the aqueous phase (m2s-1) (e.g. 7.76×10-11 m2s-1 for 
ovalbumin in water at 25°C [17]), ϑ is the tortusity, and ε is the porosity. Assuming that PLGA 
and PLLA follow a pseudo-first order degradation rate [16], the average time-dependent polymer 
MW can be estimated by: 
( )tKMWtMW d−= exp)( 0                                                                                  (5.5) 
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where Kd is the polymer degradation rate constant (s-1).  
Under the assumptions that the protein is homogenously distributed within the matrix and that 
the mass transfer resistance at the surface of the nanoparticle is negligible, the boundary 
conditions (Fig. 5.2a) of Eq. (5.2) can be defined by: 
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where C is the total protein concentration in the release medium, R is the radius of the 
nanoparticle, γ is the partition coefficient that relates the interfacial protein concentrations at the 
interface between the nanoparticle surface and the release medium, fcoreC〉〈  and fshellC〉〈 are the 
interfacial local volume averaged protein concentrations at the interface between core and shell 
matrices with corresponding effective diffusivities of coreeffD  and shelleffD and core and shell 
thicknesses of Rcore and Rshell, respectively. The initial condition is given by: 
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where ψ is the loading capacity in terms of mass of protein per unit mass of encapsulating 
nanoparticle, ρw is the density of the fluid phase (aqueous phase) (kgm-3) and polρ is the average 
polymer density (kgm-3).   
5.3.2. Numerical simulation and estimation of the release mechanistic parameters  
Assuming that i) the protein denaturation in the nanoparticle is negligible due to the presence of 
buffering excipients that neutralize acidic degradation products; ii) the mass transfer resistance at  
 240 
 
Figure 5.2. (a) the boundary and initial conditions associated with the LVA-based 
mechanistic model to describe controlled release from a bi-layer nanoparticles and (b) 
schematic diagram of the developed Geno-Mechanistic  model. 
the particle-release medium interface is negligible due to sufficiently high mixing, iii) 
nanoparticles are spherical with relatively uniform size distribution associated with reasonably 
low PDI, iv) at each differential time step, time-dependent polymer MW, porosity and effective 
diffusivity can be averaged over PLGA core and PLLA shell independently, and v) the solubility 
of ovalbumin in water is sufficiently high to allow for rapid dissolution in the water-filled pores, 
Eqs. (5.2)-(5.6) were numerically solved using the finite element method in COMSOL (4.4) for 
core-shell bi-layer nanospheres at three PLLA/PLGA mass ratios. The protein concentration 
across the nanosphere that was computed at each temporal and spatial step of the numerical 
solution was normalized with respect to the initial condition, and the time-dependent cumulative 
protein release (X(t)) corresponding to each time step was calculated from: 
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where S(t) is the cumulative fraction of protein retained in the core and shell at each time step. 
Simulation parameters, including the nanoparticle size and the shell to core thickness, were 
identified based on the measurement from dynamic light scattering and the measurements of 
PLLA shell to PLGA core thickness ratios from extrapolated results corresponding to bi-layer 
microspheres (Fig. 5.3k). The initial polymer MW was adopted from polymer information 
supplied by the supplier. Starting from initial values of the parameters suggested by GA, the 
model was numerically solved in an iterative fashion to search for optimal core and shell 
transport and degradation properties such that sum of squared of prediction error and coefficient 
of determination between experimental data and the predicted values of cumulative release were 
minimized and maximized, respectively. Then, the estimated degradation and diffusivity values 
were compared to those reported by Wu and Wang (2001) [22]. Also, the estimated values of 
core and shell transport and degradation properties were then compared to the volume-averaged 
values predicted by the Geno-Mechanistic model presented in the following. 
5.3.3. Development of the Geno-Mechanistic model   
5.3.3.1. Governing equations 
It is reasonable to develop the governing equations of release based on a pseudo bi-layer 
nanoparticle that exhibits similar release kinetics as a core-shell bi-layer nanoparticle. The 
pseudo bi-layer nanoparticle is assumed to be a PLLA-PLGA composite nanosphere that 
possesses volumetrically averaged properties of release. Unlike the LVA approach in which the 
local volume averaged transport and degradation properties and equations are used to predict 
spatial and temporal release behaviour of core and shell, the pseudo bi-layer nanoparticle-based 
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properties and governing equations approximate the temporal release and property changes that 
are volumetrically averaged over the entire nanoparticle.  
When the nanoparticles are placed in a release medium, the hydration is occurred quickly for 
bulk eroding polymers such as PLGA [18] where the protein molecules attached to the 
nanoparticle surface or entrapped within the superficial pores are quickly dissolved and released 
into the medium, a process called ‘initial burst release’. Although often happening within a short  
period of time, the burst release is a non-linear process, depending on the protein concentration 
and solubility. The time-dependent cumulative protein release, X(t), due to the burst effect [20] 
can be defined by: 
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                                   (5.9) 
where Mb is the volume-averaged amount of surficial protein (mg), M∞ is the total amount of the 
protein which can be eventually released over an infinite time from the entire nanoparticles, K0 is 
the burst release rate constant (day-1).  
With the assumption of the quick polymer matrix hydration [18], polymer bonds begin to break 
down because of hydrolysis where the kinetics of the polymer degradation can be described by 
Eq. (5.5). While polymer degradation begins after hydration, it is assumed that the diffusion of 
the degradation products of the polymer matrix considerably takes place after the onset of bulk 
erosion of the matrix. As such, depending on the induction time and bulk erosion period, the 
polymer degradation rate (Kdeg) in Eq. (5.5) may take different values accordingly.    
Assuming that the polymer degradation and pore formation take place heterogeneously with 
spatially equal probability of pore formation within a polymeric matrix, porosity simply exhibits 
time-dependent with a random fashion of pore formation that is normally distributed within the 
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polymeric matrix during bulk degradation. Taking into account the coalescence of pores that 
makes the pore formation cumulative, the time-dependent porosity is defined by: 
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where 2σ is the variance in the time for pore formation that represents the degree of crystallinity 
of the polymeric matrix, and τ is the mean time of pore formation for PLGA and PLLA that 
follows the first order degradation rate given by: 
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where Kdeg is the average pseudo-first order degradation rate, MW(t) is the time-dependent 
polymer MW.  
After the induction time when the polymer MW and pores are sufficiently decreased and formed, 
respectively, diffusional mass transfer takes control over the protein release across the matrix and 
can be expressed by the modified dimensionless Fickian diffusion model:   
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Combining Eqs. (5.9) and (5.12), the total cumulative mass fraction of the released protein from 
nanoparticles is: 
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where Xb is the cumulative mass fraction of the protein (Mb/M∞) released during the initial burst, 
R is the radius of the nanosphere, and Deff is the time-dependent effective diffusivity that relies 
on the average polymer MW, which changes with time as a function of degradation rate constant 
(Kdeg) associated with the induction time and bulk erosion period. Based on the average pseudo-
first order degradation rate constant (Kdeg), the distribution of mean time of pore formation (τ ) is 
obtained from Eq. (5.11) for the given initial MW, the associated standard deviation is calculated 
and adjusted by crystallinity-based factors of 5, 4, and 4.5 corresponding to PLGA lactide to 
glycolide ratios of 50:50, 75:25 [20], and composite PLGA and PLLA. The variance ( 2σ ) is 
calculated using the adjusted standard deviation of the mean time of pore formation, and then 
used for estimation of time-dependent porosity in Eq. (5.10). 
5.3.3.2. Geno-Mechanistic modeling approach 
GA, which is based on biological concepts of evolution and genetics, is an iterative and 
population-based search algorithm for optimization problems [21]. Coupled with the governing 
equations of controlled release, GA-mathematical model, or so called “hybrid model” afterwards, 
allows for identification of multi objective inverse simulation of the release process where the 
fittest values of the release parameters can be estimated. Figure 5.2b illustrates the schematic 
diagram of the modeling approach in which a system of governing equations involving Eqs. 
(5.3), (5.5), (5.9)-(5.13) are solved simultaneously in order to map the fittest genes that are 
defined as the critical mechanistic release parameters in an evolutionary fashion. Gens undergo 
genetic operators (crossover, mutation, selection and elitism), and then are applied to the 
mathematical model to predict the outcome of each individual in the generation. The outcome is 
evaluated by a fitness function to generate the next generation. The evolving process continues 
until the fitness of the genes is maximized (Fig. 5.2b). Based on a preliminary sensitivity 
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analysis, an initial population of 500, number of generations of 200, selection rate of 0.08, 
mutation rate of 0.05, and crossover rate of 0.6 were chosen for the hybrid model to search for 
the fittest genes (release parameters corresponding to the range of nanoparticle size measured by 
dynamic light scattering method. The release profiles predicted based on the estimated release 
parameters (the fittest genes) was statistically compared to the experimental data to verify the 
performance of the inverse simulation approach.  
5.3.4. Fabrication of PLGA and bi-layered nanoparticles 
Bi-layered nanoparticles were fabricated using a modified double emulsion solvent extraction 
technique as described in our previous study [2]. Briefly, polymers were dissolved in HPLC 
grade dichloromethane (DCM) (Sigma-Aldrich, MO) and ovalbumin (OVA) (Sigma-Aldrich, 
MO) solution was used as the protein model in the internal aqueous phase (IAP). The IAP was 
added to PLGA (DURECT Co., Cupertino, CA) organic phase followed by sonication and the 
emulsion was subsequently mixed with PLLA (DURECT Co., Cupertino, CA) solution. The 
mixture was sonicated in polyvinyl alcohol (PVA) (Sigma-Aldrich) solution and then added to 
the external aqueous phase (EAP) that stirred for 24 h. The nanoparticles were collected by 
ultracentrifugation (Optima L-Series, Becman Coulter Inc., Palo Alto, CA) and washed three 
times with de-ionized water followed by freeze drying at at -80°C for 3 days. The modified 
double emulsion solvent removal technique was applied to the preparation of single polymer 
(PLGA) nanoparticles [19]. Table 5.1 summarizes the conditions used to prepare the 
nanoparticles and their groups for the subsequent experiments.  
5.3.5. Physical, structural and morphological assessments 
Dynamic Light Scattering technique (Zetasizer, Nano ZS3000; Malvern Instruments, Malvern, 
UK) was used to measure the size, polydispersity index (PDI) and zeta potential of nanoparticles.  
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Table 5.1. Groups of  the protein-loaded bi-layered and single polymer nanoparticles and their 
fabrication conditions. 
Experimental Group Polymer characteristic 
I II III IV 
Concentration (% w/v) 9 16.6 16.6 16.6 
PLGA viscosity (dLg-1) 0.2 0.65 0.65 0.65 
PLLA viscosity (dLg-1) n/a 0.9 0.9 0.9 
PLGA L:G ratio 75:25 50:50 50:50 50:50 
PLGA to PLLA mass ratio 0 1 2 3 
 
Surface morphology of the nanoparticles was assessed under a field-emission scanning electron 
microscope (JSM-6010 LV, JEOL, Ltd., Tokyo, Japan) at 15 kV.  
To view the internal bi-layered structure and to identify the composition of the core and shell, 
microspheres were suspended in a mixture of gelatine (20%) and glycerine (5%) for 8 h at room 
temperature in a cryostat mould and frozen at -80°C for an hour before the mould was placed 
over liquid nitrogen.  The solidified gel was removed from the mould and sectioned at 10 µm 
using a cryostat at -30°C. The cross sectioned particles were viewed under a phase contrast 
microscope to view the core and shell structure. The microscope slides holding the particle cross-
sections were immersed in ethyl acetate for 12 hours allowing PLGA to be dissolved while 
leaving PLLA in place due to higher PLGA solubility (580 mgml-1) than PLLA solubility (0.1 
mgml-1) [4] in ethyl acetate. Ring shape or a solid core configuration of the remnant of the cross 
sections in ethyl acetate was viewed under a phase contrast to identify the composition of the 
shell and core of the bi-layered structures. 
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To gauge the protein distribution across the bi-layered structures, the microspheres loaded with 
labelled protein (OVA Texas Red® Conjugate, Life Technologies, Grand Island, NY) were 
cross-sectioned and viewed under a fluorescence microscope. To assess the effect of particle size 
and PLLA to PLGA mass ratio on the protein distribution and shell thickness of the bi-layered 
configurations, two dimensionless indices of shell-to-core thickness ratio and shell-to-core 
fluorescence intensity ratio defined as the average shell thickness divided by the core radius and 
the average fluorescence intensity of the shell divided by that of the core were defined, 
respectively, and evaluated for 100 microparticles at the largest diameter of the cross-sections (x-
y plane at the particle center) and statistically compared for three polymer mass ratios of 1:1, 2:1 
and 3:1.  
5.3.5. Release study and protein encapsulation capacity assessment 
To determine the protein encapsulation capacity, protein-loaded nanoparticles were re-suspended 
in 0.1 M sodium hydroxide containing 5% of sodium dodecyl sulphate followed by incubation at 
room temperature overnight in an orbital shaker. Centrifuging at 15000 rpm for 10 min, the 
supernatant was collected and used for quantifying OVA concentration based on Bicinchoninic 
acid (BCA) protein assay (Sigma-Aldrich, MO). Reading the absorbance of the samples 
including the standards at 562 nm using a UV spectrophotometer (Synergy HT, BioTek 
Instruments, Inc., Winooski, VT), OVA concentration was determined and the loading capacity 
was then calculated as: 
NP
OVA
C
C
=ψ                                    (5.14) 
where ψ is the loading capacity (mg OVA mg-1 nanoparticles), OVAC  is OVA concentration from 
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the direct extraction (mg OVA ml-1), and NPC  is the concentration (mgml-1) of OVA-loaded 
nanoparticles used for OVA extraction.  
Based on direct measurement of OVA in the release medium, the release study was conducted 
in-vitro for the protein-loaded nanoparticles. Certain amounts of nanoparticles were re-
suspended in phosphate-buffered saline (PBS) (Sigma-Aldrich, MO) in glass vials which were 
placed on an orbital shaker with a swinging sample holder to provide rotational and axial mixing 
at 37°C. At predetermined time intervals over 70 days, 800 µl of each sample was centrifuged at 
10000 rpm at 4°C. 450 µl of the supernatant was used for quantifying OVA concentration and 
then was replaced by 450 µl fresh PBS. The nanoparticles pallet in each vial was then re-
suspended in PBS on a vortex and transferred into its corresponding vial on the orbital shaker. 
The protein concentration was quantified by reading the absorbance of the samples at 562 and 
572 nm using UV spectrophotometer (Synergy HT, BioTek Instruments, Inc., Winooski, VT). 
The experiments were carried out in triplicates. 
5.4. Results and discussion 
5.4.1. Physical, structural and release characteristics of bi-layer nanoparticles 
Figure 5.3a illustrates SEM image of the cross-section of a bi-layer microsphere at a 
PLLA/PLGA mass ratio of 1. A porous core can be distinguished from the less porous shell. The 
pores in the core represent the freeze-dried IAP that is largely entrapped in the core matrix. 
Figures 5.3b, c illustrate the bright field and fluorescence microscope images, respectively, of a 
cross-sectioned bi-layer microsphere at PLLA/PLGA mass ratio of 3. The encapsulated protein 
can be largely identified in the core (Fig. 5.3c), while a scattered pattern of the protein can be 
noted in the shell. Figure 5.3d depicts ethyl-acetate treated cross-section of the bi-layer 
microsphere. The hollow ring configuration indicates that PLGA largely constitutes the core 
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because of much larger PLGA solubility in ethyl acetate than PLLA [2]. Considering that PLGA 
is the main constituting polymer of the core (Fig. 5.3d), the localization of the protein in the core 
(Fig. 5.3c) indicates that the encapsulating protein has higher affinity to PLGA than PLLA. Also, 
the first sonication in which IAP is encapsulated in PLGA contributes to localization of the IAP 
that contains protein in the core (Fig. 5.3a). The presence of the scattered pattern of protein in the 
shell may be attributed to the presence of PLGA in the shell [2]. Figure 5.3e depicts pores 
associated with PLGA dissolution in ethyl acetate. Depending on the degree of polymer phase 
separation during the preparation process, the fraction of PLGA residue in the shell increases if 
the phase separation is incomplete. As such, due to the higher PLGA affinity of the protein (Fig. 
5.3c), the presence of the protein in the shell is elevated if polymer phase separation is 
incomplete.  
Figures 5.3f-i illustrate the surface morphology, geometry and level of agglomeration of the 
nanoparticles prepared at different PLLA/PLGA mass ratios. Spherical geometry and low 
nanoparticle agglomeration can be noted from the SEM images. The size of the nanoparticles 
increases with PLLA/PLGA mass ratio from ~180 nm (Fig. 5.3f) at PLLA/PLGA mass ratio of 0 
to ~670 nm (Fig. 5.3i) at PLLA/PLGA mass ratio of 3. This observation is consistent with the 
average nanoparticle size measurements resulted from dynamic light scattering (Table 5.2). 
Surface morphology of the nanoparticles reveals no superficial pores or cracks, which can 
significantly contribute to the reduction of initial burst effect. Measurements from dynamic light 
scattering indicated reasonably low polydispersity index (PDI) at PLLA/PLGA mass ratios of 0-
2 (Table 5.2) indicating a relatively uniform size distribution of the nanoparticles. However, PDI 
of bi-layer nanoparticles increased (>0.4) at PLLA/PLGA mass ratio of 3, reflecting less uniform 
size distribution that can also be seen in the corresponding SEM image (Fig. 5.3i). 
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Figure 5.3. (a) SEM image, (b) bright field and (c) fluorescence microscopy images of the 
core-shell structures, (d) SEM image of the ethyl acetate-treated cross-section of a bi-layer 
structure, (e) the emerging pores on the shell after applying ethyl acetate assay, (f-i) surface 
morphology of the nanoparticles at PLLA/PLGA mass ratios of 0, 1, 2 and 3, respectively, 
(j, k) the effects of particle size and PLLA/PLGA mass ratios on the shell-to-core protein 
distribution ratio and shell-to-core thickness ratio; (l) the protein release profiles of the 
nanoparticles, and (m) deconvolution of the protein CD spectra compared to control.  
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Figures 5.3j, k illustrate the average values of shell/core fluorescence intensity and thickness 
ratios, respectively, corresponding to three average particle size ranging from 30 to 80 µm at 
polymer mass ratios of 1, 2 and 3. The shell/core fluorescence intensity ratio (Fig. 5.3j) and the 
shell/core thickness ratio (Fig. 5.3k) increase with the polymer mass ratio (p-value<0.05), while 
the effect of average particle size is insignificant (p-value>0.05). Statistically being independent 
of particle size, the indices may be extrapolated to explain the shell/core protein distribution and 
thickness ratios for bi-layer nanoparticles. 
Figure 5.3l illustrates the release profile of the nanoparticles that were prepared at different 
conditions (Table 5.1) over 70 days. A very distinct time-delayed release and low initial burst 
release of bi-layer nanoparticles, which were prepared at PLLA/PLGA mass ratios of 1-3 (Figs. 
5.3g-i), can be distinguished from the nanoparticles that were prepared with PLGA only (Fig. 
5.3f). The release lag phase of the bi-layer nanoparticles is followed by a zero order kinetics 
(Groups II-IV), while PLGA nanoparticles exhibit a zero order kinetics from the beginning (Fig. 
5.3l). Figure 5.3m illustrates the secondary structure in terms of relative proportion of α-helix, β-
sheets and random coil of the protein released over 70 days compared to those of the control 
sample. An independent sample t-test at a significance level of 0.05 indicate no significant 
difference between the percentage of α-helix, β-sheets and random coil of the released protein 
and those of the standard sample (p-value>0.05), suggesting that the structural integrity of the 
encapsulated protein has been preserved during the release process (Fig. 5.3m). 
Table 5.2 summarizes measured values of size, PDI and loading capacity of the nanoparticles 
corresponding to the experimental groups.  
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Table 5.2. Measured physical characteristics of the nanoparticles corresponding to the 
experimental groups.  
Experimental Group Physical characteristic 
I II III IV 
Size (nm) 258±12 340±29 490±16 685±43 
PDI 0.30±0.03 0.32±0.08 0.38±0.05 0.46±0.04 
Loading capacity (µg/mg) 0.2 0.05 0.02 0.01 
 
5.4.2. Evolutionary-based parameter estimation and predictability of the Geno-Mechanistic  
model 
Figures 5.4a-e illustrate the evolution of the fitness of the best individual and major release 
mechanistic parameters, so called genes, of each generation over 500 generations. The best 
fitness value of each generation is significantly improved after 50 evolutions and is further 
enhanced and reaches its best and constant value after 300 generations (Fig. 5.4a). Consistent 
with the improving fitness value, the gens that represent the mechanistic release parameters such 
as initial effective diffusivity of the matrix (D0), degradation rate constant (kdeg) and the release 
lag phase evolve and converge to their fittest values over 500 generations (Figs. 5.4b-e). 
Applying the fittest values of the release parameters to the system of governing equations (Eqs. 
5.2-5.5), the release profiles corresponding to the nanoparticle polymeric groups I-IV (Table 5.1) 
were predicted using the Geno-Mechanistic model. Figure 5.4f illustrates the predicted values 
and the experimental data of cumulative release of the protein associated with different designs 
of nanoparticles. The coefficient of determination of 0.98 indicates a very good agreement 
between experimental data and predicted values (Fig. 5.4g) where the mean prediction error 
 253 
(MPE) is less than 5% and the residual of errors exhibits a random distribution that indicates 
unbiased predictability of the Geno-Mechanistic  model (Fig. 5.4h). High coefficient of 
determination, low MPE and random distribution of residual of errors indicate that the model can 
successfully predict the zero order kinetics of the PLGA nanoparticles (Group I) and the time-
delayed release pattern of the bi-layer nanoparticles of groups II-IV. Figure 5.4i illustrates the 
variation of the volume-averaged MW of the nanoparticles during the release. The PLGA 
nanoparticles (Group I) undergo 50% and 90% of the polymer degradation within 12 and 40 
days, respectively (Fig. 5.4i). The PLGA degradation profile that was predicted by the Geno-
Mechanistic model in terms of temporal changes in fractional MW was consistent with the 
datasets reported by Batycky et al. (1997) [23], Wang et al. (2006) [24] and Xi et al. (2010) [25]. 
In contrast, the MW of the bi-layer nanoparticles exhibit two-phase degradation profiles where 
MW decreases by ~13% within 25, 30 and 32 days for Groups II, III and IV, respectively, 
followed by a relatively sharp MW reduction (Fig. 5.4i). The trend of the MW degradation of the 
bi-layer nanoparticles is generally consistent with the experimental data reported by Xu et. al 
(2013) [26]. The fact that PLLA is a weaker hydrophilic polymer than PLGA suggests that 
PLLA undergoes a slow hydrolysis which reduces the overall degradation rate of the bi-layer 
polymeric nanoparticles associated with the first degradation phase. As a result, with increasing 
PLLA/PLGA mass ratio from 1 to 3, the first degradation phase becomes longer for the 
nanoparticles in Groups II to IV, respectively (Fig. 5.4.i). The sharp reduction in MW in the 
second phase of degradation can be attributed to PLGA degradation. Since PLGA is more 
hydrophilic and degrades faster than PLLA, the acidic degradation products from PLGA 
hydrolysis catalyze PLLA degradation that results in a steep MW reduction of the bi-layer 
nanoparticles in Groups II-IV (Fig. 5.4i). Despite the consistency in the trend, the discrepancy 
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between the predicted values and the reported data [26] can be attributed to the assumption of 
pseudo bi-layer nanoparticles in the GA-Mechanistic model. Also, since the reported data [26] 
are associated with microparticles, rather than nanoparticles, the mass transfer resistance 
associated with the larger particle size contributes to slower polymer erosion that can delay the 
bulk degradation of microparticles, compared to that of nanoparticles.           
Table 5.3 presents the volume averaged values of the major release transport and degradation 
parameters involved in release mechanism of the nanoparticles corresponding to the 
experimental groups. The initial effective diffusivity of 3.24×10-17 m2s-1 that was estimated by 
the Geno-Mechanistic model was consistent with the value of 9.4×10-17 m2s-1 suggested by the 
regression analysis in literature [20]. The difference between the effective diffusivity values can 
be attributed to the lower hydrophilicity associated with L:G ratio of 75:25 of PLGA 
nanoparticles in this study compared to L:G ratio of 50:50 that provides a higher hydrophilicity 
[20]. The higher hydrophilicity enhances hydrolytic PLGA degradation rate that contributes to 
increase the effective diffusivity. In addition, since the regression analysis [20] was based on the 
data of microparticles, there might be an error originated from the extrapolation of the regression 
equation to estimate the average effective diffusivity of the nanoparticles. The volume-averaged 
initial effective diffusivity (Di) of the bi-layer nanoparticles was significantly lower than that of 
the single polymer nanoparticles. Notably, the effective diffusivity decreases with PLLA/PLGA 
mass ratio, indicating that the shell thickness may have a significant influence on reducing the 
volume-averaged diffusivity of the bi-layer nanoparticles (Table 5.3). The average degradation 
rate constant of 0.064 day-1 that was estimated for PLGA nanoparticles by the Geno-Mechanistic  
model was consistent with the reported values of the average degradation rate constants (Kdeg)  of 
0.068 day-1 [22], 0.05 day-1 [27], and 0.056 day-1 [28]. Moreover, the estimated degradation rate 
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Figure 5.4. (a-e) the variations of the fitness value and the evolved genes over 500 
generations, (f, g) agreement between experimental data and simulation results of protein 
release, (h) the distribution of the residual of prediction errors associated with the Geno-
Mechanistic  model; (i) the temporal changes in the volume-averaged MW predicted by the 
Geno-Mechanistic  model compared to the reported values in literatures. 
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Table 5.3. Volume averaged values of major release parameters of the nanoparticles estimated by 
the Geno-Mechanistic  model. 
Nanoparticle experimental Group Release parameter 
I II III IV 
Di (m2day-1) ×10-17 3.24 0.41 0.22 0.10 
Kdeg (day-1) 0.064 0.075 0.077 0.080 
Td (day) 0.1 27 30 33 
Xb  0.27 0.05 0.04 0.03 
K0 (day-1) 0.91 0.52 0.43 0.21 
τ (day) 21.8 28.2 26.7 23.2 
2σ (day) 3.6 3.2 3.3 3.4 
K (m2day-1 kDa) ×10-17 2.11 19.7 75.3 68.0 
 
constant of PLGA nanoparticles (Group I) is lower than that of bi-layer nanoparticles. This may 
be explained by the influence of the PLLA shell on the internal build-up of acidic degradation 
products catalyzing the degradation of core and shell. In a PLGA nanoparticle, the acidic 
degradation products can more easily diffuse and be released into the releasing medium; 
however, in bi-layered nanoparticles the PLLA external layer contributes to the accumulation of 
the acidic products in the core catalyzing the matrix degradation. By increasing the thickness of 
the shell, the accumulation of the acidic degradation products in the core may be improved so 
that the matrix degradation rate constant increases with PLLA/PLGA mass ratio. The Geno-
Mechanistic model also suggests that the degradation rate constant increases from 0.075 to 0.077 
and 0.08 with PLLA/PLGA mass ratios corresponding to Groups II-IV (Table 5.3). 
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The lag phase of release increases with PLLA/PLGA mass ratio from 27 to 33 days that may be 
explained by the effect of the shell thickness on controlling the protein release from the core. 
Moreover, the bi-layer nanoparticles provide an initial burst release (Xb) of <6% which remains 
significantly lower than 27% associated with PLGA nanoparticles (Table 5.3). The model also 
suggests that the volumetric mean time of pore formation (τ ) of bi-layer nanoparticles is 
significantly higher than that of PLGA nanoparticles (Table 5.3), while the mean time of pore 
formation decreases with PLLA/PLGA mass ratio of bi-layer nanoparticles (Table 5.3).     
5.4.3. 3D-simulation of controlled release from bi-layer nanoparticles using LVA approach  
Figure 5.5a illustrates the time course of the protein spatial distribution across a bi-layer 
nanoparticle at PLLA/PLGA ratio of 1 over 70 days. The protein is initially confined in the core, 
and notably the diffusion across the shell remains so slow over 35 days (Fig. 5.5a). Over time, 
the protein diffusion across the shell is enhanced so that the core reaches a uniform protein 
concentration and the mass transfer is controlled by the concentration gradient across the shell by 
50 days of release. The time course of the protein distribution across the bi-layer nanoparticles 
(Fig. 5.5a) is consistent with the release kinetics of the bi-layer nanoparticles depicted in Fig. 
5.5b. The cumulative release remains very limited within 30 days of release but gradually 
increases with time (Fig. 5.5b). Moreover, a very good agreement between the predicted values 
from the LVA-based 3D mechanistic model and experimental data can be noted in Fig. 5.5b. The 
MPE of <5% and the coefficient of determination of 0.98 between predicted and experimental 
results indicate a very good predictability of the model (Fig. 5.5c). Furthermore, the random 
distribution of the residual errors of predictions suggests unbiased predictability of the model 
(Fig. 5.5d). Figure 5.5e illustrates the spatiotemporal protein concentration across the core and 
shell of a bi- layer nanoparticle at PLLA/PLGA mass ratio of 1. Initially the protein is uniformly 
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Figure 5.5. (a) Spatiotemporal variation of the encapsulated protein in a bi-layer 
nanoparticle (Group II) predicted by LVA-based 3D mechanistic model over 70 days; (b, c) 
the agreement between experimental data and simulation results, (d) random distribution 
of prediction errors with a MPE of <5%; (e) variation of protein concentration with time 
and position across a bi-layer nanoparticle at PLLA/PLGA mass ratio of 1; (f) predicted 
MW variation of PLGA core and PLLA shell compared to the values in the literature. 
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distributed and confined in the core by the PLLA shell. Due to a large reduction (>50%) in MW 
of PLGA core within 10 days (Fig. 5.5f), the effective diffusivity of the core relatively increases 
and subsequently allows for the protein diffusion into the core-shell interface (Fig. 5.5e). At the 
same time, the protein concentration at the interfacial region of the shell gradually increases but 
the diffusion rate remains very limited due to the low effective diffusivity of the shell that is 
attributed to the relatively low degradation rate of PLLA shell (Table 5.4). The protein 
concentration in the shell begins to increase after 20 days (Fig. 5.5e) and subsequently reduce the 
interfacial concentration gradient. Despite a significant improvement in PLGA core diffusivity, 
which is attributed to a sufficiently high polymer degradation rate by 30 days (Fig. 5.5f), the 
shell predominantly limits the mass transfer from the core-shell interface to the nanoparticle 
surface (Fig. 5.5e). Further reduction in PLLA shell MW after 40 days improves the shell 
effective diffusivity (Eq. 5.3) that facilitates the mass transfer across the shell (Fig. 5.5e). After 
45 days of release, PLGA MW is so low (Fig. 5.5f) that the effective diffusivity is no longer a 
limiting factor in the core, and a relatively uniform protein concentration in the core together 
with a linear concentration gradient across the shell provides a steady diffusional mass transfer 
(Fig. 5.5e) that results in zero order release kinetics (Fig. 5.5b). The protein concentration 
continues to linearly decline across the nanoparticles for the rest of the release period. As shown 
in Fig. 5.5f, there is a good agreement between the simulation results of temporal MW changes 
of PLLA shell and PLGA core and the experimental data reported by Wu and Wang (2001) [22]. 
The discrepancy between simulated and experimental data of PLGA MW within the first 10 days 
can be associated with the acidic degradation products in the core that accelerate PLGA 
degradation, while the reported experimental data [22] have been collected at pH>5.   
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Table 5.4. Core and shell averaged transport and degradation properties estimated by LVA-based 
3D model compared to the volume-averaged values estimated by the Geno-Mechanistic  model. 
 PLLA/PLGA mass ratio of bi-layered nanoparticles 
 1:1  2:1  3:1 
 Hybrid 
model 
3D model Hybrid 
model 
3D model Hybrid 
model 
3D model 
Properties Volume- 
averaged 
Core Shell Volume- 
averaged 
Core Shell Volume- 
averaged 
Core Shell 
ad (nm) 340 120 50 490 172 73 680 216 124 
MW0 (kDa) 95 60 130 95 60 130 95 60 130 
Deff (×10-16) (m2day-1) 0.041 28.3 0.25 0.022 430 0.061 0.010 432 0.052 
Kd (day-1) 0.075 0.150 0.078 0.077 0.199 0.085 0.080 0.219 0.089 
aParticle diameter, core radius and shell thickness.  
5.4.4. A comparison between Geno-Mechanistic model and LVA-based 3D simulation   
Table 5.4 presents the transport and degradation properties of the core and shell of bi-layered 
nanoparticles corresponding to the size and core-shell polymer mass ratios compared to those 
estimated by the hybrid (Geno-Mechanistic) model. For all levels of PLLA/PLGA mass ratios 
and particle size, the averaged effective diffusivity of shell is significantly smaller than that of 
the core (Table 5.4), indicating that PLLA shell performs as a rate-limiting layer controlling the 
time-delayed release. Furthermore, the volume-averaged values of the effective diffusivity that 
were estimated by the Geno-Mechanistic (hybrid) model are similar to the values of shell 
effective diffusivity predicted by LVA-based 3D model (Table 5.4). This comparison suggests 
that PLLA shell transport properties pre-dominantly control the overall mass transfer behaviour 
that is described by the governing equations of the Geno-Mechanistic model (Table 5.4). Being 
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consistent with the fact that PLLA is less hydrophilic than PLGA, the polymer degradation rate 
constant of the core is predicted to be larger than that of the shell for all levels of PLLA/PLGA 
ratios (Table 5.4). Furthermore, the values of the volume-averaged degradation rate constant, 
which was estimated by the Geno-Mechanistic model, is very close to the values of the shell 
degradation rate constant for all levels of PLLA/PLGA ratios, indicating that overall degradation 
of a bi-layer nanoparticle may be approximated by the degradation rate of PLLA shell. The 
estimated values of PLLA shell and PLGA core degradation rate constants (Table 5.4) are 
consistent with the measured values ranging from 0.04 to 0.09 day-1 reported by Wu and Wang 
(2001) [22].   
5.5. Conclusions   
This paper presents a study on the development of models to represent the controlled-release of 
bioactive agents from nanoparticles for tissue engineering applications. A porous media 
approach based on LVA was applied to a bi-layer nanoparticle composed of PLGA core and 
PLLA shell, resulting the mechanistic model; while the Geno-Mechanistic  model consisting of a 
system of governing equations of controlled release coupled with GA was developed to predict 
the release patterns and to estimate the fittest values of mechanistic parameters involved in 
protein release. Both models were set for describing the mechanism of release from bi-layer 
nanoparticles by predicting the transport and degradation parameters. The Geno-Mechanistic 
model takes into account the transport and degradation properties that are averaged over the 
entire nanoparticle, while the LVA-based mechanistic model is based on local volume averaged 
properties and mass transfer governing equations of the shell and core to predict the release 
behaviour of the bi-layer nanoparticles. A very good agreement between predicted values and 
experimental data (r2>0.98, MPE<5%) was observed for both models, indicating the reliability 
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of the models for predicting the release behaviours. The estimated values of release parameters 
including effective diffusivity and degradation rate constants were consistent with the 
corresponding measured values reported in literatures. A comparison between the mechanistic 
model and the Geno-Mechanistic model revealed that the transport and degradation properties of 
PLLA shell predominantly control the time-delayed release from the bi-layer nanoparticles. 
Based on the estimated degradation and transport parameters, the mechanistic model suggests a 
rapid degradation of PLGA core within a time course of ~35 days. Moreover, the mechanistic 
model suggests that all three formulations of the bi-layer nanoparticles exhibit similar PLGA 
core and PLLA shell erosion despite different PLLA/PLGA mass ratios. In contrast, the Geno-
Mechanistic  model predicted two-phase (gradual and rapid) polymer degradation and a single-
phase degradation for the bi-layer and PLGA nanoparticles, respectively, which were consistent 
with experimental data reported in literatures. 
The models developed in this study provide a better insight on the release mechanism and offer 
great potentials for designing and optimization of PLGA and bi-layer nanoparticles in a broad 
range of applications of tissue engineering. Specifically, since controlled release of multiple 
growth factors is an important issue for development of bio-functional tissue engineered 
constructs, the developed models can be employed for designing and optimizing growth factor-
loaded PLGA and bi-layer nanoparticles to provide simultaneous and sequential release of bio-
active agents.   
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CHAPTER 6 
LOW-DOSE PROPAGATION-BASED PHASE CONTRAST COMPUTED 
TOMOGRAPGY FOR NON-INVASIVE QUANTITATIVE ASSESSMENT 
OF IMPLANTED DUAL-COMPONENT CARDIAC PATCH  
“This chapter has been submitted as “M. Izadifar, P. Babyn, M. Kelly, and X. B. Chen, 2016, 
Low Dose Synchrotron-based Phase Contrast Computed Tomography for Quantitative 
Assessment of Implanted Tissue Engineered Cardiac Patch, Journal of Cardiovascular 
Computed Tomography, (Under Review)” According to the Copyright Agreement, "the authors 
retain the right to include the journal article, in full or in part, in a thesis or dissertation". 
6.1 Abstract 
Due to low density and weak X-ray attenuation coefficient of engineered patches for cardiac 
tissue engineering, conventional radiography and micro-computed tomography are unable to 
visualize these patches upon their implantation.  In this paper, we present the development of a 
non-invasive imaging technique based on the synchrotron X-ray propagation-based phase 
contrast imaging computed tomography (PCI-CT),  for the visualization and quantitative 
assessment of the cardiac patch implanted in a rat heart model. The cardiac patches were 
fabricated from alginate strands created by three-dimensional (3D) printing, with the pores filled 
out by fibrin; these so-called “dual-component" patches were then surgically implanted on rat 
hearts induced with myocardial infarction. A week after surgery, the hearts including patches 
were excised and embedded in a soft tissue-mimicking gel for imaging by using PCI-CT at a X-
ray energy of 25 keV. During imaging, the sample-to-detector distances, CT-scan time, and 
regions of interest (ROI) were varied and examined for their effects on both imaging quality and 
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radiation dose received by the samples. Our results illustrated that the sample-to-detector 
distance was critical to the imaging quality and one value was thus identified for subsequent 
imaging of the implanted patch. Our results also illustrated that in the phase-retrieved PCI-CT 
images, the dual component of alginate strands and fibrin-filled pores could be clearly 
distinguished from each other, thus providing a means to characterize the microstructural 
features of implanted patches. Furthermore, our phase-retrieved PCI-CT images provided visible 
structural details for quantitative assessment of the patch, which, however, were not seen from 
the images by means of phase non-retrieved PCI-CT and a 3T clinical magnetic resonance 
imaging. By reducing the total CT-scan time per slice and ROI, PCI-CT was examined for 
lowering the effective dose (<100 mSv), meanwhile without much loss of imaging quality for 
quantitative assessment of the implanted patch. The microstructural features of patch evaluated 
from the lowered-dose PCI-CT were in agreement with the ones identified from the 
stereomicroscope images. Taken together, we illustrate the PCI-CT is of great potential for non-
invasive and quantitative assessment of microstructural features of the dual-component patch at 
the low dose allowed in clinical use. 
6.2. Introduction 
 Myocardial infarction (MI) is the major cause of heart failure associated with cardiovascular 
disease. Due to the limited regeneration capacity of cardiomyocytes, the injured myocardium is 
unable to regenerate on its own. Cardiac tissue engineering aims to develop implantable 
engineered constructs such as cardiac patches to re-establish functional myocardium and 
associated vasculature following myocardial infarction. A cardiac patch is a soft biomaterial 
platform that provides physical and biochemical cues to allow for cell attachment, migration, 
differentiation and organization in order to support new tissue formation on the MI territory. 
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Hydrogels have been extensively used in the development of functional cardiac constructs in 
cardiovascular tissue engineering because of their ability to support cell adhesion, retention and 
growth [1-6], and provide tunable mechanical properties to support cardiomyocytes for secretion 
of extracellular matrix as they degrade [8, 9]. Moreover, hydrogels can be micro-patterned by 
using three-dimensional (3D) bioprinting techniques to stimulate vascularization and/or direct 
the alignment of the cardiomyocytes for a functional cardiac construct [3].  
The visualization of hydrogel-based cardiac constructs, once implanted in animal models, is 
essential for longitudinal studies of cardiac tissue regeneration. However, examination using 
conventional histological and imaging methods is destructive and demands invasive procedures, 
for which the animal must be euthanized. The development of non-invasive, quantitative and 
longitudinal imaging methods for visualization and assessment of 3D microstructures of the 
implanted cardiac constructs is a strategic priority in cardiac tissue engineering. Magnetic 
resonance imaging (MRI) is a well-known non-invasive imaging technique for soft tissue 
imaging but is limited by poor spatial resolution. Ultrasound is limited by access and penetration 
depth especially if a high spatial resolution is required. Microcomputed tomography (µCT) is an 
X-ray absorption-based imaging technique that possesses high spatial resolution with deep tissue 
penetration for non-invasive and quantitative imaging but it only relies on X-ray absorption 
contrast. Since hydrogels are low density biomaterials with weak X-ray attenuation coefficients, 
conventional µCT provides little or no information on microstructural properties of the hydrogel-
based tissue constructs.  
Unlike X-ray absorption-based imaging methods, phase contrast imaging (PCI) techniques have 
shown promise for soft tissue imaging without contrast agents [7]. Propagation-based PCI, also 
known as in-line PCI, is an X-ray phase-sensitive imaging technique based on X-ray refraction 
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rather than absorption index of soft tissues. As the X-ray travels through an object, the X-ray 
wave field is distorted at the interface between soft tissues. The transmitted wave filed 
propagates in free space after the object before its intensity is captured by the detector. The phase 
contrast is accentuated by propagation and results in edge enhancement corresponding to the 
projected soft tissue interfaces on the image. The advantages of X-ray PCI over absorption-based 
imaging stem from the fact that soft tissue refractive index variations are typically greater than 
the X-ray absorption coefficient variations by orders of magnitude [10]. With ever improving 
high resolution X-ray detectors, highly brilliant and coherent synchrotron X-ray PCI offers great 
promise for visualization and non-invasive assessment of hydrogel-based tissue engineered 
constructs and soft tissues that possess very similar X-ray absorption coefficients. 
Several groups have applied X-ray in-line PCI for visualization of tissue engineered constructs 
such as polyethylene glycol in water [11], poly(glycolic acid)- polyethylene glycol in-vitro [12], 
poly(α-hydroxy-ester) in water [13], implanted polyglycolic acid scaffold for spinal cord injury 
[14], poly(L-lactide) (PLLA) and chitosan scaffold in the air and water [15] and 
polycaprolactone-alginate in-vitro [16]. Although the potential of PCI for visualization of soft 
tissue has shown promise by these previous studies, little has been published in the hydrogel-
based cardiac tissue engineering. In addition, most of the studies have investigated planar PCI for 
visualization of soft biomaterials. The imaging performance of planar PCI dramatically declines 
with increasing thickness and complexity of the sample. Combined with computed tomography, 
PCI-CT may overcome the limitations for visualization of microstructural features of implanted 
hydrogel-based cardiac constructs and anatomical characteristics of the myocardium. However, 
PCI-CT requires much longer total scan times for numerous planar images, which subsequently 
increases the delivered dose. Therefore, the PCI-CT imaging parameters need to be rigorously 
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adjusted and optimized to provide reasonably high quality images at low absorbed dose, thus 
allowing for potential application of this imaging technique to live animal studies and possibly 
human trials in cardiac tissue engineering. To the best knowledge of us, there is no prior report 
on low-dose propagation-based PCI-CT for visualization of implanted soft cardiac constructs. As 
inspired, this study aimed to develop non-invasive, quantitative, three dimensional (3D) and 
longitudinal imaging technique based on in-line PCI-CT to visualize the dual-component 
fibrin/alginate cardiac patch implanted in a rat model at the low dose allowed in clinical use. The 
reason of using fibrin, along with alginate, in the patch stems from the fact that fibrin gel has the 
ability to enhance angiogenesis; particularly when it is incorporated with angiogenic factor-
loaded nanoparticles [17]. Our previous study has shown that nanoparticle-incorporated fibrin 
hydrogels significantly improves sprouting angiogenesis for cardiac tissue engineering [17]; 
however, the non-invasive quantitative visualization of the fibrin hydrogel as well as alginate in 
the patch remains a challenge which is addressed in this study.      
6.3. Materials and methods 
6.3.1. Fabrication of dual-component cardiac patch 
Using a 3D-bioplotter fabrication system (Envisiontec GmbH, Gladbeck, Germany) (Fig. 6.1a),   
sodium alginate (Sigma-Aldrich Co., Saint Louis, MO, USA) (2.5% w/v) solution in sterile de-
ionized water was printed layer-by-layer into polyethyleneimine- (PEI) coated culture plate wells 
(Fig. 6.1b) filled with 50 mM calcium chloride as the cross-linking solution and 0.1% w/v PEI 
(Sigma-Aldrich). By this way, 3D constructs were fabricated with an overall size of 8 mm × 8 
mm × 2.5  mm (W×L×H) with 0/90° perpendicular pattern of strands (Figs. 6.1c-e). The 3D 
plotting was performed at a dispensing head speed of 8 mm/s under a pneumatic pressure of 0.1 
bar through a plastic cone tip dispensing needle (Fig. 6.1b) of 250 µm (EFD Nordson, Westlake, 
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OH, USA). The clearance between centers of two succeeding strands of each layer was set at 700 
µm. The printed micro-construct in the cross-linking solution was incubated for 30 min before 
being transferred to a sterile saline solution. Sterile fibrinogen (8 mg/ml) and thrombin (2 U/ml) 
(Baxter Healthcare Co., Westlake Village, CA) were mixed by pipetting in a vial and quickly 
infused into the pores of the 3D construct before the fibrin gel set (Fig. 6.1f), forming the so-
called “dual-component" patches for the subsequent studies.  
6.3.2. Surgical procedure and implantation of cardiac patch  
Male Lewis rats (~200 g) were anesthetised with a mixture of oxygen and isoflurane (2.5%), 
intubated, and mechanically ventilated at 70 breath per minute and 2 ml tidal volume using a 
Physiosuit ventilator (Kent Scientific Corporation, Torrington, CT). Following an anterior 
thoracotomy through the fourth intercostal space, the heart was exposed, pericardium was 
carefully removed and the proximal left anterior descending (LAD) coronary artery at ~4 mm 
below the junction of the left atrium and pulmonary artery was ligated with a 7-0 silk suture 
under a surgical microscope. The alginate-fibrin patch was then implanted on the myocardium 
proximally below the LAD ligature using surgical fibrin glue which was prepared at a final 
fibrinogen concentration of 1 mg/ml (Fig. 6.1g-i). 
The intercostal space and then the skin were closed using a 4-0 silk and 4-0 prolene sutures, 
respectively. After recovery, the rat was housed under standard conditions in the laboratory of 
animal study unit vivarium for 7 days before being euthanatized prior to synchrotron PCI-CT 
imaging. Shortly before performing the imaging, the animal was euthanized in a carbon dioxide 
euthanasia chamber.The experiments were conducted in compliance with the guidelines and 
ethics set by Canadian Council on Animal Care and the animal use protocol approved by the 
Animal Research Ethics board if the University of Saskatchewan. 
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Figure 6.1. Fabrication of an implantable dual-material cardiac patch composed of 3D-
printed porous alginate filled with fibrin. Using a 3D-bioplotter (a) alginate (2.5%) strands 
are plotted layer by layer into the crosslinking solution (b) where the hydrogel construct is 
set (c) and results in a porous 3D structure (d) with strand size and orientation of ~300 µm 
and 0/90° pattern (e). The fibrin matrix (f) is infused into the 3D patch pores (g) before the 
fibrin gel sets resulting in the dual-component patch (h) that is implanted on the rat heart 
(i) prior to PCI-CT.  
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6.3.3. Synchrotron X-ray PCI-CT of the implanted cardiac patch 
6.3.3.1. Sample preparation for imaging 
After cutting the ribs, the thorax cavity was exposed followed by the clipping the vena cava, 
pulmonary vein and artery and aorta in order to avoid trapping air bubbles in the heart chambers 
during the excision of the heart. Agar gel that exhibits absorption and scattering characteristics 
similar to soft tissues was used as the soft tissue mimicking medium [18] fully embedding the  
heart in a plastics sample holder tube. The heart was carefully excised and immediately laid on 
the surface of the agar gel inside the sample holder in such a way the cardiac patch was facing 
upward. Clips were removed and the tube was carefully filled with low melting point agar 
(Sigma-Aldrich) solution (1% w/v) at 39-40°C, ensuring no trapped bubbles around the patch 
and the surrounding tissue. The agar was allowed to set for 15 min on ice and then the tube was 
positioned on the CT imaging stage for PCI-CT imaging.  
6.3.3.2. Propagation-based PCI-CT set-up and parameters 
PCI-CT was performed under ambient conditions at Biomedical Imaging and Therapy bending 
magnet (BMIT-BM) beam-line, Canadian Light Source (CLS), Canada. Figure 6.2 illustrates the 
schematic diagram of the PCI-CT set-up at BMIT-BM. Upstream of the imaging stage, the white 
beam, was shaped using fully absorbing slits to provide sufficient horizontal beam width. 
Filtered through an aluminum filter, a highly collimated monochromatic X-ray beam at 25 keV 
was picked using a Si (2, 2, 0) double crystal Monochromator (Fig. 6.2). Passing through the ion 
chamber, the X-ray beam illuminates the sample at a beam width and height of 25.56 mm and 
4.04 mm, respectively. The X-ray was collected at a Hamamatsu ORCA detector, with an 
effective pixel size of 12.48 µm, after travelling over a propagation distance, which was 
optimised by displacing the sample towards or away from the detector (Fig. 6.2). For examining  
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Figure 6.2. Schematic diagram of the synchrotron PCI-CT imaging set-up with adjusted 
phase propagation distance at BMIT bending magnet beam-line. The deflection of the 
electron trajectory at the bending magnet provides synchrotron light so called ‘white 
beam’ that is shaped by fully absorbing slits and filtered. The double crystal 
monochromator provides monochromatic X-ray beam (25 keV) that passes through the 
shutter and ion chamber to used for imaging.  The collimitated monochromatic X-ray 
beam travels through the sample holder containing the heart and implanted patch 
embedded in the tissue mimicking gel. The small phase shifts attributed to the structural 
features are developed in free propagation distance after the sample and the accentuated 
phase contrast is recorded by the detector at three sample-to-detector distances. PCI-CT 
Tomography projections are collected by rotating the sample in the beam. 
the effect of the propagation distance on the imaging quality, in this study PCI-CT was 
performed at three distinct phase propagation distances of 22 cm, 76 cm and 147 cm. Since the 
FOV was restricted by the beam height, a full scan of the heart needed multiple vertical 
scanning. 
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Unlike conventional CT in a clinic, where the patient is still and X-ray source and detectors are 
rotated, for synchrotron X-ray in-line PCI-CT, the source of X-ray beam is still while the sample 
stage is rotated. The rotational increments of the sample stage were set as 0.06, 0.12, 0.18 and 
0.24 degrees, which resulted in four levels of CT-acquisition time per slice of the sample over 
180 degrees in a step-shoot fashion. The collected planar X-ray projections at different distances 
of phase propagation, CT-acquisition times and the area of the region of interest (ROI), which 
can be adjusted by the fully absorbing slits, were normalized over flat and dark images. The 
background corrected images were then used for phase-retrieval and CT image reconstruction. 
6.3.4. Retrieving phase information of PCI-CT images 
While X-ray phase-sensitive imaging CT relies on phase shift rather than attenuation 
information, the collected imaging signals on the detector (Fig. 6.2) are combinations of X-ray 
absorption and phase information. Phase-retrieval was performed to extract phase information 
allowing for edge-enhanced visualization of the boundaries of the object features. In this study, 
phase-attenuation duality Born Algorithm (PAD-BA) that utilizes single propagation distance for 
objects with weak X-ray absorption and phase-attenuation duality was used for phase retrieval 
[16, 18-21]. PAD-BA was implemented by using phase-sensitive X-ray image processing and 
tomography reconstruction (PITRE) software to retrieve phase information as reported in [22]: 
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where F denote the Fourier transform, λ is the wavelength, Ζ is the sample-to-detector 
propagation distance, ξ and η are the spatial frequencies in the Fourier space corresponding to 
the coordinates of x and y in the real space, α and β are the X-ray refractive and absorption 
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indices, θ is the tomography rotation angle, Ι  is the photon intensity and ),( yxθφ is the phase 
corresponding to the image coordinates of x and y at the tomography angel of θ. 
Given that PAD-BA in PITRE assumes a constant value for α/β, a sensitivity analysis was 
performed to approximate α/β of the sample. Considering that myocardium is a soft tissue and 
the implanted cardiac patch is largely composed of water, an initial α/β value of 2180 
corresponding to the absorption and refractive indices of water (α=0.14×10-6, β=0.0658×10-9) 
was used for assessing the width of the fringes at the boundaries with respect to α/β ranging 
from 1500 to 4000. The best α/β value was determined based on a sensitivity analysis of the 
frindge size at the myocardium and patch boundaries and then applied to the phase-retrieval 
algorithm and CT-image reconstruction in PITRE. Applying filtered back projection algorithm, 
the dual phase-absorption images (non-phase retrieved images) and phase-retrieved images were 
reconstructed. The signal intensities of the phase-retrieved and dual phase-absorption (non-phase 
retrieved) CT reconstructed images were corresponding to apparent refractive index (α ) and 
apparent attenuation coefficient ( µ ), respectively. PAD modified Bronnikov Algorithm (PAD-
MBA) was also applied for phase-retrieval of single planar PCI of the myocardium and the 
implanted patch compared to PAD-BA. 
6.3.5. Magnetic resonance imaging (MRI) of the heart and cardiac patch 
Following synchrotron PCI-CT experiments, the sample of heart with cardiac patch embedded in  
agar was imaged by a clinical MRI at Royal University Hospital, Saskatoon, Canada. MRI was 
performed on a 3T Siemens MAGNETOM Skyra scanner (Erlangen, Germany) equipped with a 
XQ gradient system capable of 45 mT/m maximum strength. The heart sample-containing tube 
was stabilized in a MRI-compatible wrist holder for planar scanning along the patch longitudinal 
axis. T2 measurements were performed at 25°C with a T1 weighted SWI sequence (TE1=7.01 
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ms, TE2=20 ms) at TR of 28 ms, number of echo images of 2, FOV of 50 mm × 50 mm, slice 
thickness of 0.4 mm, and resolution of 128×128×44 µm3. Relaxation data were analyzed with the 
VE11A software.   
6.3.6. X-ray radiation dose assessment    
The synchrotron radiation dose rate is typically measured using a calibrated ion chamber at 
BMIT-BM [23]. To determine the dose rate variations over the CT scan during which the storage 
ring current changes, a multiple regression equation that relates dose rate to the storage ring 
current (150-250 mA) and photon energy (20-35 keV) was developed: 
213.0163.087.10103.198 EE +Θ+−=•ϑ            (6.2) 
where E is X-ray energy (keV), Θ  is the storage ring current (mA) and •ϑ is the dose rate 
(mGy/s). For X-ray energy of 25 keV at which the dose rate only depends on the storage ring 
current, Eq. (6.2) results in a mean prediction error of 4% and coefficient of determination of 
0.995, where the variation of dose rate with time during PCI-CT scan can be described as: 
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Evaluating Eq. (6.3) based on the first derivative of Eq. (6.2), recorded data of storage ring 
current during the PCI-CT scan and taking the integral of Eq. (6.3) results in: 
 τϑϑ 5008.00 −= ••                (6.4) 
where •0ϑ is the initial value of the dose rate corresponding to the ring current at the beginning of 
the PCI-CT scan, and τ is the total exposure time, which is defined by: 
( )Nrc τττ +=                (6.5) 
where cτ is the time for signal capturing of the detector per tomography projection, rτ is time for 
the angular rotation step of the CT imaging stage, and N is the total number of tomography 
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projections. Applying the normalized dose rate (dose rate divided by the area of the beam), the 
total X-ray radiation dose of the PCI-CT was evaluated as: 
( ) •+= ϑττ ROIrc SND                         (6.6) 
where ROIS is the area of ROI (mm2), •ϑ is the normalized dose rate (mGy/mm2 s), and D is the 
total absorbed dose (mGy). To provide clinically interpretable evaluation of the radiation dose, 
the absorbed dose was weighted with respect to radiobiological risks of the exposed tissue to 
evaluate the effective dose equivalent in Sievert (Sv) as: 
tr WWDSv =                (6.7) 
where Wr and Wt are radiation weighting factor, that is equal to 1 for X-ray photons [24] and the 
tissue radiosensitivity weighting factor, respectively. A cardiac tissue radiosensitivity weighting 
factor of 0.12 [25] was used in this study.     
6.3.7. Low-dose PCI-CT for quantitative assessment of the implanted cardiac patch 
CT- acquisition time per slice, the area of ROI, X-ray energy and dose rate are the main factors 
affecting the total delivered dose. At the dose rate assigned by the picked X-ray energy (25 keV) 
and the storage ring current, the total delivered dose was investigated at three levels of the area 
of region of interest (ROI) (~100, 6, 3 mm2) and four levels of CT-scan time corresponding to 
tomography projections of 3000, 1500, 1000 and 750. The beam dimension, which can be 
adjusted using fully X-ray absorbing slits, was adjusted to provide reduced ROI for visualization 
and quantitative assessment of the implanted patch. Also, the orientation of the heart with respect 
to the beam incident was adjusted horizontally to reduce the cardiac tissue exposure to the beam. 
The combination of decreased CT scan time and reduced ROI was analysed with the associated 
image quality criteria to identify optimum imaging parameters for an effective low-dose PCI-CT.   
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6.3.8. Qualitative and quantitative criteria for assessing image quality 
The image quality criteria of image correlation coefficient (r), peak of signal to noise ratio 
(PSNR), contrast to noise ratio (CNR) and structural similarity (SSIM) index [26] were used to 
compare CT images of the heart and implanted patch associated with different levels of delivered 
dose. The image quality criteria per unit delivered dose per pixel were defined as: 
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where SSIM and CNR are the normalized SSIM index and CNR per unit absorbed dose per image 
pixel, ROIµ  and bµ  are the mean intensity of image signals of ROI and background, respectively, 
ROIσ and bσ are intensity standard deviations of image signals of the object ROI and background 
with equal surface area, respectively, ROIbσ is the inner product of the standard deviations, C1 and 
C2 are stability constants [26], and xyP is the pixel size (mm). The apparent refractive index 
profiles across the ROI of the implanted cardiac patch were used to identify the boundaries  
between fibrin-filled pores and alginate strands and quantitatively evaluate the features of the 
patch compared to the actual values measured from stereomicroscope images.  
6.4. Results 
6.4.1. Effect of the phase propagation distance of the PCI-CT 
A sensitivity analysis of the phase retrieval revealed that the width of phase contrast fringes at 
the boundaries between myocardium and implanted patch decreased as α/β was increased from 
1500 to 3500. Further increase in α/β resulted in no significant improvement in the width of the 
fringes; thus, α/β of 3500 was applied to PAD-BA for the phase retrieval in the study.  
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Figure 6.3 depicts the axial and coronal slices associated with phase-attenuation duality (phase 
non-retrieved) and phase-retrieved images of the implanted patch on the myocardium at three 
phase propagation distances. The edge illumination is clearly enhanced with propagation 
distance (Figs. 6.3a-c, g-i). As the phase propagation distance increases from 22 cm to 147 cm, 
the edge illumination at interface between alginate strands and fibrin-filled spaces (yellow 
arrows) and between patch and the myocardium (black arrows) significantly improves. At the 
distance of 147 cm, the phase retrieved images clearly depict the structural and morphological  
 
Figure 6.3. Phase-nonretrieved and phase-retrieved PCI-CT images of coronal (a-c, g-i, 
scale bar=2 mm) and axial (d-f, j-l, scale bar=1 mm) slices of the dual component patch 
implanted on the rat myocardium at three phase propagation distances of 22 cm, 75 cm 
and 147 cm. 
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information of the patch (Fig. 6.3i) including the vertically assembled alginate strands that 
demonstrate circular cross-sections (yellow arrows) (Fig. 6.3l). Moreover, the microvessels 
(yellow arrows) can be clearly identified from the coronal views at the propagation distance 
of147 cm (Figs. 6.3c, i).  
Figures 6.4a and 6.4b depict the structural details of the 3D-printed alginate construct and the 
alginate-fibrin patch, respectively. As the propagation distance increases from 22 cm (Fig. 6.4c) 
to 76 cm (Fig. 6.4d) and 147 cm (Fig. 6.4e), the edge illumination so improved that the  
 
Figure 6.4. Comparison of structural similarity between stereomicroscope images of the 
3D-printed alginate strands (a), dual component alginate-fibrin structure (b), and the 
coronal slice of the phase-retrieved images from PCI-CT at the phase propagation 
distances of 22 cm (c), 76 (cm) and 147 cm (e) at α/β=3500; a quantitative comparison of 
the alginate strand thickness evaluated from the PCI-CT at the phase propagation distance 
of 147 cm (f) and the corresponding measured value from the stereomicroscope image (g) 
(scale bar=500 µm). 
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boundaries between alginate and fibrin can be clearly identified and the thickness of the strands  
can be characterized from the PCI-CT slice (Fig. 6.4e). Figure 6.4f illustrates the apparent 
refractive index profile across the alginate strand (Fig. 6.4e), indicating an strand thickness of  
~300 µm (Fig. 6.4f) which is in agreement with the strand thickness (Fig. 6.4g) evaluated from 
the intensity profile of the stereomicroscope image (Fig. 6.4a). It is noted that there is an 
approximately 20% increase in the strand thickness (~300 µm) as compared to the internal 
diameter of the dispensing needle (250 µm) used for printing the strands of cardiac patch, which 
is mainly due to the spreading or stretching of strands during their cross-linking process. 
6.4.2. Planar PCI to assess the patch implantation 
Figures 6.5a-c show the sample holder orientation on the imaging stage with respect to the beam 
monitoring Scintillator for sagittal and axial planar PCI (single projections) at the phase 
propagation distance of 147 cm. Figures 6.5d and j depict the sagittal and axial phase-absorption 
duality planar images where the myocardium (yellow arrows) and part of the aorta (blue arrows) 
boundaries can be identified (Figs. 6.5d, j). The edges of the left atrium appendage (green arrow) 
can be distinguished (Fig. 6.5d); however, the profiles of the apparent attenuation coefficient 
across the region of the patch implantation show no significant contrast for locating the 
implanted patch (Figs. 6.5e, k). In contrast, the phase retrieved planar images from PAD-MBA 
(Figs. 6.5f, l) and PAD-BA (Figs. 6.5h, n) can depict boundaries attributed to the edge 
enhancement of the myocardium (yellow arrows), patch (red arrows), appendage (green arrow) 
and the aorta (blue arrow). Notably, PAD-BA results in better phase contrast of the implanted 
patch (Figs. 6.5h, i) compared to PAD-MBA (Figs. 6.5f, g), although both algorithms can 
retrieve phase contrast of the myocardium (yellow arrows) from the planar PCI (Figs. 6.5l-o).  
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Figure 6.5. The sample-beam monitor orientation in the imaging stage (a) for single 
projection-based phase contrast imaging of the sagittal (b) and axial (c) views associated 
with phase non-retrieved (d, j) and phase retrieved images from PAD-MBA (f, l) and PAD-
BA (h, n) of the myocardium and the implanted patch, and the intensity profiles of the 
apparent attenuation coefficient (e, k) and refractive index (g, i, m, o) across the 
myocardium and the implanted patch. 
6.4.3. PCI-CT imaging performance compared to the clinical MRI 
The MRI images provide no detailed information of the patch but only indicate the region of 
patch implantation (Figs. 6.6a, b). As seen in Fig. 6.6c, the MRI horizontal long axis plane is so 
poor that even chambers are unidentifiable. The magnetic resonance signal intensity profile 
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across the patch suggests that MRI may only provide sufficient contrast only for locating the 
implantation landmark but no details of the patch structure (Fig. 6.6d). The axial slice from 
phase-absorption duality PCI-CT of the patch clearly depicts the patch size and the strand nodes 
of the patch (Fig. 6.6e). Moreover, the apparent attenuation coefficient profile across the patch 
and myocardium provides relatively sufficient contrast to identify alginate strands but hardly the 
exact boundary between the myocardium and the patch (Figs. 6.6f, h). Also, the four chamber 
long axial plane from phase non-retrieved slices reveals some anatomical details that include left 
and right ventricles (red arrows), aorta (yellow arrow) and the right atrium (green arrow) 
(Fig.6.6g). The axial slice of the phase- retrieved images not only provides the size, geometry 
 
 
Figure 6.6. Coronal slices and signal intensity profile from MRI images (a-d) compared to 
the corresponding slices from phase non-retrieved (e-h) and phase retrieved PCI-CT 
images (i-l) of the heart and the implanted patch. 
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and the strand nods but clearly visualizes the thickness and orientation of the strands with 
quantifiable fibrin-filled pores (Fig. 6.6i). Unlike MRI and the phase-absorption duality PCI-CT 
images, the phase retrieval significantly improves the contrast between myocardium and 
implanted patch, thus being able to assess the patch attachment to the myocardium post 
implantation (Fig. 6.6j). Notably, the apparent refractive index profile across the patch and 
myocardium clearly shows the contrast between the implanted patch and the native myocardium, 
as well as the information associated with the myocardium microvessel and patch strands (Fig. 
6.6l). Furthermore, the axial plane reveals anatomical details of the interior heart such as atriums 
(green arrows), mitral valve  (blue arrow), tendinous cords of the tricuspid valve (pink arrow), 
left and right ventricles (red arrows), aorta (yellow arrow) and the left atrium appendage (white 
arrow) (Fig. 6.6k). 
The patch microstructure (Fig. 6.7a) and the associated periodic ‘hill-valley’ pattern of the 
apparent refractive index profile associated with the fibrin-alginate periodic structure (Fig. 6.7b) 
can be seen in the axial slice of the phase-retrieved PCI-CT image. The size of the fibrin-filled 
pores and alginate strands can be approximated from the apparent refractive index profile (Fig. 
6.7b), with their values of ~256 and 400 µm, respectively. Notably, these identified values are in 
agreement with those measured from stereomicroscope images, i.e., ~300 and ~500 µm. 
Compared to the phase-retrieved image, the axial plane (Fig. 6.7c) and the associated apparent 
absorption coefficient profile (Fig. 6.7d) from the phase-absorption duality PCI-CT suffers from 
insufficient contrast, making it very difficult to morphologically and quantitatively assess the 
patch microstructure. 
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Figure 6.7. Quantitative assessment of the dual component implanted alginate-fibrin patch 
using phase retrieved (a, b) and phases non-retrieved horizontal long axis slice from the 
PCI-CT at the phase propagation distance of 147 cm and α/β of 3500. 
6.4.4. Low dose PCI-CT imaging 
Figures 6.8a-h depict the volume rendered images utilizing 3000, 1500, 1000 and 750 
tomography projections, respectively. The patch microstructural features such as patch volume, 
dimensions, and the strands and pores, and anatomical details including the left atrium 
appendage (yellow arrow), microvessel branches (red arrows) and the ligature (suture) (blue 
arrow) can be seen in the images using 3000 projections (Figs. 6.8a, e). The anatomical and 
structural features remain relatively distinguishable when the number of tomography projections 
is reduced by 50% (1500 projections) (Figs. 6.8b, f). At 1000 tomography projections, it 
becomes difficult to identify the microvessels although the patch microstructure can be  
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Figure 6.8. Coronal (a-d) and sagittal (e-h) views of the volume rendered PCI-CT images of 
the heart and implanted cardiac patch, and the horizontal long axial plane of the patch (i-l) 
attached to the myocardium (m-p) with the associated apparent refractive index profiles 
(q-t) at tomography projections of 3000 (a, e, i, m, q), 1500 (b, f, j, n, r), 1000 (c, g, k, o, s) 
and 750 (d, h, l, t) to assess image quality criteria (w) for a low dose PCI-CT (x) (scale 
bar=1 mm). 
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visualized (Figs. 6.8c, g). Despite the poor resolution provided by 750 tomography projections, 
the suture (blue arrow), appendage (yellow arrow) and a few microvessels (red arrows) are  
identifiable (Fig. 6.8h) and the patch volume, the area of the implantation, the size of strands and 
pores can be approximated (Fig. 6.8d, h).  
A comparison between axial slices of the patch corresponding to full dataset and the reduced 
tomography projections suggests that the key structural features of the patch remain identifiable 
at the reduced number of tomography projections despite the decreased resolution (Figs. 6.8i-l).  
The anatomical features such as the internal structure of the appendage (yellow arrow) and 
microvessels (red arrows) can be also distinguished from the surrounding tissue at the lower CT 
scan times corresponding to the reduced number of tomography projections compared to the 
standard PCI-CT (Figs. 6.8m-p).  
The associated apparent refractive index profiles indicate that the phase contrasts of the 
anatomical features are sufficient to distinguish myocardium anatomical features and the patch at 
the reduced tomography projections (Figs. 6.8q-t). Although two microvessels (red arrows) out 
of three can be located from the apparent refractive index profile associated with 750 
tomography projections (Fig. 6.8t), 1500 and 1000 tomography projections provide sufficient 
phase contrast to identify the three microvessels (red arrows) (Figs. 6.8r, s). 
Compared to the standard PCI-CT, the total delivered dose significantly declines when the 
tomography projections are decreased (Fig. 6.8w) but notably, the image correlation coefficient 
and CNR per pixel are not significantly affected (Fig. 6.8x). Although SSI per image pixel is 
significantly decreased as a result of the reduced tomography projections, no significant 
difference in SSI can be noted among the images associated with 1500, 1000 and 750 
tomography projections (Fig. 6.8x).       
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Figures 6.9a, b illustrates the variation of the effective dose (mSv) with tomography projections, 
photon energy and the area of ROI, as described by Eqs. (6.2), (6.4)-(6.7). The effective dose 
exponentially decreases with increasing energy for all levels of tomography projections so that 
low effective dose (<100 mSv) may be achieved at higher energies under the reduced number of 
tomography projections (e.g. 750-1000) (Fig. 6.9a). Although higher energies could be applied to 
reduce the dose, the trade-off assessment associated with the higher flux, sufficient penetration 
depth, and preliminary evaluation of alginate-fibrin phase contrast led to selection of 25 keV 
picked for this study. At 25 keV, the effective dose can be dramatically reduced from ~2200 mSv 
for ROI of 20 mm2 to <100 mSv for ROI of 3 mm2 corresponding to 3000 and 750 tomography 
projections, respectively (Fig. 6.9b).  
Figures 6.9c-f depict the axial slices of the implanted patch for ROI of 3 mm2. Notably, the 
alginate strands of the patch remains identifiable and measurable from the images when the 
effective dose is reduced from 246 mSv to 123, 82 and 62 mSv corresponding to of 3000, 1500, 
1000 and 750 tomography projections, respectively (Figs. 6.9c-f). The refractive index profiles 
associated with the patch strands reveals the periodic ‘hill-valley’ patterns attributed to the edge 
illumination of the alginate strands, which can be used for approximation of the strand thickness 
(Figs. 6.9g-j). 
Table 6.1 presents the image quality criteria evaluated for different levels of PCI-CT doses. 
Obviously the image correlation coefficient decreases at the lower dose but the correlation 
coefficient generally remains above 0.8 with no significant change in PSNR except for the image 
at ROI of 3 mm2 and 750 tomography projections (Table 6.1). CNR  and SSIM  increase despite 
significant reductions in the effective dose, indicating that the image quality can be largely 
preserved at the lower doses (Table 6.1). The average strand thickness (ds) and fibrin-filled pore  
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Figure 6.9. Variation of the effective dose with tomography projections and photon energy 
(a) and area of ROI and tomography projections at 25 keV (b), and the patch structural 
feature assessment using low dose PCI-CT based on the combined effect of the reduced 
ROI (3 mm2) at tomography projections of 3000 (c), 1500 (d), 1000 (e) and 750 (f) to 
quantitatively evaluate the size of strands and pores from the apparent refractive index 
profiles across the patch (g-j). 
size (df), which were evaluated from the phase-retrieved PCI-CT images, are generally consistent  
with measured values from stereomicroscope imaging (Figs.6.4a, b), suggesting that the low 
dose PCI-CT may be implemented for quantitative assessment of the implanted cardiac patch. 
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Table 6.1. Quantitative criteria for image quality assessment and patch structural feature 
evaluation using low dose PCI-CT at two levels of ROI and four levels of tomography 
projections.  
aSROI 
(mm2) 
N bD 
(Gy) 
mSv r PSNR CNR
 
(×10-6) 
SSIM
 
(×10-6) 
cds 
(µm) 
ddf 
(µm) 
1×6 3000 4.1 492 1 en/a 1.10 0.88 358 459 
 1500 2.1 246 0.95 24.5 1.98 1.50 360 401 
 1000 1.4 164 0.93 20.5 2.92 1.72 420 348 
 750 1.0 123 0.83 20.7 3.71 2.37 442 332 
1×3 3000 2.1 246 1 en/a 12.51 1.18 319 433 
 1500 1.0 123 0.89 23.0 21.63 2.37 351 436 
 1000 0.7 82 0.80 20.4 30.84 3.55 413 358 
 750 0.5 62 0.76 12.4 40.30 4.74 415 402 
aBeam height×width; bTotal dose at •ϑ of 3.08×10-7 mGy/µm2s; cAverage alginate strand 
thickness of the implanted patch measured from PCI-CT image; dAverage size of the fibrin filling 
spaces between alginate strands of the patch; eThe reference for evaluation of PSNR, r and SSIM. 
6.5. Discussion 
It has been shown that cardiomyocyte encapsulation efficiency of alginate is of great [3-6, 27] 
and that angiogenesis can be improved by means of fibrin [3, 4, 28-17]. Inspired by these 
findings, it is rationale to develop micro-patterned alginate-fibrin cardiac patches for cardiac  
tissue engineering. However, the ability to non-invasively and quantitatively visualize the 
alginate and fibrin is one of the key challenges. For this, the phase propagation distance has been 
shown critical and been optimised for achieving desirable phase contrast to depict 
microstructural features of the implanted cardiac patch, as illustrated in this study. It should be 
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noted that both alginate and fibrin are made of more than 95% water, which provide very low 
density to the patch microstructure. As such, the patch microstructural features associated with 
the interface between the alginate strands and fibrin-filled pores produce very small phase shifts 
as the X-ray travels through the implanted patch, which is also true for the surrounding soft 
tissues such as microvessels. In the synchrotron-based PCI-CT, the small phase shifts associated 
with microstructural features are magnified over the free propagation distance, thus being able to 
produce sufficient phase contrast on the detector. Ideally, the phase propagation distance should 
allow the phase shift being developed as large as one pixel size. If the phase distortion 
development is smaller than the pixel size, phase shifts of multiple features are integrated within 
one pixel, making the projected boundaries fuzzy on the detector (Figs. 6.3g, 6.4c). As the free 
propagation distance increases, the phase contrast of the edges can be enhanced (Figs. 6.3h,4d). 
In this study, we illustrated that the best phase propagation distance for edge illumination of 
alginate-fibrin interface of the patch was 147 cm among the three distance examined for the 
effective pixel size of 12.48 µm at BMIT-BM. Likewise, microvessel features illuminated at the 
phase propagation distance of 76 cm and measurable (~25 µm) (Fig. 6.4i) at sample-to-detector 
distance of 147 cm. Although a longer free propagation distance might improve the phase 
contrast of the microstructural features, it should be noted that projected boundaries become 
blurry if the phase shift developments become larger than one pixel size, which can be occurred 
over a propagation distance longer than the optimum value. 
At the optimum phase propagation distance, phase-retrieval of the planar PCI provided sufficient 
contrast to identify the boundaries of the implanted patch distinguishable from the surrounding 
soft tissues (Figs. 6.5h, i). This PCI capability, coupled with the extremely low delivered dose 
(~1.5 mSv), offers a great potential for serial monitoring of the implanted patch, for example, to 
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visualize degradation and to ensure that the patch is not detached or dislocated after surgery in a 
live animal study.  
The phase retrieved axial slice of the patch depicted no gap at the interface between the 
myocardium and the implanted patch, a non-invasive qualitative assessment of a successful 
implantation procedure. Furthermore, phase retrieved PCI-CT slices enabled non-invasive 
quantitative assessment of the thickness of the alginate strands and the size of fibrin-filled pores 
which were consistent with the measured values from stereomicroscope.  
In addition to the qualitative and quantitative information of the patch, the phase retrieved slices 
of the heart revealed descriptive anatomical features including the atrium appendage internal 
structure, mitral valve, tricuspid valve cords, aorta and myocardium microvessels. Notably, these 
microstructural and anatomical features of the patch and heart were achieved without the usage 
of any contrast agent, suggesting that the PCI-CT is of great potential for non-invasive 
assessment of the patch structural changes, myocardium regeneration and vascularization in live 
animal studies for cardiac tissue engineering. 
Application of the PCI-CT technique to live animal studies relies on not only the image quality 
but also the total radiation dose. For a given storage ring current and the chosen photon energy, 
the total CT-acquisition time and the area of ROI are the main factors to be optimized in order to 
reduce the radiation dose. The standard PCI-CT (3000 tomography projections) at a reduced ROI 
of 1mm×6 mm (Height×Width) delivered an effective dose of 492 mSv, which is within the 
range of  the annual dose limit (500 mSv) suggested by the International Commission on 
Radiological Protection (ICRP) for skin [30]. However, a recommendation from ICRP indicates 
that no tissue undergoes clinically relevant functional deterioration at the absorbed X-ray doses 
up to ~100 mSv [30]. The reduced CT scan time corresponding to 1000 tomography projections 
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at ROI of 6 mm2, which covers a large area of the implanted patch, decreased the effective dose 
to 164 mSv with no significant changes in image quality criteria. Further reductions in ROI (3 
mm2), which can be considered as a representative volume of the implanted patch (Figs. 6.9c-f) 
reduced the effective dose as low as 123 and 82 mSv corresponding to 1500 and 1000 
tomography projections, respectively. Effective dose can be further reduced by use of higher X-
ray energies (e.g. 26-30 keV) and/or lower resolution of imaging (e.g. binning 2×2). In the 
future, a multi-objective optimization of the low dose PCI-CT needs to be investigated to 
minimize the delivered effective dose but maintain PCI-CT capability to visualize critical 
features of the patch and the surrounding tissues.  
Taken together, the PCI-CT developed in this study offers a great potential for non-invasive 
qualitative and quantitative assessment of microstructural features of the implanted alginate-
fibrin cardiac patch at reduced effective dose consistent with the ICRP recommended dose limits, 
especially for live animal studies and possible human trials in the future.    
6.6. Conclusion 
In this study, a low dose synchrotron propagation-based PCI-CT demonstrated promise for 
qualitative and quantitative assessments of implanted 3D-printed dual-component cardiac patch 
on the rat heart without usage of contrast agent. The microstructural features of fibrin and 
alginate, which are low-density (>97% water) constituents of the patch, were clearly visualized 
and quantitatively characterized from the phase-retrieved PCI-CT slices of the implanted patch. 
The PCI-CT technique provided anatomical details including the microvessels surrounding the 
implanted patch. Owing to the notable phase contrast at the optimized phase propagation 
distance, no contrast agent was needed for quantitative assessments of the patch and 
myocardium. By decreasing CT scan time and ROI, the effective dose was considerably reduced 
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without significant changes in the image quality for assessing the anatomical and microstructural 
features of the implanted alginate-fibrin patch. The evaluated thickness of alginate strands and 
fibrin-filled pores at the reduced effective dose within the dose limit recommended by ICRP 
were in agreement with the measured values from stereomicroscope. Findings from this study 
pave the road for applying the low dose PCI-CT for in-vivo studies of patch-based cardiac tissue 
regeneration therapy.  
In future experiments, the PCI-CT at the imaging parameters identified in this study will be 
applied to the imaging of implanted cardiac patch in a freshly euthanized rat allowing further 
refinement of the imaging parameters for the development of a robust gated PCI-CT for in-vivo 
live animal studies.    
 
 
 
 
 
 
 
 
 
 
 
 296 
References 
[1] Pedron S, van Lierop S, Horstman P, Penterman R, Broer DJ, Peeters E 2011 Stimuli 
responsive delivery vehicles for cardiac microtissue transplantation. Adv. Funct. Mater. 21 1624.  
[2] Camci-Unal G, Nichol JW, Bae H, Tekin H, Bischoff J, Khademhosseini A 2013 Hydrogel 
surfaces to promote attachment and spreading of endothelial progenitor cells. J. Tissue Eng. 
Regen. Med. 7 337. 
[3] Izadifar M, Kelly ME, Chen XB 2014 Engineering Angiogenesis for Myocardial Infarction 
Repair: Recent Developments, Challenges, and Future Directions. Cardiovasc. Eng. Technol. 5 
281.  
[4] Izadifar M, Haddadi A, Chen XB, Kelly M 2014 Rate-Programming of Nano-Particulate 
Delivery Systems for Smart Bioactive Scaffolds in Tissue Engineering. Nanotechnology 26 
012001.  
[5] Fang R, Qiao SP, Liu Y, Meng QY, Chen XB, Song B, Hou XL, Tian, WM 2015 Sustained 
co-delivery of BIO and IGF-1 by a novel hybrid hydrogel system to stimulate endogenous 
cardiac repair in myocardial infarcted rat hearts. Int. J. Nanomedicine 10 4691. 
[6]  Bai XP, Fang R, Zhang S, Shi SL, Wang ZL, Chen XB, Yang JY, Hou XL, Nie YZ, Li Y, 
Tian WM 2013 Self-Cross-Linkable Hydrogels Composed of Partially Oxidized Alginate and 
Gelatin for Myocardial Infarction Repair. J Bioact. Compat. POL. 28 123. 
 [7] Izadifar Z., Honaramooz A, Wiebe S, Belev G, Chen XB, Chapman D 2016 Low-Dose 
Phase-based X-ray Imaging Techniques for In Situ Soft Tissue Engineering Assessments. 
Biomaterials 82 151. 
[8] Li ZQ, Guan JJ 2011 Hydrogels for cardiac tissue engineering. Polymers 3, 740. 
 297 
[9] Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B, Ganser A, Knapp 
WH, Drexler H 2005 Monitoring of bone marrow cell homing into the infarcted human 
myocardium. Circulation 111 2198. 
 [10] Lewis RA 2004 Medical phase contrast x-ray imaging: current status and future prospects. 
Phys. Med. Biol. 49 3573. 
[11] Brey EM, Appel A, Chiu YC, Zhong Z, Cheng MH, Engel H, Anastasio MA 2010 X-ray 
imaging of poly(ethyleneglycol) hydrogels without contrast agents. Tissue Eng Part C Methods 
16 1597. 
[12] Albertini G, Giuliani A, Komlev V, Moroncini F, Pugnaloni A, Pennesi G, Belicchi M, 
Rubini C, Rustichelli F, Tasso R, Torrente Y 2009 Organization of extracellular matrix fibers 
within polyglycolic acid-polylactic acid scaffolds analyzed using X-ray synchrotron-radiation 
phasecontrast micro computed tomography. Tissue Eng Part C Methods 15, 403. 
[13] Appel AA, Larson JC, Somo S, Zhong Z, Spicer PP, Kasper FK, Garson AB, Zysk AM, 
Mikos AG, Anastasio MA, Brey EM 2012 Imaging of poly(α-hydroxy-ester) scaffolds with X-
ray phase-contrast microcomputed tomography. Tissue Eng Part C Methods. 18 859.  
[14] Takashima K, Hoshino M, Uesugi K, Yagi N, Matsuda S, Nakahira A, Osumi N, Kohzuki 
M, Onodera H 2015 X-ray phase-contrast computed tomography visualizes the microstructure 
and degradation profile of implanted biodegradable scaffolds after spinal cord injury. J. 
Synchrotron Rad. 22 136. 
[15] Zhu N, Chapman D, Cooper D, Schreyer DJ, Chen XB 2011 X-Ray Diffraction Enhanced 
Imaging as a Novel Method to Visualize Low-Density Scaffolds in Soft Tissue Engineering. 
Tissue Eng Part C Methods 17 1071. 
 298 
[16] Olubamiji AD, Izadifar Z, Zhu N, Chang T, Chen XB, Eames BF 2016 Using synchrotron 
radiation inline phase-contrast imaging computed tomography to visualize three-dimensional 
printed hybrid constructs for cartilage tissue engineering. J. Synchrotron Rad. 23 802. 
[17] Izadifar M, Kelly ME, Chen XB 2016 Regulation of sequential release of growth factors 
using bi-layer polymeric nanoparticles for cardiac tissue engineering. Nanomedicine (Under 
Review). 
[18] Liliana AL, Eugenio TG, Rigoberto OP 2014 Biological Tissue Modeling with Agar Gel 
Phantom for Radiation Dosimetry of 99mTc. OJRad 4 44. 
[19] Gureyev TE, Davis TJ, Pogany A, Mayo SC, Wilkins SW 2004 Optical phase retrieval by 
use of first born- and rytov-type approximations. Appl. Opt. 43 2418e2430. 
[20] Chen RC, Rigon L, Longo R 2013 Comparison of single distance phase retrieval algorithms 
by considering different object composition and the effect of statistical and structural noise. Opt. 
Express 21 7384. 
[21] Wu X, Liu H, Yan A 2005 X-ray phase-attenuation duality and phase retrieval. Opt. Lett. 30 
379e38. 
[22] Chen RC, Dreossi D, Mancini L, Menk R, Rigon L, Xiao TQ, et al 2012 PITRE: software 
for phase-sensitive X-ray image processing and tomography reconstruction. J. Synchrotron 
Radiat. 19, 836e845. 
[23] Canadian Light Source 2015 BMIT-BM quality assurance for cycle 21. Rev. A 26.5.1.5 6.  
[24] The 2007 recommendations of the international commission on radiological protection. 
ICRP publication 103, Ann. ICRP 37 1e332. 
[25] SCENIHR. Health effects of security scanners for passenger screening (based on X-ray 
technology). European Union, 22-27, 2012. 
 299 
[26] Wang Z, Bovik AC 2004 Image Quality Assessment: From Error Visibility to Structural 
Similarity. IEEE T. Image Process. 13 1. 
[27] Lim GB 2015 Alginate-hydrogel in chronic HF. Nat. Rev. Cardiol. 12 443  
[28] Hadjipanayi E, Kuhn PH, Moog P, Bauer AT, Kuekrek H, Mirzoyan L, Hummel A, 
Kirchhoff K, Salgin B, Isenburg S, Dornseifer U, NinkovicM, Machens HG, Schilling AF 2015 
The Fibrin Matrix Regulates Angiogenic Responses within the Hemostatic Microenvironment 
through Biochemical Control. PLoS One. 10, e0135618,  
[29] Lovett M, Lee K,  Edwards A, Kaplan DL 2009 Vascularization Strategies for Tissue 
Engineering. Tissue Eng Part B Rev. 15, 353. 
[30] Wrixon AD 2008 New ICRP recommendations. J. Radiol. Prot. 28, 161e168. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 300 
CHAPTER 7 
CONCLUSIONS AND FUTURE RESEARCH  
7.1. Conclusions drawn from the development of rate-modulating nanoparticles  
Engineering cardiac constructs aims to provide physical and biochemical cues for myocardium 
regeneration. Spatiotemporal control of growth factor (GF) release is of critical importance for 
bio-functional engineered cardiac constructs to guide myocardium regeneration and 
revascularization at the injured territory of the heart. Widely used GF immobilization and 
encapsulation techniques suffer from limited control over the release rate and the possible loss of 
GF bioactivity due to covalent bonding and cleaving reactions during the immobilization and 
release processes. Polymeric particulate delivery systems have shown a lot of promise to 
overcome these limitations. Especially, engineered PLLA- and PLGA-based nanoparticles have 
attracted attentions due to their biocompatibility, biodegradability and approval for use by FDA. 
Furthermore, through adjusting release characteristics of PLGA/PLLA nanoparticles, it will be 
increasingly possible to modulate GF release rate, a process so called ‘rate-programming’ of the 
nanoparticles. However, there are some challenges that need to be overcome to achieve rate-
modulated nanoparticles for controlled release of the GFs. Some of important properties of the 
nanoparticles such as size, polydispersity, loading capacity, zeta potential and morphology, 
which are essential to system functions, are regulated by fabrication variables in a complicated 
manner. This raises a great need to optimize fabrication process variables to ensure the desired 
nanoparticle characteristics.  
In the first section of this Ph.D. thesis, a comprehensive experimental study was conducted on 
this matter, along with a novel method, the so-called Geno-Neural approach, to analyze, predict 
and optimize fabrication variables for desired nanoparticle characteristics. The experimental 
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results revealed that the polymer and the external aqueous phase concentrations and their 
interactions with other fabrication parameters were the most significant variables to affect the 
size, polydispersity index, zeta potential, loading capacity and initial burst release of the 
nanoparticles. By means of the verified Geno-Neural model, optimum conditions to achieve low 
polydispersity index, higher negative zeta potential and higher loading capacity were identified 
for desired particle sizes of 150, 200, 250 and 300 nm, respectively. Electron microscopy images 
of the nanoparticles showed their spherical geometries with no sign of large pores or cracks on 
their surfaces. Furthermore, Circular dichroism (CD) spectroscopy unveiled the structural 
integrity of a releasing protein model from the nanoparticles designed at the optimum fabrication 
conditions proposed by the Geno-Neural model. Findings from this part of the thesis would 
greatly contribute to the design of PLGA nanoparticles for prolonged release patterns of GFs in 
an engineered cardiac construct for myocardium tissue engineering. 
Although the PLGA nanoparticles can provide prolonged release of GFs, generally, the use of 
single polymer nanoparticles/microparticles are undermined by some limitations including the 
initial burst effect and lack of time-delayed release pattern, which is essential for GF sequential 
release in cardiac constructs. Moreover, the controlled release of multiple GFs demands rate-
modulated nanoparticles to provide simultaneous and/or sequential release patterns for guided 
vascularization and myocardium regeneration. In the second part of this thesis, Bi-layer 
polymeric nanoparticles composed of a GF-encapsulating core surrounded by an adjustable shell 
thickness have been developed for sequential GF release. The bi-layer nanoparticles featured low 
burst effect, structural integrity of the encapsulated protein and time-delayed release patterns. 
Allowing for adjusting the timing of release, preconditioned nanoparticles demonstrated 
bioactive in the context of angiogenesis. The bi-layer nanoparticles successfully regulated 
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sequential release of platelet-derived GF following co-release of vascular endothelial GF and 
basic fibroblast GF, and significantly promoted angiogenesis in fibrin matrix, which is 
considered as an outstanding bio-component of cardiac constructs. Moreover, a novel  
Geno-Neural model was developed and validated for rate-programming of the nanoparticles. By 
means of the proposed model, various GF release patterns can be pre-programmed by adjusting 
the polymeric characteristics of the nanoparticles such as polymer concentration, molecular 
weight, PLLA/PLGA mass ratio, carboxyl/ester terminal group, lactide:glycolide ratio and the 
nanoparticle size. In addition, a representative mathematical relationship was presented so that 
the Geno-Neural model may be easily implemented in a spreadsheet program by various users 
with different backgrounds. The mathematical relationship was successfully tested on two sets of 
experimental data, offering a great potential for the rate-modulation of PLLA/PLGA 
nanoparticles for different tissue engineering applications. 
Besides, the release behavior of the nanoparticles relies on the physical and chemical properties 
of the nanoparticles, which may be optimized for achieving desired release profiles. 
Mathematical models are powerful and efficient tools that facilitate the development and 
optimization of the GF delivery systems. Furthermore, mechanistic modeling combined with 
precise experimental evaluation of the nano-particulate delivery systems improves the 
understanding of the mechanisms of GF release, and thus help to determine crucial parameters 
that regulate the release rate. Also, predictive models can reduce and even eliminate the need for 
experiments, thus saving time and the associated costs. Despite numerous models for controlled 
release, there is no report on mechanistic models to elucidate governing mechanism and provide 
predictive means on release behavior and parameters for bi-layer polymeric nanoparticles. In the 
third part of this thesis, two novel modeling approaches based on local volume averaging (LVA) 
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and Geno-Mechanistic modeling to represent the controlled-release of bioactive agents from bi-
layer polymeric nanoparticles were presented. From a porous media perspective, differential 
mass transfer governing equations based on LVA method were derived and numerically solved 
to provide the insight on the transport and degradation properties of the nanoparticles. In 
contrast, a system of analytical governing equations of release of pseudo bi-layer nanoparticles 
was coupled with genetic algorithm to provide a hybrid model, so called ‘Geno-Mechanistic’ 
model, to predict volume-averaged release properties of the nanoparticles at various conditions. 
A very good agreement between predicted values and experimental data (r2>0.98, MPE<5%) 
was observed for both models, indicating the reliability of the models for predicting the release 
behaviors. Moreover, the estimated values of release parameters including effective diffusivity 
and degradation rate constants were consistent with the corresponding measured values reported 
in literatures. Predictions from both models indicated that the transport and degradation 
properties of the shell of bi-layer nanoparticles predominantly control the release rate. The Geno-
Mechanistic model predicted two-phase (gradual and rapid) polymer degradation and a single 
phase degradation for the bi-layer and PLGA nanoparticles, respectively, which were consistent 
with experimental data reported in literatures. The developed models will be powerful, effective 
and efficient tools to predict and optimize the controlled release of bioactive agents from 
polymeric nanoparticles for many tissue engineering applications. 
7.2. Conclusions drawn from the development of synchrotron phase contract-based 
assessment techniques  
Hydrogels have been extensively used for development of functional cardiac constructs in 
cardiovascular tissue engineering because of their ability to support cell adhesion, retention and 
growth. Micro-patterning of hydrogel-based cardiac constructs enables spatial control over 
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microstructural characteristics of the patch. Moreover, different hydrogels combined with rate-
modulating nanoparticles can be precisely assigned to the structure of the patch by use of 3D-
bioprinting techniques. By optimizing dispensing speed, extrusion rate, and strand thickness, a 
dual-component 3D-printed cardiac patch was successfully created from alginate (the micro-
construct framework), with pores filled out by fibrin. Overall structural and morphological 
assessemnt of the 3D-printed dual-component constructs showed the feasibility of micro-
patterning of very soft hydrogel (e.g alginate containing 97.5% water). Also, the patch 
demonstrated good attachment post implantation on the rat heart using surgical fibrin glue. 
Synchrotron in-line phase contrast tomography was optimized and successfully implemented to 
visualize and quantitatively assess the details of the implanted patch microstructure through an 
ex-vivo study. Results illustrated that in the phase retrieval of the PCI-CT images, alginate 
strands could be distinguished from fibrin-filled pores, thus being able to characterize the 
microstructural features of implanted patches and surrounding microvessels and ligature in the 
myocardium. Furthermore, the phase-retrieved PCI-CT images provided clear structural details 
for quantitative assessment of the patch as compared to the images from phase non-retrieved 
PCI-CT and a 3T clinical magnetic resonance imaging. By reducing the total CT-acquisition time 
per slice and ROI, PCI-CT was examined for lowering the effective dose (<100 mSv), 
meanwhile it was illustrated that there were no  significant changes in imaging quality for 
quantitative assessment of the implanted patch microstructure. The features of the patch 
evaluated from the low dose PCI-CT were in agreement with the measured values from 
stereomicroscope images. Taken together, it has been illustrated that the PCI-CT is of great 
potential for non-invasive qualitative and quantitative assessment of microstructural features of 
the implanted alginate/fibrin cardiac patch at the low dose allowed in clinical use.  
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7.3. Future research 
One of the challenges that smart bioactive cardiac patches are facing to is spatiotemporal control 
of GF release to facilitate cellular fate regulation in situ. Development of such scaffolds requires 
precise design and optimization of structural, architectural and physicochemical characteristics 
of the GF-loaded nanoparticles for pre-programmed GF release profiles within the scaffolds. 
Precise 3D printing technique can be used to fabricate customized cardiac patch constructs with 
the ability of spatiotemporal control of release of multiple GFs. The development of the rate-
modulated nanoparticles and the 3D-printed dual-component patch as discussed in this 
dissertation can greatly contribute to achieve the fabrication of pre-programmed bioactive 
cardiac patches. With the predictive models proposed in this thesis, the nanoparticles can be 
designed, rate-programmed and prepared. Each design of the nanoparticles is then assigned to 
particular layer in the patch microstructure through 3D printing of the nanoparticle-incorporated 
alginate and fibrin, as disscused earlier. Thus, spatiotemporal control of GF release will be 
achieved across the patch microstructure to guide vascularization and myocardium regeneration.  
Another challenge is attributed to weak mechanical properties of hydrogel-based micro-
fabricated cardiac patches. To address this issue, further research and assessments are required to 
improve structural properties of micro-patterned hydrogel-based cardiac patches. The PCI-CT 
imaging technique that was developed in this research for visualization of the implanted 3D-
printed cardiac patch will be eventually used for monitoring the cardiac patch degradation, tissue 
regeneration and vascularization in-situ after surgery. The optimum imaging parameters that 
were identified and discussed in this dissertation may be refined for the development of a robust 
gated PCI-CT for in-vivo live animal study in the future. 
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Appendix A: Matrices and vectors for evaluation of Eq. (3.4) 
 




















−−
−−
−−
−−−
−−
−−−
=
0675.01823.00524.22818.02104.02512.0
0801.02215.02768.02897.02109.08385.1
0684.02684.00484.03550.03019.17223.0
2020.00636.05142.26355.03500.00480.0
0382.02597.03509.00128.06035.00619.1
1491.01380.09678.00658.12258.06699.0
M  












−−
−−−
−−
−−
=
3418.03029.07825.02445.00225.03795.0
1426.02096.17704.04718.01053.04070.0
4429.11851.00472.08325.00848.19412.0
4019.03206.02091.01288.05171.12394.0
N  
 




















=
5326.0
0057.0
0338.0
1779.0
8215.0
5984.0
q , 












−
−
−
=
1138.0
0734.0
3708.0
1365.0
r  
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Appendix B: The neural network synaptic weights associated with Eq. (4.3) 
 












−−−−−−
−−−−
−−
−−−
=
8461.13141.02980.01040.03234.02979.00621.03067.0
0057.02959.00778.03645.00332.02705.00048.07418.0
5058.13364.01105.01059.02060.00798.00795.07418.0
5668.02840.00825.04615.00184.00977.01556.02066.0
M  












−
−
−
=
1318.0
0892.0
1056.0
5194.0
q  






−−−
−−−−
=
0086.01765.10038.00069.0
9719.03748.06768.17205.0
N  






−
=
0496.0
0972.0
r  
 
 
 
 
 
 
 
 
 
 
 
